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         “People in this world look at things mistakenly, and 
think that what they do not understand must be the void. 
This is not the true void. It is bewilderment.” 
 
                                
      Miyamoto Musashi, A Book of Five Rings (1645) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT  
                      
                 The understanding of the ageing process and of ageing-associated diseases 
represents a significant challenge for the scientific community, governments and society at 
large. I identified in skeletal muscle of murine models by microarray an increase in PPAR-β/δ 
expression during acute phase of hindlimb suspension (accelerated ageing), with a possible 
compensatory role, and an increase in expression levels of NR4A family of nuclear receptors 
in the skeletal muscle of caloric restricted rats (decelerated ageing). Adipose tissue has an 
endocrine role being actively involved in cross-talk with peripheral organs such as skeletal 
muscle. Visfatin is a recently discovered adipokine with pleiotropic functions. Unlike in other 
types of cells, in differentiated C2C12 myoblasts exogenous added visfatin (eNampt) did not 
act as an insulin-mimetic factor as shown by western blot and fluorescent assays. Visfatin 
treatment of differentiated C2C12 myotubes generated nevertheless an increase in the levels 
of reactive oxygen species as shown by fluorescent microscopy that was dependent on de 
novo transcription and translation of a new set of genes as revealed by RT-PCR. This increase 
in oxidative stress was independent of activation of the stress-activated protein kinases 
(MAPKs) such as ERK and p38, but dependent on NFkB activation as proved by western 
blot. 
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                                       1.1 Ageing as a challenge for biomedical research in the 
21
st
 century        
                            Based on World Health Organization predictions, by 2050 the aged segment of 
human population will grow from 650 million today to almost 2 billion and will have also an 
increased lifespan. Therefore, an in-depth theoretical understanding of the biological changes 
occurring during ageing is required for a better management of the pathological conditions 
associated (Benz and Yau, 2008; Franco et al., 2009; Vasto et al., 2009). As many as 300 distinct 
explanatory theories of ageing have been developed and the list is continuously growing 
(Medvedev, 1990). Ageing has been approached from different perspectives brought by different 
disciplines within biological research including evolutionism, developmental biology, genetics, 
genomics, cell biology, physiology and biochemistry. Ageing was initially conceptualized within 
the framework of evolutionary theories by A. Weismann who  explained it as a normal 
consequence of natural selection (Gavrilov and Gavrilova, 2003). In 1952 P. Medawar developed 
the “mutation accumulation” theory by integrating within the evolutionary perspective the corpus 
of knowledge of classical genetics, conceptualizing ageing as the final state of  a gradual 
accumulation of mutations with age, leading in the end to a reduced level of fitness culminating 
with death (Ljubuncic and Reznick, 2009). The “antagonistic pleiotropy” theory explained the 
ageing process as an accidental consequence of the action of genes that were selected as favourable 
during early life development, but were deleterious during later stages (Williams and Day, 2003). 
The evolutionary “disposable soma” theory (Drenos and Kirkwood, 2005) is the last theoretical 
construct in this line of thought explaining ageing as a consequence of the trading-offs required 
during development between reproduction, growth and repair. The scientific breakthroughs brought 
by biochemistry and cell and molecular biology fields in the last decades have also been 
incorporated into ageing research, the most notable paradigm proposed being the free radical 
theory of ageing discussed below.  
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                                  1.1.1 The free radical theory of ageing 
                                  The idea that metabolism is the critical factor in determining the limits of  
lifespan was initially proposed in 1928 by Pearl’s “rate-of-living” hypothesis that assumed a finite 
energy expenditure available to each living organism (Lints, 1989). Therefore, an accelerated 
metabolic rate and an increased rate of oxygen consumption should result in a reduced lifespan. 
Although not accepted anymore by scientific community due to the lack of a strict correlation 
between the rate of metabolism and lifespan or ageing phenotypes (Van Voorhies, 2004), the “rate-
of-living” hypothesis nevertheless nurtured further research into the roles of oxygen and reactive 
oxygen species (ROS) in metabolism that culminated later in the “oxygen poisoning” hypothesis. 
The theory that oxygen can have deleterious effects on cellular structures and metabolism was 
proposed in 1954 by R. Gerschman when she noticed that the process of “oxygen poisoning” 
shares similar mechanisms of action with the phenomenon of x-irradiation through the generation 
of various species of free oxygen radicals (Gerschman et al., 1954). This idea was further employed 
by D. Harman two years later in his seminal paper (Harman, 1956). Harman based his theory on the 
assumption that the accumulation of ROS as by-products of normal cellular redox reactions will 
slowly, but certainly, lead to an increased number of genetic mutations, impaired cellular functions 
and eventually ageing. Harman predicted correctly that the main factors in this process are the 
proteins which directly use oxygen, especially those containing iron. The later identification of 
genes involved in oxygen metabolism like superoxide dismutase (SOD) gave Harman’s theory 
solid empirical grounds (McCord and Fridovich, 1969). The basic components of initial Harman’s 
theory were the following:  
                        1. The ageing process correlates with metabolic rate; 
                        2. The metabolic rate is proportional to the molecular oxygen used; 
           3. Oxidation process, catalyzed by multiple enzymatic reactions, generates      
 free radicals that can have a deleterious impact on cell constituents. 
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                     4. A functional antioxidant defence system is critical for delaying or ameliorating the 
  ageing process. 
                       Recently, the “free radical theory of ageing” (FRTA) expanded to include other 
forms of activated oxygen such as peroxides and aldehides, and was renamed the “oxidative stress 
theory of ageing”(Sohal and Weindruch, 1996). The two versions are nevertheless considered to be 
identical for the communication purposes in the present thesis. After two decades of detailed 
research Harman further modified his initial hypothesis by focusing only on the specific roles of 
mitochondrial-derived free radicals, proposing the “mitochondrial theory of ageing” (MTA) 
(Harman, 1972). Recently, the mitochondrial theories of ageing (MTA) received additional support 
from independent studies exploring also the roles of mitochondrial genome stability and 
mutagenesis in cellular ageing (Miquel, 1992) and from the research on the roles of mitochondrial 
bioenergetics mechanisms in the production of ROS, such as electron transfer and oxidative 
phosphorylation (Lenaz et al., 2000). Besides their differences all FRTA and MTA theories can be 
classified broadly in two main categories: the “accidental” versions and the “programmed” 
versions of the free radical theory of ageing (Medvedev, 1990). The accidental version considers 
that the number and the amplitude of stochastic deleterious effects of oxygen metabolism shape the 
ageing process, while the programmed version states that ageing is the inevitable final stage of a 
predetermined developmental programme. Since both variants of the theory nevertheless assumed 
the core idea that the free radicals produced by living cells are regulating the rate and the extent of 
ageing process, it was possible to derive predictions based on theory that were tested 
experimentally. There are two main research directions in this aspect (Agarwal and Sohal, 1993). 
First of all, based on the theory, an accelerated rate of ageing should correlate with an increased 
production of free radicals resulting in a reduced lifespan. This led to a line of research that 
compared the levels of free radicals with the ageing phenotypes in different experimental animals 
or tissues (Adelman et al., 1988). Second, an increase in antioxidant defence should decelerate the 
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ageing process, eventually increasing the lifespan. This line of research is based on the results of 
the studies of the effects of different mutations of antioxidant genes on the ageing process and on 
the effects of pharmacological/dietary interventions (Gems and Doonan, 2009).  Both lines of 
research gathered significant arguments for and against the theory of free radicals of ageing. So far 
a comprehensive, widely accepted unified theory integrating all the relevant experimental data 
concerning the effects of the free radicals on ageing in a single explanatory system  has  not been 
achieved (Beckman and Ames, 1998). Nevertheless, it is generally accepted at least that the 
progression of ageing phenotype is dependent on the overall balance between the rate of free 
radicals produced and the action of the antioxidant defence system, and that a progressive 
imbalance between the two forces toward a reduced or impaired antioxidant status will result in an 
accelerated ageing process (Muller et al., 2007).  
                       Simultaneously with the studies of the roles of free radicals on lifespan and ageing, 
other independent lines of research revealed their critical role in the development of many 
pathological conditions associated with ageing such as neurodegenerative diseases, cancer, 
cardiovascular diseases and impaired immunity (Ames et al., 1993). These studies were 
incorporated in the FRTA set of theories as arguments to justify the hypothesis that free radicals 
play a significant role in the development of the ageing process itself, not only in the modulation of 
its associated pathogenic aspects (Ku et al., 1993). The main postulate of this direction of research 
is that the differences in the generation of free radicals are the main cause of the differences in 
lifespan between individuals of the same species and also between species. Therefore, the scientific 
community dedicated to decipher ageing is currently divided between those defending the “weak” 
version of FRTA, that considers that free radicals play a major role only in the development of 
ageing-associated diseases which indirectly affects the lifespan, and those dedicated to defend a 
“strong”, supposedly the original interpretation of FRTA, that considers that the levels of the free 
radicals directly limit the lifespan and shape the ageing profile of any species (Beckman and Ames, 
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1998). While the “weak” concept has a broad support, the “strong” version is still highly debated 
and controversial. It was also shown that there are close relationships between antioxidant defence 
mechanisms and inflammatory status (Mulholland et al., 1999). For example, the death of 
endothelial cells occurring in models of atherogenesis generated by oxidative stress inducers or 
cytokines is reduced by the pre-incubation with antioxidants such as catalase (CAT) or N-acetyl-L-
cysteine  (NAC) (Dimmeler and Zeiher, 2000). In addition, antioxidants such as SOD and 
tocopherol are able to reduce the skin inflammation in mice (Lange et al., 1998).  Since reactive 
oxygen species are by-products of usual cellular biochemical reactions, understanding the 
mechanisms that protect the integrity and the functionality of mammalian proteome and genome 
against their deleterious effects represents a central research goal of the study of ageing and 
regulation of lifespan. For example, it was shown that Drosophila models lacking copper/zinc-
containing superoxide dismutase presented decreased lifespan (Phillips et al., 1989) and that 
homozygous null mice for Mn-superoxide dismutase (MnSOD) are not viable (Li et al., 1995). 
These reports proved the essential role of antioxidant protection not only for a proper ageing but 
also for a normal early development. In addition, they inspired a subsequent research based on the 
assumption that by improving the antioxidant capability of cells to resist the oxidative stress, the 
ageing process could be delayed or even reversed. The experimental attempts using genetic, 
dietary/lifestyles or pharmacological intervention strategies have had only partial or modest 
successes, sometimes leading even to contradictory results. For example, whilst the expression of 
the human mitochondrial catalase extended the lifespan in mice models (Schriner et al., 2005), the 
heterozygous mice lacking one allele of MnSOD did not present nevertheless any significant 
change (Van Remmen et al., 2003). Similarly, while null mice lacking CuZnSOD had reduced 
lifespan (Elchuri et al., 2005), its ubiquitous overexpression failed to increase it in the same model 
(Huang et al., 2000).             
       There are a few reports published that even seem to contradict the basic tenets of the 
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FRTA-derived predictions. For example, C. elegans mutants lacking mitochondrial SOD2 
presented increased levels of ROS levels in mitochondria simultaneously with an increased 
lifespan, and incubation of these longevive mutants with antioxidants such as NAC cancelled the 
effects  (Yang and Hekimi, 2010). Similarly, chronic conditioning of the same wild-type nematode 
models with a low concentration of an ROS-inducer such as paraquat not only generated higher 
global ROS levels, but increased also the lifespan values. In Drosophila, the simultaneous 
overexpression of catalase and MnSOD in mitochondria had surprisingly toxic effects reducing the 
lifespan, although improved the antioxidant defence and reduced the levels of free radicals 
produced (Bayne et al., 2005). The overexpression of the antioxidant genes in murine models had 
also toxic effects in some cases (Rando and Epstein, 1999). For example, the overexpression of the 
wild-type form of SOD1 in skeletal muscle led to significant myopathy and an accelerated aged 
phenotype due to an increased level of protein aggregation, and surprisingly higher levels of ROS 
(Wong and Martin, 2010). These results do not necessarily reject the FRTAs sets of predictions 
because they could be still explained through the concept of hormesis described below. 
Alternatively, such results might indicate that the quantification of oxidative stress levels cannot be 
reduced only to the measurement of the free radicals produced, a better understanding of the 
antioxidant defence status and of the mechanisms regulating it being crucial in this respect. For 
example, it was shown that while during physical exercise the production of the free radicals in 
skeletal muscle is greatly increased (Bejma and Ji, 1999), this event is nevertheless simultaneously 
activating the antioxidant defence mechanisms which in long term has a beneficial effect on 
myocytes  physiology (Zainal et al., 2000).  Ageing lowers and degrades the ability of skeletal 
muscle to activate during physical exercise the elements of antioxidant defence system such as 
heat-shock proteins (Liu and Steinacker, 2001), therefore the production of free radicals has a 
higher physiological impact with increased age. Better conceptual and experimental tools have to 
be developed in order to obtain a more accurate estimation of the levels of oxidative stress and of 
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the ability of antioxidant defence to protect the cellular constituents against the deleterious effects 
of the free radicals. In addition, less it is known about the roles of repair mechanisms that do not 
counteract  the free radicals produced per se, but remove afterwards the oxidised products 
generated by such ROS such as carbonylated proteins, lipid peroxides or oxidized bases (Beckman 
and Ames, 1998). The reasons why some oxidative stress inducers induce a senescent phenotype 
and other do not could be explained through a differential ability of such repair mechanisms to 
remove the toxic by-products generated. Therefore, the main driving force behind the differential 
development of the senescent phenotype between different species or different individuals of the 
same species could lie in fact in the differences in the ability to react to the ROS experienced, not 
necessarily in the amount of free radicals produced.       
             The pharmacological interventions based on the administration of the known 
antioxidant supplements such as NAC (Miquel et al., 1995) or Ginko Biloba extracts (Sastre et al., 
1998) successfully improved mitochondrial enzymatic parameters and antioxidant defence in mice 
models, but had no effect on lifespan.  The only dietary intervention that proved so far to be 
effective in extending lifespan and delaying ageing of any experimental model employed is the 
caloric or dietary restriction (Fontana et al., 2010; Piper and Bartke, 2008; Zahn and Kim, 2007).  
The mechanisms through which caloric restriction improves the ageing phenotype are still unclear 
but it was shown at least to be partially dependent on reduced levels of inflammation and oxidative 
stress and a changed genomic expression profile leading to an improved antioxidant defence 
(Merry, 2002, 2004, 2005). Caloric restriction effects in an ageing context can be explained 
through the concept of hormesis, i.e. low level of damaging stimuli applied continuously which will 
have in the end global positive effects.  
               The future understanding of the relationships between oxidative stress and ageing 
will require the exploration of the distinct effects of ROS/antioxidant defence on individual tissues 
and organs, as well as an estimation of the contribution each tissue has on the development of the 
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overall ageing phenotype. Of great theoretical and practical importance will be the identification of 
tissue-specific ageing markers or of mediators that could have pleiotropic or even opposite effects 
in different cellular types or physiological contexts. For example, genes that have a pro-apoptotic 
role in one cell type but are anti-apoptotic in other cases, genes that have a prooxidant role in some 
of peripheral tissues and antioxidant in others, or genes that are associated with an insulin-resistant 
and pro-inflammatory state in some cases but with an insulin-sensitive and anti-inflammatory state 
in others. This will allow for differential genetic or pharmacological interventions at molecular, 
cellular or organism levels that will offer a good model to test the predictions made by the theories 
of ageing described above, by correlating the state of ageing in a particular tissue with the levels of 
cellular stress.  
 
 
                          1.2     Adipose tissue- a critical regulator of the development of the 
inflammation and oxidative stress characterizing ageing-associated diseases  
 
            In the last decades many genes regulating the limits of lifespan and the 
development of ageing have been discovered in experimental models. For example, the transgenic 
C. elegans nematode models of daf-16 gene that encodes for a transcriptional factor regulating 
insulin signalling presented not only an increased lifespan but also a healthier phenotype (Ogg et 
al., 1997). Similarly, Drosophila models overexpressing methuselah gene that encodes for a G-
coupled receptor lived longer (Lin et al., 1998). The discovery that S. cerevisae yeasts 
overexpressing sirtuin-2 (sir-2) gene that  regulates epigenetic aspects of chromatin function 
showed an increased replicative lifespan (Kaeberlein et al., 1999) initiated an extensive stage of 
screening research of synthetic or natural compounds that can activate the human sirtuins to delay 
or prevent ageing (Alcain and Villalba, 2009). The first genetically-modified murine model 
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showing an increased lifespan was developed in 1996 when it was discovered that Ames dwarf 
mice (df/df) that were deficient in growth hormone, prolactin and thyroid-stimulating hormone 
lived longer (Brown-Borg et al., 1996). Recently it was found that the gene klotho that encodes for 
a type I membrane protein, possibly belonging to the beta-glucuronidase family, is also a hormone 
that has anti-ageing properties by inhibiting insulin signalling (Kuro-o, 2008). For example, while 
klotho null mice had a shorter lifespan with an accelerated ageing phenotype, khlotho transgenic 
mice had an increased lifespan (Kurosu et al., 2005). These reports indicate that regulation of 
lifespan, the rate of ageing and the development of ageing-associated diseases are affected by 
changes in gene expression of main regulators of insulin metabolism, changes in epigenetic status 
and changes in the signalling of the networks monitoring metabolism.  The essential roles of 
inflammation, oxidative stress and of a dysfunctional metabolic regulation in the pathogenesis of 
ageing-associated diseases are already known. A persistent, chronic  low level of inflammation is 
also a central element of the immunosenescent status (Krabbe et al., 2004). The ageing phenotype 
correlates with a change in the expression profile or in the activity pattern of the circulating 
cytokines and with an increased risk of mortality (Licastro et al., 2005).      
  In recent years adipose tissue has started to be understood not only as a fat depot, 
but also as an important endocrine organ (Jazet et al., 2003; Mohamed-Ali et al., 1998; Trayhurn 
and Wood, 2005). Adipokines are cytokines secreted by white or brown adipocytes that act in 
autocrine/paracrine (Karastergiou and Mohamed-Ali, 2010) or endocrine fashion (Kos and 
Wilding, 2009). Adipokines have complex roles such as the regulation of the adipose mass 
(Cawthorn et al., 2007; Cawthorn and Sethi, 2008), inflammation (Wang et al., 2005) or glucose 
(Rabe et al., 2008) and lipid metabolism (Lago et al., 2009). Since inflammation and oxidative 
stress characterize the ageing phenotype (Beauloye et al., 2007; Maury and Brichard, 2010; Maury 
et al., 2007; Rousseau et al., 1997) and since adipose tissue has an important endocrine impact on 
the physiology of other peripheral tissues, it is reasonable therefore to expect that there are close 
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relationships between the ageing process affecting peripheral tissues and adipokines (Picard and 
Guarente, 2005). In addition, the relationships between other closely related mediators of 
inflammation such as the cytokines and ageing are well established and deciphered. It is known for 
example that the levels of interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interleukin-6 
(IL-6) change with age (Grubeck-Loebenstein and Wick, 2002), and it has also been shown that the 
ageing of immune system has a central role in the development of the overall ageing phenotype 
(Fulop et al., 2006). Similarly, it is reasonable to expect that changes in adipokine expression or 
activity could also have a major impact in the development of ageing-associated diseases, in whose 
progression inflammation and oxidative stress play a major role   (Picard and Guarente, 2005). The 
list of adipokines is continuously growing and includes besides already known cytokines (TNF-α, 
IL-6, IL-8, IL-10) other members with a less understood biology such as adiponectin, leptin, 
resistin, omentin, apelin, vaspin, chemerin, visfatin and monocyte chemotactic protein-1 (MCP-1) 
(Wozniak et al., 2009).   
       
                    1.2.1 Visfatin- a new adipokine and modulator of oxidative stress and 
inflammation            
                     Visfatin is a multifunctional protein belonging to adipokine family with a 
multistep history. The first historical stage started seventeen years ago when it was discovered that 
it had  a synergistic effect on the maturation of human pre-B cell colonies in association with other 
interleukins, and it was named PBEF (Pre-B-cell colony-enhancing factor) (Samal et al., 1994). 
The precise nature of its cellular function remained obscured for another seven years until 2001 
when it was discovered that PBEF gene sequence  has a high level of homology with NadV gene 
from the prokaryote Haemophilus ducreyi (Martin et al., 2001). In the following year it was 
discovered that both human and bacterial genes were coding for a nicotinamide 
phosphoribybosiltransferase enzyme (Rongvaux et al., 2002) that synthesizes nicotinamide 
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mononucleotide (NMN) from nicotinamide (NA) and diphosphate, the human gene getting 
consequently two more names, Nam-PRTase and Nampt. The fact that intracellular form of visfatin 
synthesizes NMN, an intermediate of nicotinamide adenine dinucleotide (NAD), could indirectly 
impact the ageing process and the development of ageing-associated diseases. For example, it was 
discovered that sirtuin-2 gene that regulates the rate of lifespan and ageing phenotype encodes for a 
histone deacetylase in yeasts which requires NAD as a substrate (Wenzel, 2006). Multiple 
homologues of sirtuin-2 gene have been identified in human genome and all use NAD as a 
substrate. The next stage of visfatin research was opened in 2005 when a controversial paper was 
published (Fukuhara et al., 2005) that reported that PBEF/Nam-PRTase/Nampt is also an adipokine 
being secreted into plasma by visceral fat adipocytes and acting as an insulin mimetic agent. As an 
adipokine PBEF/Nampt is also known as visfatin (visceral fat-derived hormone) or extracellular 
Nampt (eNampt), to distinguish it from the intracellular form of PBEF/Nampt (iNampt). The 
identity of visfatin as an adipokine actively secreted by white and brown adipocytes from both 
subcutaneous and visceral adipose depots is widely accepted today. Nevertheless, it is still unclear 
if visfatin is a genuine insulin mimetic agent and the issue is still debated.  Only a few independent 
experiments were able to confirm the original hypothesis (Adya et al., 2008a, 2009; Lim et al., 
2008; Xie et al., 2007). Moreover, the original paper has been retracted by the publishing journal.  
         The present stage of research is focused on the exploration of the differential 
roles of both intracellular (iNampt) and extracellular (eNampt) forms of visfatin in the modulation 
of oxidative stress and inflammation. Independent experiments performed in vivo, ex vivo and in 
vitro led to divergent conclusions. There are good arguments to consider that in some tissues or in 
some physiological conditions visfatin has a protective role, defending cells from different types of 
threatening stimuli like genotoxic stress (Rongvaux et al., 2008), ER-stress (Li et al., 2008) or 
oxidative stress (Borradaile and Pickering, 2009). Such protection can have short-term anti-
apoptotic effects (Kendal-Wright et al., 2008) and in some cases even  longer-term, anti-ageing 
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effects (van der Veer et al., 2007). However, there are solid arguments to assert that in other cells 
or tissues visfatin is in fact a powerful inducer of oxidative stress and inflammation, its 
overexpression or its increased function being involved in a large variety of pathological conditions 
associated with ageing ranging from leukaemia (Hasmann and Schemainda, 2003), lung injury (Ye 
et al., 2005), Alzheimer’s (Adams, 2008) and arthritis (Nowell et al., 2006) to obesity (Berndt et 
al., 2005) and diabetes (Chen et al., 2006). So far the experiments measuring the synthesis of NMN 
by the intracellular form of visfatin (Busso et al., 2008), the levels of tissue-specific expression 
(Choi et al., 2007) or the levels of plasma circulating visfatin (Otero et al., 2006) showed that 
visfatin is associated with particular pathological conditions in some experimental models. 
Nevertheless, until now there is no global, unified theory about the underlying mechanisms and 
overall effects of either form of visfatin. Also, even when it is possible to make a reliable statistical 
correlation between a pathological biomarker and the level of visfatin expression or function, the 
precise physiological roles and relevance of such observed changes are still obscure. An increase in 
visfatin intracellular expression or extracellular secretion could be a causative factor in some of the 
diseases listed above, but in the same time it could have a compensatory or even a preventive 
function in other cases. The murine null knock-out models are unviable and the experiments that 
used PBEF-heterozygous mice did not clarify the most crucial questions about visfatin 
relationships with the regulation of oxidative stress and inflammation (Revollo et al., 2007). The 
usefulness of other types of models like lower invertebrates or prokaryotes to elucidate all 
functional properties of visfatin is also doubtful, although some progress has been made recently in 
this matter (Vrablik et al., 2009). Therefore, at the present stage of research it is not possible to 
definitively corroborate or dismiss any of the opposing hypotheses concerning the relationships 
between extracellular visfatin and cellular stress.                                                           
          One important fact about visfatin is that it is highly expressed in skeletal muscle, 
which led to the suggestion that it might also act as a myokine (Krzysik-Walker et al., 2008). So far 
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there are just a few papers dedicated to explore the role of skeletal muscle intracellular visfatin in 
the generation or protection against oxidative stress and inflammation (Costford et al., 2010; Fulco 
et al., 2008), and until our published paper (Oita et al., 2010) there were no reports published about 
the effects of exogenous visfatin (eNampt) on skeletal muscle physiology.  
          Visfatin looks to have complex, even antagonistic effects in different tissues or in 
different pathological conditions, being associated with a prooxidant state/insulin resistance in 
certain tissues and with increased oxidative stress/insulin-sensitivity in others, with a pro-
inflammatory state in some pathological cases and with an anti-inflammatory state in others. 
Therefore, a detailed research of its biology could offer a solid base for building a theoretical 
model to test the validity of the predictions made by different theories mentioned above about the 
relationships between the levels of oxidative stress and the extent or the intensity of ageing.  
 
 
                           1.3     Nuclear receptors and ageing    
   
                             Nuclear receptors (NRs) are a family of transcription factors that in the human 
genome are encoded by 48 different genes (Bensinger and Tontonoz, 2008).  The general structure 
of NRs is composed of a ligand binding domain, a DNA binding domain and other modulator 
domains required for protein-protein interactions (Evans, 2005). Nuclear receptors can reside in the 
nucleus or in the cytoplasm. The majority of nuclear receptors are activated after the binding of 
ligand, while some are active in a constitutive fashion (Mangelsdorf et al., 1995).  Based on 
structure and ligand, nuclear receptors can be classified in three main classes:  
           1. steroid subgroup that binds to DNA as heterodimers, comprising different subtypes such 
as glucocorticoid, androgen, estrogen and progesterone;  
           2. orphan subgroup that has no ligand identified yet, such as NR4As;  
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           3. adopted orphan receptors subgroup that act as heterodimers with retinoid x receptors 
(RXRs) and need a ligand  for activation, such as peroxisome proliferator activated receptors 
(PPARs) and liver X receptors (LXRs) (Chawla et al., 2001).   
                            Nuclear receptors have important roles in regulating the transcription (by 
activation or repression) of genes that control the metabolism, inflammation and stress-
responses (Giguere, 1999). Besides their role as transcriptional regulators nuclear receptors 
have also crucial non-genomic effects such as the cytosolic modulation of the activity of ion 
channels, protein kinases, protein phosphatases or phospholipases, therefore indirectly 
regulating the glucose and lipid metabolism or the antioxidant status (Ordonez-Moran and 
Munoz, 2009). The ability of nuclear receptors to bind hydrophobic, lipophilic ligands 
opened the possibility of screening new compounds (natural or synthetic) to be used in 
clinical practice to target the associated signalling networks regulating inflammation, 
metabolism or oxidative stress that are underlying the mechanisms of pathological conditions 
associated with ageing (Carlberg and Dunlop, 2006). It is already known the roles of some of 
nuclear receptors such as retinoid receptors (Saurat, 1995) and glucocorticoid receptors 
(Djordjevic-Markovic et al., 1999) in ageing, but less is known about relationships between 
PPARs and ageing.           
  Some of PPAR agonists were discovered to have PPAR-independent effects.  
For example, troglitazone could not increase PPRE activity in SZ95 cells without the 
previous overexpression of exogenous PPAR-γ and several types of antagonist treatment or 
ectopic expression of a dominant negative PPAR-γ form failed to change the inhibition of 
cyclin D1 expression and the regulation of the cell cycle (He et al., 2004). The safety of 
PPAR agonists came also into question recently after it was showed that TZDs administration 
in human patients with diabetes increased the risk for bone fracture (Kahn et al., 2008). 
Similarly, rosiglitazone increased the risk of cardiovascular diseases. The explanation 
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proposed was based on the fact that the above mentioned agonist blocked also the 
phosphorylation levels of PPAR-γ by Cdk5 at Ser273 residue, changing the expression of 
many genes involved in obesity and insulin-resistance.  
  
 
 
                1.3.1 PPARs and the ageing phenotype         
     Peroxisome proliferator activated receptors (PPARs) are a type of ligand-activated 
nuclear receptors that were considered as a distinct class because of a shared, typical domain 
structure.  PPAR-α was the first member of the PPAR family to be identified when it was found to 
be activated by rodent hepatocarcinogenic agents that also caused proliferation of peroxisomes 
(Issemann and Green, 1990). The other two members, PPAR-γ and PPAR-β/δ, were cloned two 
years later due to structure similarity with PPAR-α (Dreyer et al., 1992). The PPARs large Y-
shaped hydrophobic pocket of the ligand-binding domain can accommodate a large variety of 
lipophilic compounds with an acidic head group (Gampe et al., 2000). This distinct feature was 
exploited experimentally in order to screen for natural or synthetic compounds that could activate 
or block PPARs function. The first clue came from clinical trials of patients with type 2 diabetes 
that showed a reduced level of fasting glucose in plasma upon administration of clofibrate (Barnett 
et al., 1977), and later it was discovered that clofibrate is a ligand of PPAR-α (Mehendale, 2000). 
Recently it was also discovered that thiazolidinediones are potent PPAR-γ agonists that can be used 
in the treatment of insulin resistance (Ghazzi et al., 1997), and activation of PPAR-β/δ by its 
specific agonists such as L-165041 was shown to reduce the levels of circulating insulin and 
triglycerides in animal models of obesity (Leibowitz et al., 2000). These initial scientific 
breakthroughs stimulated an exploratory stage of screening new compounds targeting PPARs in 
order to treat many pathological conditions associated with ageing, although many of these 
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molecules were later shown to have significant clinical side effects (Cheatham, 2010).   
  The administration of PPARs agonists or changes in PPARs expression had so far 
no obvious effect on lifespan, but there are good reasons to consider that PPARs can influence 
indirectly the development of ageing phenotypes. For example, it was discovered that PPAR-γ 
agonists treatment increased in human embryonic kidney 293 cell line (HEK293) the expression of 
antiageing gene klotho, discussed above, through the binding to a noncanonical PPAR-response 
element (Zhang et al., 2008). Although PPAR-α agonists property of  hepatocarcinogenicity in 
rodents (although not in humans) was shown to increase with age (Youssef and Badr, 2005), the 
activation of the receptor was able to reduce the inflammation in a model of T-cell ageing through 
the repression of T-bet (Jones et al., 2002). PPAR-β/δ signalling is also involved in ageing-
associated diseases since it was shown that its activation induced myonuclear accretion and 
increase in the number of oxidative fibers in the skeletal muscle, delaying sarcopennia (Giordano et 
al., 2009). It was also shown that PPAR-β/δ is regulating the expression level of sirtuin1 gene that 
has anti-ageing properties (Okazaki et al., 2010). All PPARs have important antioxidant and anti-
inflammatory effects in different tissues, with a few minor and specific differences not fully 
understood yet. Nevertheless, within PPAR family only PPAR-β/δ has the most consistent 
behaviour as an antioxidant and anti-inflammatory mediator across multiple tissues, especially in 
skeletal muscle (Luquet et al., 2003). In addition, PPAR-β/δ is expressed in skeletal muscle at 
higher values compared to the other two types (Muoio et al., 2002), which suggest a possible local 
preeminent role. Therefore, in the next chapters dedicated to PPARs a special attention will be paid 
to PPAR-β/δ.  
               I will present below the accumulated knowledge underlying the possible 
connections between PPAR-β/δ and the regulation of cellular stress and inflammation in the 
context of ageing-associated diseases. Although the focus of my thesis will be on skeletal muscle 
models of ageing, summarizing the current knowledge about the role of β/δ in regulating the 
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mechanisms of oxidative stress and inflammation in other tissues will be useful in interpreting the 
results presented in following chapters.                    
 
 
 
                       1.3.1.1          The role of PPAR-β/δ in regulating oxidative stress and 
inflammation   
                        The first PPAR-β/δ knock-out model developed had no obvious skin defects, but the 
skin from  mutant mice treated with the compound o-tetradecanoylphorbol-13-acetate (TPA) to 
induce epidermal differentiation showed a much bigger hyperplastic phenotype than the control 
group (Peters et al., 2000). In addition, the skin from PPAR-β/δ knock-out models showed an 
impaired or delayed reduction in TPA-induced inflammatory response compared to wild-type 
control group, when co-treated with the nonsteroidal anti-inflammatory (NSAID) anti-
inflammatory drug sulindac. The increased degree of inflammatory cells infiltration in the 
epidermis of PPAR-β/δ knock-out models indicated that PPAR-β/δ has a significant function as an 
anti-inflammatory regulator. In addition, PPAR-β/δ expression was induced in primary 
keratinocytes by the treatment with cytokines such as TNF-α and interferon-gamma (IFN-γ) via 
activator protein 1 (AP-1) signalling, acting subsequently both as an anti-apoptotic factor and as a 
regulator of the keratinocyte differentiation and proliferation (Tan et al., 2001). The treatment of 
cultured keratinocytes with PPAR-β/δ agonists such as GW1514 significantly reduced the cytokine 
production upon TPA challenge and UV-B, and  treatment with cytokines such as 
lipopolysaccharide (LPS) or TNF-α increased PPAR-β/δ expression in the same type of cells 
(Schmuth et al., 2004). Another relevant discovery was that PPAR-β/δ is upregulated in psoriasis 
by lipoxygenase products due to an aberrant interaction of PPAR-β/δ with nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB) that could trigger an activation of a cellular 
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hyperproliferative programme in the skin (Westergaard et al., 2003). In another experiment the 
keratinocytes from PPAR-β/δ-null mice treated with TPA had increased myeloperoxidase (MPO) 
activity levels compared to the control keratinocytes, a marker of skin inflammation (Kim et al., 
2006). Subsequent independent studies proved that PPAR-β/δ is more than a simple inhibitor of 
inflammation, having complex roles. For example, it was shown that  PPAR-β/δ is involved in the 
regeneration process of wounded skin by modulating the temporal expression and spatial 
localization of growth factors such as fibroblast growth factors (FGFs) and platelet-derived growth 
factor (PDGF) and of pro-inflammatory cytokines  such as TNF-α and interleukin-1β (IL-1β) at 
certain sites around the injury (Michalik et al., 2001; Tan et al., 2004; Tan et al., 2002), events that 
are required for an efficient and fast regeneration. These discoveries proved that PPAR-β/δ could 
be an important target in the treatment of ageing-associated diseases affecting skin by modulating 
the expression of crucial genes regulating oxidative stress and inflammatory response.   
      PPAR-β/δ is the most promising member of PPARs family in treating skeletal muscle 
dysfunctionalities during ageing. It was shown for example that PPAR-β/δ has a major role in 
regulating oxidative stress responses and inflammation in skeletal muscle. An important clue came 
from a conditional transgenic model mice expressing PPAR-β/δ in skeletal muscle that showed a 
considerable increase in oxidative fibers in various fibers types like tibialis, plantaris and soleus 
based on the number of succinate dehydrogenase-positive cells (Luquet et al., 2003). PPAR-β/δ 
skeletal muscle-specific transgenic mice had also increased activities of antioxidant enzymes like 
citrate synthase and β-hydroxyacyl-CoA dehydrogenase, a leaner phenotype and a reduced amount 
of fat that it is similar with the phenotype of the exercise models of muscle activity in rat, mice and 
humans. Other studies showed that the administration of the PPAR-β/δ agonist GW-501516 
improved the metabolic syndrome phenotype in skeletal  muscle induced by a high-fed diet, 
enhancing metabolic rate and fatty acid β-oxidation, proliferation of mitochondria and reducing the 
levels of  lipid droplets (Grimaldi, 2005; Luquet et al., 2005). The mechanisms regulated by the 
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PPAR-β/δ were deciphered in vitro by using rat L6 skeletal myotubes treated with GW-501516 
agonist that showed an upregulation of genes involved in fatty acid transport, β-oxidation and 
mitochondrial respiration, switching therefore the fuelling choice from glucose to lipids (Tanaka et 
al., 2003). The transfection of mouse C2C12 skeletal myotubes with a PPAR-β/δ dominant 
negative construct reduced the anti-inflammatory effects induced by the compound 
tricarbonyldichlororuthenium (([Ru(CO)3Cl2]2)) that  inhibits NFkB activation by TNF-α (Woo et 
al., 2006). A significant proof that PPAR-β/δ is critical for antioxidant defence came from the 
discovery that in skeletal muscle PPAR-γ coactivator-1α (PGC1α) is also a target of PPAR-β/δ 
(Hondares et al., 2007). The role of PPAR-β/δ in regulating inflammatory response in muscle was 
suggested by the discovery that NFkB-signalling was activated in vitro in mouse C2C12 myotubes 
upon incubation with palmitate, event that was inhibited by the activation of PPAR-β/δ with the 
agonist L-165041 (Jove et al., 2005). Therefore PPAR-β/δ activation could effectively reduce the 
oxidative stress and inflammation underlying the development of ageing-associated diseases 
affecting skeletal muscle.                
      PPAR-β/δ is widely expressed in brain, especially in late embryonic stage 
(E18.5) (Woods et al., 2003). It is expressed  mainly in the entorhinal cortex, cerebellum and 
hippocampus, with a higher level of expression in neurons and oligodendrocytes than in astrocytes 
(Heneka and Landreth, 2007). PPAR-β/δ null mice showed also a defective CNS myelination 
especially in corpus callosum (Peters et al., 2000). The modelling of focal cerebral ischemia in 
mice showed that infarct size was increased in PPAR-β/δ null animals that had bigger levels of 
lipid peroxidation and reduced levels of glutathione, uncoupling protein 2 (UCP-2) and superoxide 
dismutase (Arsenijevic et al., 2006), known antioxidants. The administration of PPAR-β/δ agonist 
GW0742 increased the overall protection in an animal model of experimental encephalomyelitis 
(EAE) by reducing the astroglial and microglial inflammatory activation (Polak et al., 2005). The 
administration of PPAR-β/δ agonists such as L-165041 and GW-501516 protected further against 
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damaging agents by reducing ROS levels in human dopaminergic neuroblastoma SH-SY-5Y cell 
line  treated with thapsigargin to model  Parkinson’s effects (Iwashita et al., 2007). Furthermore, 
the activation of PPAR-β/δ in this SH-SY-5Y cellular model reduced the level of oxidative stress 
and the activation of caspase-3/7, a main executioner of apoptosis (Arsenijevic et al., 2006). The 
modelling of postnatal development of the brain in vitro by re-aggregating neuronal cultures 
showed that enzyme acyl coA synthetase 2 (ACS2) is a target for PPAR-β/δ (Basu-Modak et al., 
1999), being involved in fatty acid metabolism, neurite outgrowth and inflammatory responses in 
spinal cord (Benani et al., 2003). PPAR-β/δ is therefore a potent antioxidant and anti-inflammatory 
mediator in brain.             
            PPAR-β/δ has an important hepatic function by decreasing glucose 
consumption and by increasing insulin sensitivity (Lee et al., 2006), by promoting fatty acid 
synthesis and by reducing the lipid droplets content (Nagasawa et al., 2006). In addition, PPAR-β/δ 
has immunomodulatory properties, interfering with IL6-induced acute phase reactions in liver and 
inhibiting the transcriptional activity of STAT3 (Kino et al., 2007).  PPAR-β/δ agonist treatment 
also decreased the level of expression of cyclooxigenase-2 (COX-2) in human hepatocellular 
carcinoma line HepG2 (Glinghammar et al., 2003), which is a known regulator of inflammatory 
mechanisms and oxidative stress.         
            PPAR-β/δ is also an important regulator of lipid-induced inflammation and 
oxidative stress in the cardiovascular system. For example, the activation of PPAR-β/δ by its 
specific agonist GW0742X reduced the atherosclerotic markers in low density lipoprotein receptor 
(LDLR) null mice (Graham et al., 2005). Surprisingly, the deletion of PPAR-β/δ from macrophages 
further reduced the atherosclerotic lesions areas by 50% in LDLR null mice and lowered 
considerably the levels of inflammatory cytokines (Lee et al., 2003). The possible explanation 
could be the binding of PPAR-β/δ in unligated form to the transcriptional repressor Bcl-6, blocking 
its activation.  Once activated by a specific ligand PPAR-β/δ releases Bcl-6 that will further block 
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the expression of pro-inflammatory cytokines such as MCP-1. In knock-out models Bcl-6 is 
constitutively activated and therefore constantly represses inflammation, which explains the 
reduction in atherosclerotic lesions observed. In the current proposed model PPAR-β/δ acts a non-
conventional switch by selectively repressing or activating the inflammatory pathways, depending 
on the status of the ligand binding to it. In the free form it sequesters inflammation repressors, but 
once interacting with the ligand it releases the regulators of inflammation. This proves that PPAR-
β/δ has complex roles in regulating inflammatory mechanisms, and further research is still required.  
 
 
       1.4 Skeletal muscle and ageing  
 
                              During ageing skeletal muscle progressively develops an atrophic phenotype 
characterized by a reduced mass, fewer fibers and impaired contractility, a condition described also 
as frailty (Faulkner et al., 2007). The sarcopenic pathological condition affecting skeletal muscle is 
multifactorial (Fujita and Volpi, 2004). Sarcopenia can be managed by interventional approaches 
such as diet and exercise (Bautmans et al., 2009),  strategies also known as healthy ageing (Franco 
et al., 2009). The roles of an improved antioxidant defence system and of a reduced level of 
inflammation in the development of a successful healthy ageing phenotype have been deciphered 
recently (McArdle et al., 2002). The progression of ageing and of ageing-associated diseases 
changes also the functionality of the signalling pathways regulated by different classes of nuclear 
receptors (Baltgalvis et al., 2010; Diep and Constantinou, 1999; Kannisto et al., 2006; Oudin et al., 
1998; Steinbach and Chen, 1995; Torlinska et al., 2000). Particular attention  was paid to PPARs 
family (Lopez-Soriano et al., 2006) since, as described in the previous subchapter, their agonists 
have been employed with moderate success in many clinical trials for the treatment of pathological 
conditions affecting skeletal muscle such as insulin resistance (Cha et al., 2001; Shibasaki et al., 
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2003; Ye et al., 2001), metabolic inflexibility (Sugden et al., 2009), muscle waste (Moore-Carrasco 
et al., 2008), inflammation (Jove et al., 2005), sustained oxidative stress (Ceolotto et al., 2007) and 
hypoxia (O'Hagan et al., 2009).  Therefore a deep understanding of the functional and structural 
changes in nuclear receptors-associated signalling pathways during myocyte ageing is required for 
a proper management of the diseases affecting skeletal muscle. The physiology of skeletal muscle 
is also modulated by the action of adipokines and cytokines (Dyck et al., 2006; Vu et al., 2007), 
especially in the case of antioxidant defence mechanisms and inflammatory mediators (Eckardt et 
al., 2008; Havekes and Sauerwein, 2010). The exploration of the effects of newly identified 
adipokines such as visfatin on skeletal muscle antioxidant defence mechanisms and inflammatory 
mediators will further improve our knowledge about relationships between adipokines and ageing, 
and hopefully it will make possible the development of effective and safe clinical interventions.         
          My thesis will explore the possible existence of any changes occurring during skeletal 
muscle ageing in the expression of nuclear receptors families and of their associated signalling 
pathways, especially PPARs, by using multiple in vivo and in vitro models. The thesis uses 
opposite in vivo models of ageing:  a model of accelerated ageing affecting skeletal muscle 
(hindlimb suspension in mice), and a model of skeletal muscle healthy ageing strategy (caloric 
restriction in rats).  The hypothesis is that during ageing there are major changes affecting nuclear 
receptors (NR) expression levels (especially PPARs) that could have an impact on the progression 
of ageing-associated diseases. To explore them I will use microarray assays to identify any changes 
in NR expression by the above mentioned modelling strategies followed by RT-PCR and western 
blot.                  
                     The second part of my thesis will be focused on the exploration of any possible effects 
of extracellular form of visfatin (eNampt) on skeletal muscle physiology, with a special emphasis 
on the oxidative stress production and antioxidant defence mechanisms, insulin sensitivity and 
inflammation. The hypothesis is that a possible increase in visfatin plasma concentration during 
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ageing (yet to be determined) could have a significant impact on cellular processes affecting 
skeletal muscle relevant for the development of ageing-associated disease. For this I will employ an 
in vitro model (C2C12 mouse myotubes) and incubation with purified visfatin, followed by 
measurements of the levels of ROS, of the levels and pattern of oxidized products, estimation of the 
status of the antioxidant defence, of the activation/inhibition of signalling pathways relevant for 
insulin sensitivity and stress responses by using western blot and RT-PCR (PI3K/Akt, MAPKs and 
NFkB). The changes in NR expression such as PPARs will be monitored by RT-PCR and western 
blot. The study will hopefully offer a better theoretical understanding of the roles of nuclear 
receptors and visfatin in regulating oxidative stress and inflammation in skeletal muscle, 
information that could be used in the clinical practice focused on the treatment of ageing-associated 
diseases.  
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Chaptter  2--   MATERIALS  AND  METHODS  
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Cell culture  
            Murine-derived C2C12 cells were purchased from ECACC (European Collection of Cell 
Culture, 91031101) and proliferated as myoblasts in 4.5 g/l glucose Dulbecco's Modified Eagle's 
Medium (Sigma, Dorset UK D6546) supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin (Sigma, P0791), 2mM glutamine  (Sigma, Dorset UK G7513) and 15% FCS (Sigma, 
Dorset UK C5280). The medium was changed every two days and the semi-confluent cultures were 
seeded at a density of 2000/cm2. To obtain the differentiated myotubes C2C12  myoblasts were 
grown until reaching 95% confluence and further incubated for 4-6 days in differentiation medium 
consisting of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 2mM glutamine 
and 5%  horse serum (Sigma, Dorset UK H1270). The differentiation medium was changed every 
day, and after reaching the level of optimal fusion and differentiation C2C12 myotubes were 
further cultured in antibiotic-free and serum-free medium for an additional 24 hrs before being 
subjected to any experimental procedures.  
 
Visfatin and other pharmacological treatments  
             All visfatin and blocking treatments experiments were performed in antibiotic-free and 
serum-free differentiation medium. Murine visfatin produced in bacteria by using a His-tag 
(Biovision, Inc, Mountain View Ca, USA 4908-50; or MBL, Woburn, MA USA JM-4908-50) or in 
HEK 293 cells by using a FLAG-tag (Axxora, San Diego, CA USA ALX-201-364-C010) was 
resuspended initially in PBS at a concentration of 0.1 mg/ml and divided in small aliquots which 
were frozen at -20○C. Before each experiment one vial was de-frozen and further diluted to the 
final concentration of 100ng/ml in PBS. For the blocking experiments the following inhibitors 
diluted in DMEM were added to the C2C12-differentiated myotubes 1hr prior visfatin treatment:  
10 µM U0126 to block MEK1/2, the upstream activator of ERK 1/2 (Cell Signalling, Danvers, MA 
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USA9903); 10 µg/ml of the InSolution™ p38 MAP Kinase Inhibitor III (Calbiochem, Darmstadt, 
Germany 506148) to block p38 kinase; 0.1 µM of Cycloheximide Ready-Made Solution (Sigma, 
Dorset UK C4859) to block translation; 1 µg/ml of Actinomycin D ( Sigma, Dorset UK A9415) to 
block transcription; 50 µg/ml IκB Kinase Inhibitor Peptide (Calbiochem, Darmstadt, Germany 
401477) to inhibit IKK α/β, the upstream activator of NFkB; 1 mM N-acetyl-L-cysteine (NAC, 
Sigma Dorset UK A9165) to scavenge ROS. Before incubation with visfatin cells were washed 
three times with antibiotic-free and serum-free differentiation medium to remove any trace of 
inhibitor.                                  
     To activate PPAR-β/δ signalling the agonist GW-501516 (Axxora, San Diego, CA 
USA ALX-420-032) was resuspended initially in DMSO and diluted to the antibiotic-free and 
serum-free differentiation medium to the working concentration of 10 nm before being added to 
C2C12 cells for 24 hrs, DMSO being employed as a vehicle. To model the effects of accumulation 
of lipids in cultured myotubes StructolipidTM  emulsion (Fresenius Kabi, Bad Homburg v.d.H. 
Germany) was diluted 1/100 in the antibiotic-free and serum-free differentiation medium to a 
concentration of 0.2 mg/ml of triglycerides and incubated for indicated times.  
 
Measurement of oxygen free radical production  
           Cells were washed three times in PBS and incubated at 37○C with 25 µM carboxy-
H2DCFDA diluted initially in DMSO than in PBS at the working concentration (Invitrogen, 
Paisley UK I36007) for 30 minutes, used for the detection of reactive oxygen species at 495/529 
nm.  In order to visualize the nuclei at 360/450 nm1 µM Hoechst 33342 from the same I36007 kit 
was added in the last 5 minutes of incubation. For the detection of superoxide anions the kit 
MitoSOXTM (Invitrogen, Paisley UK M36008) was used by diluting the fluorescent compound in 
initially in DMSO than in PBS at the working concentration of 5 µM for the same range of time, 
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followed by imaging at 510/580 nm. For the detection of hydrogen peroxide I used the compound 
pentafluorobenzenesulfonyl fluorescein (Cayman Chemical, Ann Arbor MI USA 10005983) 
diluted initially in DMSO than in PBS at the working concentration of 1 µg/ml for the same range 
of time, followed by imaging at 485/529. Cells were further washed three times in PBS, re-
incubated in fresh PBS and subjected to the fluorescent-based assays that were performed in two 
ways. The first was based on fluorescent microscopy imaging by using a Leica DFC420 camera 
(Leica Microsystems, Wetzlar Germany) attached to a Leica DMIRBE microscope with the 
following filter cubes: A, I3 and N2.1.  Image analysis was performed with the Image J 1.37c 
(Wayne Rasband, NIH, http://rsb.info.nih.gov/ij/plugins/imagej-updater.html).   The quantification 
of the fluorescent signal from 4-5 cells from each well was divided to the background/noise of the 
well and the statistical values (mean, standard deviation and significance) were computed by using 
Excel (Microsoft Office 2003, Microsoft Redmond, WA USA). The second choice was based on 
the Fluorometric Imaging Plate Reader FlexStation II (Molecular Devices, Sunnyvale CA USA) 
that performed automatically the detection of signal and the computation of values at the same 
wavelengths as specified above. In this case the nuclear staining step was avoided. The recording 
values were divided to the blank and the statistical values (mean, standard deviation and 
significance) were computed by using Excel (Microsoft Office 2003, Redmond, Washington, 
USA). 
 
Measurement of the rate of glucose uptake  
                  C2C12 cells were washed after treatment 3 times in warm PBS and incubated for 30 
minutes at 37°C  with 0.1 mg/ml of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose (2-NBDG) (Invitrogen, Paisley UK N13195), diluted in warm PBS. After the 
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incubation cells have been washed for 5 times with warm PBS, and the signal detection was 
performed by imaging at 495/529 nm.  
Western blotting 
              Differentiated C2C12 myotubes grown in 12 wells plates were washed three times in ice-
cold PBS and lysed by using ice-cold cell lysis buffer (Cell Signalling, Danvers, MA USA 9803) 
with 1mM PMSF. For the detection of phospho-proteins 5 mM NaF was also added (Sigma, Dorset 
UK). In the case of the experiment that tested the possibility of visfatin transport (Fig. 6.1) an 
additional step of cell washing for three times by using warm DMEM before the ice-cold PBS wash 
step was performed, in order to detach the visfatin that could have been bound to any receptor 
localized at the plasma membrane. Cells were scraped from the wells and transferred to 1.5 ml 
Eppendorf® Biopur™ tubes, which were incubated for an additional 40 minutes on ice with gentle 
inversion every 10 minutes, the degree of lysis being inspected visually. Cell lysates were 
centrifuged at 14,000 rpm at 4°C for 15 min, and the supernatant was transferred to a new tube 
from which five microliters of cell lysates were sampled for protein quantification by using the 
BCA kit (Perbio Science, North Nelson Industrial Estate Cramlington, Northumberland 23225).    
  For the detection of oxidized proteins the OxyblotTM kit was used (Millipore, Billerica MA 
USA S7150). To detect the levels of oxidized proteins 50 mM DTT was added to the cell lysis 
buffer. From each sample 5 µl was mixed with 5 µl of 12% SDS to denature the proteins. To 
derivatize the proteins 10 µl of 1x DNPH was added and the tube was incubated for 15 minutes at 
RT. To end the reaction 7.5 µl of neutralization solution was added and the proteins were loaded on 
the gels without boiling. For the experiment described in chapter 3, skeletal muscle sample tissues 
taken from control and HLS-mice were homogenized initially in ice-cold cell lysis buffer by using 
a Precellys®24 system (Bertin Technologies, Enim group France) with CK28 ceramic beads, 
followed by the same procedure as above.                       
     For the detection of phospho-proteins I used the following kits and antibodies: phospho-
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Akt-pathway sample kit (Cell Signalling, Danvers, MA USA 9916); NFkB pathway sampler kit 
(Cell Signalling, Danvers, MA USA 9936); and phospho-MAPK family sampler kit (Cell 
Signalling, Danvers, MA USA catalogue number 9910). For the detection of visfatin I used a rabbit 
polyclonal antibody (Abcam, Cambridge UK catalogue number ab72128) or an antibody raised in 
mouse against the FLAG-tag (Abcam, Cambridge UK 18230). In chapter 3 I used the rabbit UCP-3 
(Abcam, Cambridge UK ab3477) and rabbit PPAR-β/δ (Abcam, Cambridge UK 8937) antibodies. 
As loading controls, mouse monoclonal antibodies against GAPDH (Abcam, Cambridge UK 9484) 
and beta-actin (Abcam, Cambridge UK 8224) have been used.  To detect the levels of nitro-
tyrosines a mouse monoclonal antibody was used (Millipore, Billerica MA USA CC22.8C7.3).                    
  Briefly, 60 µg of protein supplemented with 1x NuPage sample reduction agent 
(Invitrogen, Paisley UK NP0004) was boiled in NuPage LDS sample buffer (Invitrogen, Paisley 
UK NP0007) for 10 minutes at 70○C and then separated in 10 wells Novex Bis-Tris 4-12% gels 
(Invitrogen, Paisley UK NP0335BOX) or in 12 wells Novex Bis-Tris 10% gels (Invitrogen, 
NP0322BOX) by using NuPAGE SDS-MOPS (Invitrogen, Paisley UK NP0001) or NuPAGE SDS-
MES running buffer (Invitrogen, Paisley UK NP0002). For electrophoresis I used XCell 
SureLock™ Mini-Cell system (Invitrogen, Paisley UK EI0001) attached to PowerEase® 500 power 
supply (Invitrogen, Paisley UK EI86000). The proteins were transferred onto a nitrocellulose 
membrane (Schleicher and Schuell, Dassel Germany) by using NuPAGE transfer buffer and Mini 
Trans-Blot Cell system (Bio-Rad, Hemel Hempstead UK 170-3930) connected to  PowerEase® 
500 power supply (Invitrogen, Paisley UK EI86000).  After transfer the membrane was washed for 
5 minutes in TBS before being blocked for 1 hr in TBS with 5% BSA and 0.1% Tween-20. All 
primary antibodies were diluted 1:1000 in 1x TBS with 5% BSA and 0.1% Tween-20 and 
incubated with the blot overnight at 4○C with gentle rocking (30 rpm). The membrane was washed 
with TBST three times for 15 minutes each, and then incubated for 1 hr with the goat anti-rabbit-
HRP secondary antibodies (Cell Signalling, Danvers, MA USA 7074) provided by each kit 1:2000 
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in 1x TBS with 5% BSA and 0.1% Tween-2. For the detection of mouse-raised antibodies I used a 
secondary horse anti-mouse-HRP antibody (Cell Signalling, Danvers, MA USA 7076) or a donkey 
anti-mouse-HRP antibody (Jackson laboratories, 715-035-150) diluted 1:10,000 in 1x TBS with 5% 
BSA and 0.1% Tween-20. The membrane was further washed three times in TBST for 15 minutes 
each, followed by another wash for 5 minutes in TBS. The chemiluminescent signal was detected 
using SuperSignal West Pico substrate (Perbio Science, North Nelson Industrial Estate 
Cramlington, Northumberland 34077) and a ChemiDoc XRS system (BioRad, 170-870). The 
images were saved electronically by using Quantity One 1 (Bio-Rad, Hemel Hempstead UK 160-
9601) and exported to Adobe Photoshop CS2 (Microsoft Office, Microsoft Redmond, WA USA). 
As a loading control, the HRP-bound GAPDH antibody was used (Abcam, Cambridge UK ab9482) 
diluted 1:5000 in 1x TBS with 5% BSA and 0.1% Tween-20. 
 
RNA extraction and cDNA synthesis  
                 To extract RNA from cells and tissues I used the TRIzol method (Invitrogen, Paisley UK 
15596018) and Qiagen RNeasy kit (Qiagen, Düsseldorf Germany catalogue number 74104). I 
added 1ml of TRIzol directly on wells after a three-cycle washing step with warm PBS and 
transferred the cells to a tube to which I added 0.2 ml of chloroform. The tube was vortexed 
vigorously at RT for 10 seconds, and then incubated for another 2 minutes at RT. The tube was 
centrifuged at 4○C for 10 minutes at 14,000 rpm and after that 0.5 ml of the aqueous (upper phase) 
was taken from the tube. To this phase I added 0.5 ml volume of absolute ethanol cooled at -20C 
and mixed thoroughly, followed by filtering on a Qiagen RNeasy spin column and centrifugation 
for 1 minute at RT at 12,000 rpm. After 1 cycle of washing with 700 microliters of RW1 buffer and 
another two cycles of washing with 700 microliters and respectively 500 microliters of RPE buffer 
at RT for 30 seconds at 14,000 rpm, the column was dried by a further centrifugation for two 
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minutes at the same conditions. 50 microliters of DEPC-treated water was added to the column and 
incubated for 15 minutes at RT. The RNA was eluted by centrifugation at 12,000 rpm at RT for 1 
minute. The quantification and quality control of RNA were performed by using Bioanalyzer 2100 
system (Agilent, Santa Clara CA USA catalogue number G2938C) and RNA 600 Nano chips 
(Agilent, Santa Clara CA USA catalogue number G2938-90034).  Before cDNA synthesis I 
digested the RNA with DNase I (Sigma, Dorset UK AMP-D1) in order to remove any trace of 
genomic DNA that might affect the RT-PCR assays. 0.5 micrograms of RNA was diluted in DEPC-
treated water to a final concentration of 8 microliters and incubated with 1 microliter of 10x DNase 
reaction buffer and 1 microliter (1 unit) of Amplification Grade DNase I for 15 minutes at 37○C. 
After 15 minutes I added 1 microliter of STOP solution (50 mM EDTA) for the chelation of 
calcium and magnesium ions, and the tube was incubated at 70○C for 10 minutes followed by a 5 
minutes step of cooling the tubes on ice.  To obtain the cDNA I used the Superscript III First strand 
synthesis system (Invitrogen, Paisley UK catalogue number 18080-051). Briefly I mixed the RNA 
with 1 microliter of 10 mM dNTP mix and 1 microliter of 50 ng of random hexamers and incubated 
the mixture at 65○C for 5 minutes, then cooled it on ice for another five minutes. I further added 2 
microliters of 10x first-strand buffer, 4 microliters of 25mM MgCl2, 1 microliter of 0.1M DTT, 1 
microliter of RNaseOUT (40 units) and 1 microliter (200 unit) of SuperScript III RT to the tube. 
After gentle mixing the tube was incubated initially at 25○C for 10 minutes and later at 50○C for 60 
minutes. The reaction was stopped at 70○C for 15 minutes, and then tube was chilled on ice. To 
remove any trace of RNA I added 1 microliter (2 units) of RNase H from E. coli for 20 minutes at 
37○C.    
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     Real Time Quantitative Reverse-Transcription PCR (Q-PCR) 
                The Bio-Rad I-Cycler (Bio-Rad, Hemel Hempstead UK) with FAM-490 system detection was 
employed for real time quantitative RT-PCR by using the Platinum® Quantitative PCR SuperMix-UDG 
(Invitrogen, Paisley UK catalogue number 11730-025).  PCR thermocycler conditions were 50°C for two 
minutes, 90°C for two minutes followed by 45 cycles of 95°C for 15 seconds and 60°C for 60 seconds. 
All samples were run in triplicate with both primer sets and the control genes to normalize the differences 
in amount of starting material. Fold changes were calculated using the 2-∆∆Ct method. Statistical analyses 
were performed using Student’s t-test.  A p-value of less than 0.05 was considered significant. The 
following probes from Taqman (Applied Biosystems, Life technologies Carlsbad, California USA) have 
been used: mouse samples (PPAR-β/δ, Mm00803186_g1; PPAR-α, Mm00440939_m1; PPAR-γ, 
Mm00440945_m1; NOX4, Mm00479246_m1; TNF-α, Mm00443258_m1; IFN-γ, Mm99999071_m1; 
IL-6, Mm99999064_m1; IL-15, Mm00434210_m1; UCP-3, Mm01163394_m1; GLUT-1, 
Mm01192270_m1; GLUT-3, Mm00441483_m1; GLUT-4, Mm01245507_g1; SOD2, 
Mm01313000_m1; GPX-3, Mm00492427_m1; SOD-1, Mm01344233_g1; HIF-1A, Mm01283760_m1; 
NRF-2 Mm00477786_m1; VEGFa, Mm01281449_m1; TRAF1, Mm00493827_m1; nNOS, 
Mm00435175_m1; SOD1, Mm01344233_g1; CAT, Mm00437992_m1; NRF1, Mm00447996_m1; 
TRAF6, Mm00493836_m1; CPT-1b, Mm00487200_m1; CPT-2, Mm00487205_m1; UCP-3, 
Mm00494074_m1; ACCα, Mm01304277_m1; ACCβ, Mm01204683_m1; RXRα, Mm00436264_m1; 
AMPKα2, Mm01264789_m1; AMPKβ2, Mm01257133_m1; PGC-1α, Mm00447183_m1; PGC-1β, 
Mm01258518_m1; YKT6 homolog (Saccharomyces cerevisiae) snare protein: Mm00457727_m1; as 
control GADPH 4352932E  and ACTB 4352933E); rat samples (Arntl, Rn00577590_m1; Runx1, 
Rn00569082_m1; NR1D1, Rn00595671_m1; Tlr2, Rn02133647_s1; Mgmt, Rn00563462_m1; Uchl1, 
Rn00568258_m1; Epn3, Rn01456494_g1; Sln, Rn02769377_s1; Casq2, Rn00567508_m1; Apln, 
Rn00581093_m1; Psmb8, Rn00589926_m1; Psmb9, Rn00562296_m1; Casp3, Rn00563902_m1; 
Tmbim1, Rn01400508_g1; NR4A1, Rn00666995_m1; NR4A2,  Rn00570936_m1; NR4A3, 
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Rn00581189_m1; SREBF1, Rn01495772_g1; FASN, Rn00569117_m1; SCD-1, Rn00594894_g1; 
GPAM, Rn00568620_m1; PPAR-γ, Rn00440945_m1; PPAR-β/δ, Rn00565707_m1; PPAR-α, 
Rn00566193_m1; PGC-1α, Rn00580241_m1; PGC-1β, Rn00598552_m1; AMPK γ3, Rn01400861_g1; 
UCP-3, Rn00565874_m1; FABP-4, Rn00670361_m1; as controls ACTB, 4352931E, GAPDH, 
4352338E). 
 
Microarray assay 
Labelling                                                                                                                                                          
600 ng RNA and 3 µl Agilent One-Colour RNA Spike-In RNA were labelled with the Agilent Low 
RNA Input Linear Amplification Kit PLUS, One-Colour according to instructions as follows:  1.2 
µl T7 Promoter Primer was added to 600 ng RNA and 3 µl spike in control and denatured at 65 ºC. 
First Strand Buffer, DTT, dNTP MMLV and RNaseOut was added. The cDNA was synthesised 
during the following incubation step (2h at 40 ºC). After 10 min denaturation at 65 ºC and the 
addition of Cy-labelled CTP, Transcription Buffer, DTT, NTP, PEG, RNaseOUT, Inorganic 
Phosphatase, and T7 RNA Polymerase the synthesis of the fluorescent labelled cRNA was 
performed during the second incubation step (2 h at 40 ºC).  The labelled cRNA was purified with 
the RNeasy Mini Kit (Qiagen Ltd, Düsseldorf Germany).  
 
Hybridisation                                                                                                                                                  
The Agilent Hybridisation Kit (Agilent, Santa Clara CA USA catalogue number 5188-5242) was 
used in conjunction with Agilent Rat Oligo Arrays.  2µg of the labelled sample RNA were used for 
hybridisation according to the Agilent One-Colour Microarray-Based Gene Expression Analysis 
Protocol The hybridisation was performed for 17 h at 65 ºC at 10 rpm. Slides were them washed for 
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1 min at 22 ºC in Wash Solution 1 (catalogue number 5188-5325) and 1 min at 22 ºC in Wash 
Solution 2, pre-warmed to 37 ºC (catalogue number 5188-5326). Slides were incubated for 30s in 
Agilent Stabilisation and Drying Solution (Agilent, Santa Clara CA USA catalogue number 5185-
5979). 
 
Scanning                                                                                                                                                      
The slides were scanned with the Agilent G2565BA Microarray Scanner System. For data 
extraction and quality control, the Agilent G2567AA Feature Extraction Software (v.9.1) was used. 
 
Microarray bioinformatics Analysis                                                                                                              
Extracted data were analysed using GeneSpring GX 7.3.1 (Silicon Genetics, CA USA). Agilent 
standard scenario normalisations for FE1-colour arrays were applied to all data sets. A subset of 
genes for data interrogation was generated that excluded controls, spots of poor quality, and gene 
probes that were present in less than 50% of samples. From these selected genes, relative 
expression in animals fed the ad lib diet was compared to animals on the caloric restriction diet.  
Genes differentially regulated by greater than 2.0-fold were selected.  One-way, parametric, 
ANOVA tests were performed followed by Benjamini and Hochberg multiple test correction with a 
false discovery rate of 0.05.  Microsoft Excel templates were prepared containing genes that were 
over- and under-expressed following CR.  
 
IngenuityTM Pathway Analysis (IPA) 
                   IngenuityTM Pathway Analysis (IPA) 3.0 (IngenuityTM Systems, CA USA) was utilised 
to assemble functional networks altered by CR.  Ingenuity entry tool systematically encodes 
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findings presented in peer-reviewed scientific publications into ontologies, or groups of genes 
/proteins related by common function.  Molecular networks of direct physical, transcriptional, and 
enzymatic interactions were computed from this knowledge base using the genes differentially 
regulated by CR.  The resulting networks contain molecular relationships with a high degree of 
connectivity and every gene in the network is supported by published literature.   
 
Measurement of the levels of oxidized lipids 
                   To measure the levels of oxidized lipids I used a LPO kit (Cayman chemical, Ann 
Arbor MI USA 705002). C2C12 cells were incubated or not with 100 ng/ml of visfatin for 24 hrs. 
C2C12 cells were scrapped from wells and sonicated in HPLC-grade water (without any metals) 
followed by extraction of lipids by sonication. 500 microliters of sonicated extract from each 
sample was added to 500 microliters of Extract R provided by kit saturated with methanol, 
followed by adding of 1 ml of deoxygenated, ice cold chloroform to the tube. After centrifugation 
at 1,500xg for 10 minutes at     4°C, the bottom layer was collected which was further added to 450 
microliters of a 1:1 mixture of deoxygenated, ice cold chloroform and deoxygenated methanol, 
followed by incubation with 50 microliters of chromogen provided by the kit (1:1 mixture of FTS 
reagent 1 consisting of 4.5 mM ferrous sulphate in 0.2 M HCl and FTS reagent 2 consisting of 3% 
of methanolic solution of ammonium thiocyanate). After 5 minutes of RT incubation, 300 
microliters from each sample was taken and measured at 500 nm in a microplate reader by using a 
glass-bottom 96-well plate. The kit is based on the following reactions:  
ROOH + Fe2+      → RO· + Fe3+ 
RO· + Fe2+  + H+  → ROH + Fe3+ 
Fe3+  + 5SCN-      → Fe (SCN-)2- 5       
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Measurement of antioxidant capability of the cells 
             To measure the antioxidant status I used a kit from Cayman chemical, Ann Arbor MI USA 
catalogue number 709001. C2C12 cells were incubated or not with 100 ng/ml of visfatin for 24 hrs, 
or with 100 µM of hydrogen peroxide for 30 minutes as a negative control. C2C12 cells were 
scrapped from the wells and sonicated in ice-cold buffer provided by the kit (5mM potassium 
phosphate, pH7.4 with 0.1% glucose and 0.9% sodium chloride) and centrifuged at 10,000xg at 
4°C for 15 minutes. 10 microliters from the supernatant was mixed with 10 microliters of 
metmyoglobin resuspended in the assay buffer provided by the kit and with 150 microliters of 
ABTS chromogen (2,2’-Azino-di-[3-ethylbenzthiazoline sulphonate), resuspended in HPLC-grade 
water. 40 microliters of 441 µM hydrogen peroxide diluted in HPLC-grade water was added to 
each well to initiate the reaction and the plate was shaked at RT for 5 minutes in the dark. Trolox 
(6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a water-soluble tocopherol analogue, 
was used as a positive control instead of samples. The measurement was done at 405 nm in a 
microplate reader.   
Measurement of cell viability 
          To measure the cell viability LDH-Cytotoxicity Assay Kit II was used (Biovision, Inc 
Mountain View, CA USA K313-500). If the plasma membrane is compromised than lactate is 
released in the culture medium and the lactate dehydrogenase from the kit will further oxidize 
lactate, generating nicotinamide adenine dinucleotide (NADH) that is recognized by the WST 
compound. The LDH reaction buffer is made of 200 microliters of WST substrate resuspended in 
HPLC-grade water with 10 ml of LDH assay buffer. Briefly, 10 microliters of culture medium were 
taken from cells incubated or not with 100 ng/ml of visfatin for 24 hrs or with 100 µM of hydrogen 
peroxide for 30 minutes as a positive control. The culture medium sampled was further added to 
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100 microliters of LDH reaction mix and incubated for 30 minutes at RT. After stopping the 
reaction with the STOP solution, the absorbance was measured at 450 nm.  
ELISA 
        To detect the existence of visfatin (eNampt) in the culture medium of C2C12 cells in basal or 
stimulated an ELISA kit (Raybiotech, Norcross GA USA VIS-EIA-1) was used. 185 microliters of 
1x Assay Diluent B containing biotinylated visfatin (BV) was mixed with 62.5 microliters of 
medium taken from wells with C2C12 cells or with the standards. The final concentration of the 
biotinylated visfatin in each tube was 10ng/ml. The 96 wells plate that had been already coated 
with goat anti-rabbit secondary antibody was further incubated with a rabbit anti-visfatin antibody. 
After 1.5 hrs the plate was washed 4 times and incubated in each well with either 100 microliters of 
mixed BV-standards provided by the kit, either with 100 microliters of mixed BV-sample medium 
from C2C12 cells prepared as above. After 2.5 hrs the plate was washed and further incubated in 
each well with 100 microliters of biotin-streptavidin solution for another 45 minutes at RT. After 
another washing step the TMB One-Step substrate was added to each well for 30 minutes with 
gentle shaking. 50 microliters of STOP solution was added and the reaction was measured at 450 
nm. As positive a serial dilution of standards staring from 1000 ng until 0.1 ng was used and 
calibrated. The minimum visfatin concentration detectable was 379 pg/ml.  
Statistical analysis 
                For computation of statistical values (average, mean, standard deviation, Student’s t-Test, 
ANOVA) and for the graphical visualization I used the Excel 2003 software (Microsoft Office, 
Microsoft Redmond, WA USA). To perform ANOVA tests I used GraphPad Prism software 
(GraphPad, La Jolla, CA USA). 
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               3A. Introduction 
  As it was recently predicted by a World Health Organization report (WHO, 2011), 
between 2000 and 2050 the aged population (over sixty years) will reach the landmark of two 
billion worldwide and 85% of them will live in the developing world. This aged population is 
expected to have an increased lifespan and a higher degree of an active lifestyle than at present. 
Medical problems encountered in current aged populations include cancer, osteoporosis, 
neurodegeneration and dementia, arthritis, cardiovascular diseases, stroke, sarcopennia and frailty, 
glaucoma and hearing loss, metabolic syndrome and obesity (Fontana et al., 2010). Therefore, a 
proper theoretical understanding of the cellular signalling pathways underlying the pathogenesis of 
ageing-associated diseases is required in order to design better therapies for the groups affected or 
better preventive strategies for the groups at risk. The role of the biomedical research is 
consequently to decipher the mechanisms leading to biological ageing and to imagine new ways to 
prevent (or at least delay) the detrimental symptoms associated with increased age.                                               
During ageing the skeletal muscle is characterized by significant changes in myofibre 
number, mass, size and structure and by a defective excitation-contraction coupling system (Rossi 
et al., 2008). Such changes are associated with altered gene expression, increased cell death and 
reduced cell survival, increased oxidative and nitric stress, inflammation, ER-stress and hypoxia. 
These events result  in a reduced muscle mass and strength, impaired endurance and contractility 
and reduced regenerative properties partially due to an increased cell death rate of satellite cells 
(Gopinath and Rando, 2008), being noticeable also a transition toward a slower-twitching muscle 
fibre type which exhibits a shift to a  more aerobic-oxidative metabolism (Doran et al., 2009). In 
addition, the skeletal muscle from older human adults presents a significant accumulation of large 
intracellular lipid droplets and a changed interaction with a fewer number of mitochondria. This 
lipid accumulation during ageing is further associated with an impaired mitochondrial bioenergetic 
process that is increasing the levels of ROS (Crane et al., 2010).  
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                  This study used two approaches to model the effects of ageing on skeletal muscle.               
One was designed to study the effects of accelerated ageing process by using the hindlimb 
suspension method in mice (HLS), and one designed to explore the mechanisms of delayed or 
improved ageing phenotypes in rats subjected to caloric or dietary restriction (CR/DR). In order to 
investigate the changes induced by these two approaches a global genome profiling by using 
microarray was performed as described above, followed by data analysis. To confirm the changes 
identified by microarray the findings were further validated by using RT-PCR and western blot.  
The main goal of this chapter was to identify changes in the expression of families of nuclear 
receptors and other transcriptional regulators, since this could offer useful tools for targeting the 
ageing-associated diseases affecting skeletal muscle. 
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                          3B. Results 
                               3.1 Identification of the early-responsive genes induced by hindlimb 
suspension in mice 
                                  The hindlimb suspension method (HLS) is widely employed in animal models 
to investigate the effects of inactivity on skeletal muscle physiology characterizing human skeletal 
muscle during ageing, bed rest or spaceflight (Cartee, 1995; Chapes and Ganta, 2005; Morey-
Holton et al., 2005; Riley et al., 1995). Most studies have used this method to explore the long-
term, chronic effects of inactivity (St-Amand et al., 2001), but less is known about the short-term, 
acute effects. Our collaborators from the University of Kentucky (Dr. Reid lab, Lexington, USA)  
performed the unloading experiments by keeping murine hindlimb suspended for short-term (1 
day) or long-term (12 days), followed by the sampling of  skeletal muscle (soleus and 
gastrocnemius) as described above  (Matuszczak et al., 2004). In order to study the changes 
induced by acute HLS on global skeletal muscle gene expression profile, RNA was extracted in our 
laboratory from gastrocnemius and soleus samples from both control and 24 hrs HLS animals (n=5) 
and whole-genome microarray analysis was performed (Mazzatti et al., 2008). The raw data 
generated by the microarray experiment (GEO number GSE9802) were further analyzed by using 
GeneSpring GX 7.3.1 software. After the exclusion of probes that were absent or present in less 
than 50% of the samples, only the probes that showed at least 1.5-fold change between control and 
HLS animals and passed the ANOVA test (P< 0.05) were selected. The final list included 1,451 
genes differentially expressed in soleus and 1,065 genes in gastrocnemius. In the case of soleus 417 
genes were upregulated and 1,034 were downregulated, and in the case of gastrocnemius 318 genes 
were upregulated and 747 were downregulated. As seen from the Venn diagram depicted in Fig. 
3.1A, only 600 genes were differentially expressed in both muscle types. This subset of commonly 
regulated genes was further subjected to gene cluster analysis by using a Pearson correlation. In 
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order to visualize the genomic differences between control and HLS mice a heat map was 
constructed ordered by tree clustering and significance (Fig. 3.1B), in which each row represents a 
probe and each column represents one sample. The upper part of the map show genes that did not 
correlate between gastrocnemius and soleus, the middle part represents genes that were 
downregulated in both muscle types and the lower part represents genes that were upregulated in 
both muscle tissues. The red colour represents upregulation and the green colour represents 
downregulation in gene expression, the intensity of the colour being correlated with the degree of 
change normalized to the negative control values.        
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            Fig. 3.1 Venn analysis and hierarchical clustering of hindlimb suspension (HLS)-altered 
gene probes.             
 A. Venn analysis of the gene expression profiling of control and unloaded muscle 
demonstrated that a total of 1,451 and 1,065 genes were differentially expressed after HLS in 
soleus and gastrocnemius muscle, respectively (>1.5-fold, P < 0.05); B. A gene cluster analysis was 
performed by using a Pearson correlation and heatmap generation of the 600 gene probes 
differentially regulated in both soleus and gastrocnemius muscles. Each row represents 1 of 600 
probe sets and each column represents 1 sample. The intensity of colour in a cell represents the 
normalized expression of the probe, where green and red depict low and high expression, 
respectively (n=6).  
 
 
             A.                                                                            B. 
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                     3.2 Acute hindlimb suspension (HLS) changes the expression profile of genes 
involved in glucose and lipid metabolism                  
          Gene Ontology (GO) analysis of genes that were significantly regulated in both soleus 
and gastrocnemius was used in order to investigate the effects of muscle unloading on individual 
biological processes. Table 3.1 shows the list of the ten most modulated biological processes 
changed by hindlimb suspension ordered by the P value, based on the computation of the number 
of the genes expected in the class normalized to the number of the genes observed in microarray. 
From a total of ten ontologies altered by HLS the first seven are associated with muscle 
development, skeletal muscle function and with protein synthesis. This discovery correlates with 
previous findings that deciphered such changes in skeletal muscle during ageing in both humans 
and rodent models (Jaspers et al., 1988; Tischler et al., 1985), further supporting the assertion that 
hindlimb suspension is an accurate model of investigation of the ageing phenotypes. Other 
ontologies significantly changed were cytoskeleton organization and the response to heat 
shock/stress. The skeletal muscle during ageing is characterized not only by structural changes but 
also by an impaired defence against infection and reduced resistance to stress, and these two 
processes are regulated partially by changes in the expression of genes involved in the response to 
heat stress and heat shock (Morton et al., 2009). My findings could therefore offer an explanation 
for the perceived changes in the aged skeletal muscle.         
             It has been previously shown that long-term unloading of skeletal muscle changed 
the expression profile of genes regulating lipid and glucose metabolism (Stein et al., 2005; Stein 
and Wade, 2005), leading to an increased reliance on glucose as a main fuel and a reduced 
utilization of lipids that will accumulate intracellularly. As many as 18 glucose-related ontologies 
were altered following the short term HLS in my experiment, especially gluconeogenesis and lipid 
metabolism (Table 3.2). In my experiment, while the expression level of key enzymes in 
gluconeogenesis and glycolysis such as fructose-1, 6-biphosphatase (FBP2), glycerol-3-phosphate 
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dehydrogenase 1 (GPD1) and glucose 1-dehydrogenase (H6PD) were increased, the expression 
levels of two other critical enzymes, pyruvate carboxylase and phosphoenolpyruvate carboxykinase 
were not modified (Table 3.3). It was also noticed a reduced expression of other crucial genes for 
glucose metabolism such as hexokinase 2 (HK2), phosphoglycerate mutase 1 (PGAM1) and 
glycogen synthase 2 (GYS2). In conclusion, some of genes involved in glucose metabolism 
identified in the early stage of unloading fit to this paradigm identified in the chronic unloading, but 
others did not. In addition, in contrast  with the conclusions of independent  long-term unloading 
experiments I noticed that many genes involved in lipid metabolism presented in fact an increased 
level of expression, such as acyl-CoA thioesterase 1 (ACOT1) which is critical for unsaturated fatty 
acid biosynthesis, farnesyl diphosphate farnesyl transferase 1 (FDFT1) which is involved in 
cholesterol biosynthesis, branched chain ketoacid dehydrogenase E1 (BCKDHA) which is involved 
in branched fatty acid oxidation and acyl-CoA synthetase long-chain family member 3 (ACLS3) 
which is involved in peroxisomal lipid metabolism. Stearoyl-Coenzyme A desaturase 2 (SCD-2), 
which is involved in monounsaturated fatty acid synthesis, was nevertheless found to be 
downregulated.  The increased expression of many genes regulating lipid utilization during the 
early stage of unloading as shown by my microarray assay contrasted with the results reported 
independently about the chronic stage (Stein et al., 2005; Stein and Wade, 2005), which suggests 
that the lipid metabolism could be in fact upregulated during this initial phase. Moreover, the 
differential activation of genes involved in glucose metabolism as seen from my microarray results 
suggests that in the early stage the utilization of glucose as a main energy substrate noticed by 
independent studies in the chronic stage is in its incipient phase, but not yet fully established.   
    Therefore I can conclude that in the early stage is discernible an incipient process 
of adaptation to metabolic dysfunction characterized by an increased lipid metabolism and a 
perturbed glucose metabolism. Such putative adaptation occurs via changes in gene expression 
profile that nevertheless disappear later, in the chronic stage.  Such ontologies are not equivalent 
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nevertheless to molecular pathways and do not describe the dynamics of interactions between genes 
within the ontology.  To address this issue Ingenuity Pathway Analysis (IPA) was used to identify 
molecular pathways affected by the short term hindlimb suspension in both soleus and 
gastrocnemius. This software searches a vast manually curated proprietary database of publicly 
available research data comprising all protein-protein interactions, protein-DNA interactions, 
signalling pathways, transcriptional networks, microRNAs and drug metabolism included in peer-
reviewed scientific publications. The algorithms will identify any kind of direct and indirect 
relationships between genes in a certain given list, as the one generated by my microarray 
experiment, and the output will be represented as a network. The analysis of the 600 subset of 
genes by IPA showed that as many as 19 relevant networks were significantly changed after 24 
hours of unloading in both types of muscle (Table 3.5). These networks are associated with cancer, 
organogenesis and development, regulation of cell cycle, drug metabolism, cell death and cell 
signalling, aspects known to be involved in progression of ageing. The network regulating 
specifically the glucose and lipid metabolism contains 23 focus genes and it is ranked the fifth with 
a total score of 33. The score represents the total number of relationships (edges) between the focus 
genes included in this particular network, a higher score meaning a higher statistical probability of 
physiologically relevant interactions. These relationships are depicted in Fig. 3.2 for soleus, the 
genes coloured in red being upregulated in the experiment, the genes coloured in green being 
downregulated and the genes that were not changed in my experiment being uncoloured. A central 
node in this network involved in lipid metabolism represented by PPAR-α was downregulated in 
both muscle types, simultaneously with its target genes PGC -1α and PGC-1β (Table 3.4 and Fig. 
3.2). RXR, another central node in this network, was not changed.    
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                 Table 3.1 Top 10 most significantly regulated ontologies after acute unloading  
                 Total number of genes included in each ontology (computed from entire mouse genome), 
expected % of genes reflected in each ontology (computed from entire mouse genome), the number of 
genes differentially regulated by hindlimb suspension (HLS) in each ontology (computed from the list of 
HLS-regulated genes) and % of genes in the ontology that were differentially regulated after HLS 
(computed from the list of HLS-regulated genes) are shown. P value reflects the significance of change 
in prevalence of genes in each ontology under the HLS condition relative to the expected prevalence of 
genes in each ontology. 
 
                                      Ontology                      Total No. of             % of                No. of Genes      % of Genes    p-value 
                                                                            Genes                      Genes                changed            changed by 
                                                                             in                            in                      by HLS               HLS in      
                                                                            Ontology                 Ontology                                      Ontology                                     
 
             GO:7517:    muscle development                 299              1.305                    31               4.354        5.1E-09 
             GO:51258:  protein polymerization              82               0.358                    15               2.107        3.0E-08 
             GO:6936:    muscle contraction                    131              0.572                    18              2.528        1.3E-07 
             GO:7519:    striated muscle development     212              0.925                    23              3.23          2.1E-07 
             GO:48741:   fiber   development                   124             0.541                     17              2.388        3.0E-07   
             GO:48747:   muscle fiber development         124              0.541                    17              2.388         3.0E-07 
             GO:48637:   skeletal muscle development     139              0.607                    18              2.528        3.2E-07 
             GO:7010:     cytoskeleton organization and    917             4.238                     57             8.006        3.4E-06 
                                   biogenesis 
             GO:9408:    response to heat                           44               0.192                        9              1.264       6.9E-06 
             GO:48513:  organ development                      1937           8.462                        92             12.92      2.9E-05 
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                 Table 3.2 Ontologies associated with glucose and lipid metabolism significantly 
regulated by HLS in soleus muscle                   
     P value reflects the significance of change in prevalence of genes in each ontology under 
the HLS condition relative to the expected prevalence of genes in each ontology. 
   ontologies                                                                        p-value 
                                        
GO:19216   regulation of lipid metabolism                                          0.000178 
GO:6094     gluconeogenesis                                                                0.000675 
GO:44255   cellular lipid metabolism                                                   0.00109 
GO:45444   fat cell differentiation                                                        0.00141 
GO:43255   regulation of carbohydrate biosynthesis                            0.00242 
GO:6638     neutral lipid metabolism                                                    0.00285 
GO:6629     lipid metabolism                                                                0.00947 
GO:8610     lipid biosynthesis                                                               0.0103 
GO:19217   regulation of fatty acid metabolism                                   0.0161 
GO:45923   positive regulation of fatty acid metabolism                      0.0169 
GO:1676     long-chain fatty acid metabolism                                       0.018 
GO:7005     mitochondrial organization and biogenesis                        0.0194 
GO:6839     mitochondrial transport                                                      0.0247 
GO:6006     glucose metabolism                                                            0.0258 
GO:1678     cellular glucose homeostasis                                              0.029 
GO:19915   sequestration of lipid                                                          0.029 
GO:44242   cellular lipid metabolism                                                    0.03 
GO:45834   positive regulation of lipid metabolism                              0.0433 
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                  Table 3.3 List of the relevant genes involved in lipid and glucose metabolism, 
significantly regulated by acute HLS in both soleus and gastrocnemius     
       Gene identifier, symbol, common name and microarray fold-change observed in CR-
rats compared to ad lib  
 
gene identifier    symbol         common name                                                fold-change  
      
     NM_007994      FBP2          fructose bisphosphatase 2                                        1.89  
     NM_010271      GPD1         glycerol-3-phosphate dehydrogenase 1                   1.94 
     NM_173371      H6PD         glucose 1-dehydrogenase                                         1.66 
     NM_013820      HK2           hexokinase 2                                                         -  1.59 
     NM_023418      PGAM1      phosphoglycerate mutase 1                                  -  1.9 
     NM_145572      GYS2         glycogen synthase 2                                              -  2.1 
     NM_012006      ACOT1       acyl-CoA thioesterase 1               3.34  
     NM_010191      FDFT1        farnesyl diphosphate farnesyl transferase 1             2.37 
     NM_007533      BCKDHA    branched chain ketoacid dehydrogenase E1           1.52 
     NM_028817      ACSL3        acyl-CoA synthetase long-chain member 3             2.02 
     NM_009128      SCD-2          stearoyl-Coenzyme A desaturase 2                       - 1.56 
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                    Fig. 3.2 Analysis of lipid and glucose metabolism molecular networks regulated by HLS 
in soleus muscle.            
       Differentially expressed genes from analysis of soleus muscle after HLS were analyzed by 
the Ingenuity Pathway Analysis (IPA) tool. The most significant network involved in glucose and 
lipid metabolism is shown as regulated by HLS in soleus muscle. Differentially regulated genes are 
shown in red and green, depicting upregulation and downregulation after HLS (compared to 
ambulatory control), respectively. Bold colour indicates a high degree of regulation (2.5-fold), while 
pale colour indicates 1.5- to 2.5-fold differential regulation. Noncolored genes were not found to be 
differentially expressed after treatment. Positive regulatory interactions are marked by solid arrows 
(direct interactions) or dashed arrows (indirect interactions). Negative interactions are shown by 
inhibitory arrows. 
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                         3.3 Acute hindlimb suspension modifies PPAR-dependent signalling pathways 
                         In order to have a better picture of the PPAR-α signalling the Ingenuity Pathway 
Analysis (IPA) was used to identify possible changes in the networks that it regulates. The 
visualization of canonical PPAR-α signalling pathway which is depicted in the Fig. 3.3 shows that 
acute HLS altered in soleus the expression of some of its components such as PPAR-α, HSP90, 
STAT5B, c-FOS, IKBKG, NGFR and NCOA (Table 3.4). The fact that some of the genes modified 
by unloading are nodal points within the PPAR-α signalling pathway investigated indicates that the 
change in its expression was physiologically relevant. In order to validate the changes observed by 
microarray, I further performed RT-PCR for all three members of PPAR family and discovered that 
while PPAR-α and PPAR-γ were downregulated by HLS in both types of skeletal muscle, the 
expression level of PPAR-β/δ was upregulated in soleus. Subsequent RT-PCR assays showed that 
while the levels of PPAR-α target genes such as PPGC-1α and PGC-1β were downregulated in both 
soleus and gastrocnemius, the expression levels of other PPAR target genes such as carnitine 
palmitoyltransferase-1b (CPT-1b), carnitine palmitoyltransferase-2 (CPT-2) and uncoupling protein 
3 (UCP-3) were significantly upregulated in soleus (Fig. 3.4).                 
     In gastrocnemius the expression level of CPT-2 was downregulated while the other 
two target genes (CPT-1b and UCP-3) showed only a trend toward upregulation.  RT-PCR was 
again used to further assess the possible change in expression of several genes that are critical for 
lipid and glucose homeostasis such as AMPK and ACC. While the expression level of β2 subunit 
of AMP-activated protein kinase (AMPK) in soleus was slightly downregulated by HLS, the 
expression level of α2 subunit was upregulated. Similarly, while the expression level of α subunit 
of acetyl-CoA-carboxylase (ACC) was not changed, the expression of β subunit was upregulated in 
both muscle types by HLS. These results demonstrate the differential regulation of PPAR-
dependent signalling pathways and of genes involved in lipid and glucose metabolism in different 
types of muscle such as soleus and gastrocnemius. Western blotting was used to certify the changes 
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identified at transcriptomic level. As seen from Fig. 3.5, the acute hindlimb suspension increased 
the protein levels of uncoupling protein 3 (UCP-3) and PPAR-β/δ in soleus compared to 
ambulatory animals, confirming the microarray and RT-PCR results. To investigate whether the 
changes observed in the acute phase were present also in the chronic stage, an RT-PCR assay for 
UCP-3 and PPAR-β/δ probes was performed by using samples taken from soleus muscle of mice 
subjected to HLS for 12 days. As seen from Fig. 3.6, UCP-3 expression was upregulated but 
PPAR-β/δ expression reverted to control levels. This could indicate that UCP-3 expression is 
regulated in the chronic phase by other signalling pathway besides PPAR signalling. PPAR-β/δ 
expression is increased only in the acute phase of the unloading, suggesting that the compensatory 
effect is overwhelmed after a long-term suspension.  Alternatively, the initial increase in PPAR-β/δ 
expression during the acute phase could be functionally sufficient for the long-term increase in 
UCP-3 expression identified even after 12 days of HLS, when PPAR-β/δ expression is back to 
normal.   
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       Table 3.4 Genes belonging to PPAR-α canonical pathway significantly regulated by acute HLS 
in soleus                    
Gene identifier, symbol, common name and fold-change in microarray experiment observed in CR-
rats compared to ad lib  
 
     NM_011144      PPAR-α    peroxisome proliferator activated receptor alpha                                      -   2.512 
     NM_008904      PGC -1α   peroxisome proliferative activated receptor γ coactivator 1 alpha            -   2.05 
     NM_133249      PGC-1β    peroxisome proliferative activated receptor γ coactivator 1 beta              -   2.213 
     NM_010480      HSP90      heat shock protein 90kDa alpha                                                      -  1.8 
     NM_011489      STAT5b   signal transducer and activator of transcription 5B               1.56 
     NM_010234      c-FOS       FBJ osteosarcoma oncogene                        -   1.9 
     NM_010547      IKBKG     inhibitor of kappaB kinase gamma                        -   1.6  
     NM_033217      NGFR       TNFR superfamily, member 16                                                                    1.9 
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                         Table 3.5 Networks significantly regulated in soleus and gastrocnemius muscle 
after HLS as determined by   Ingenuity Pathway Analysis (IPA)                                                                                                     
   Network score, number of HLS-regulated genes (focus genes), and main cellular 
functions or conditions (diseases) in which these genes play a role are displayed for each of these 
networks.  
 
          44            28                     Cancer, Reproductive System Disease, Cell Cycle 
          42            27                     Auditory and Vestibular System Development and Function,  
                                                  Connective   Tissue Development and Function, Digestive System Development   
         37            25                     Cellular Movement, Cancer, Neurological Disease 
         35            24                     Cancer, Cell Cycle, Reproductive System Disease 
         33            23                     Carbohydrate Metabolism, Small Molecule Biochemistry, Lipid   
                  Metabolism 
         29            21                     Carbohydrate Metabolism, Small Molecule Biochemistry,  
                                                  Cellular Assembly and Organization 
         25            19                      Cancer, Cellular Growth and Proliferation, Nervous System Development and   
                                                   Function 
         21            17                      Cell Death, Haematological System Development and Function, Cellular  
                     Development 
         19            16                      Connective Tissue Development and Function, Immunological Disease, Lipid   
                                                   Metabolism 
         18            15                      Drug Metabolism, Gene Expression, Lipid Metabolism  
         18            15                      Gene Expression, Small Molecule Biochemistry, Cardiovascular Disease 
         18            15                      Genetic Disorder, Skeletal and Muscular Disorders, Dermatological Diseases  
                                                   and Conditions 
         18            15                      Cancer, Cell Death, Gene Expression 
         16            14                      DNA Replication, Recombination, and Repair, Cell Cycle, Cancer 
         16            14                      Organism Development, Haematological System Development and Function, 
                                          Cellular Function and Maintenance  
Score   Focus Genes   Top Functions or Conditions/Diseases 
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                  Fig. 3.3 PPAR- canonical pathway in soleus muscle after HLS.    
       Genes that were differentially expressed in soleus muscle after HLS were clustered into 
canonical pathways with the Ingenuity Canonical Pathway tool. The PPAR signaling pathway was 
significantly regulated by HLS in both soleus muscle (P < 0.001). Coloured genes were identified by 
microarray analysis as differentially upregulated or downregulated in HLS samples compared with 
control (red and green, respectively). Other uncoloured nodal genes are directly or indirectly 
associated with the differentially expressed genes but were not found to be significantly regulated by 
HLS. Genes are linked by their subcellular location (extracellular, cytoplasmic, nuclear; from top to 
bottom, respectively). Main processes modulated by transcriptional regulation are shown. The legend 
of the figure is included in Supplementary Figure 1. 
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                           3.4   Caloric or dietary restriction (CR/DR) has a significant impact on the 
global genomic profile of rodent skeletal muscle         
      Caloric or dietary restriction (CR/DR) is the only successful dietary intervention 
which extends the lifespan of all experimental animal models tested so far (Bergamini et al., 2003; 
Masoro, 2005). In addition, CR has anti-ageing properties by delaying or reducing the impact of 
ageing-associated diseases such as cancer (Longo and Fontana), sarcopenia (Colman et al., 2008), 
neurodegeneration (Contestabile, 2009), metabolic syndrome (Opie, 2009), insulin resistance and 
obesity (Palou et al. 2010). The physiological and metabolic consequences of caloric restriction 
have been extensively investigated and detailed in the literature (Colman et al., 2009; Cruzen and 
Colman, 2009). Nevertheless, the underlying regulatory mechanisms have not been explored in 
detail so far. A main goal of the present chapter was deciphering the possible roles of nuclear 
receptors in modulating the anti-ageing effects induced by caloric restriction. A theoretical 
breakthrough in this respect could offer effective intervention tools for the groups affected or at risk 
for the diseases listed above. To explore the effects of caloric restriction on skeletal muscle gene 
expression profile an whole-genome microarray (Agilent platform) was performed in our 
laboratory by using the rat gastrocnemius samples kindly offered by our collaborators from 
Liverpool University (Dr. BJ Marry laboratory).             
                     Briefly, the rats have been separated by our collaborators in two groups 
immediately after weaning: the control group that was fed ad libitum and the experimental group 
that was subjected to caloric or dietary restricted conditions for the rest of their life. This rodent 
model has been already validated and used for extensive research on mitochondrial metabolism and 
oxidative stress (Lambert et al., 2004; Merry, 2004, 2005). The rats that were subjected to caloric 
restriction lived longer, weighted slightly less and presented improved metabolic parameters 
(Merry, 2005). After 28 months of differential diet the rats have been sacrificed and the skeletal 
muscle samples taken from both control (ad libitum) and test (CR) animals were used for a whole 
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genome DNA microarray experiment. After extraction of the raw values I used GeneSpring 
software to further analyze the data. After exclusion of absent calls and probes that were expressed 
(present or marginal) in less than half of experimental samples, 20,023 out of an initial 41,105 
probes (50%) were considered for analysis. Only probes with a differential expression of at least 
2.0-fold and which passed ANOVA testing at p < 0.05 were considered to be truly differentially 
expressed by CR compared to ad libitum, the final list containing a total of 478 probes. Of these 
probes differentially expressed, 52 were upregulated and 426 were downregulated by CR 
(Supplemental Table 1). To better analyze them a gene cluster analysis was done by using a 
Pearson correlation, generating a heatmap where each row represents one of the 478 probes and 
each column represents one skeletal muscle sample from one different animal. Expression of the 
478 probes in skeletal muscle of each animal is shown in Fig. 3.7 where the intensity of colour in a 
cell represents the normalized expression of the probe, and green and red colouring depict low and 
high expression, respectively. Expression of each probe in the samples from the six animals fed the 
CR diet and six animals fed ad libitum are shown from left to right. Biological processes were 
further investigated by using Gene Ontology (GO) analysis of the genes significantly regulated in 
CR- compared to ad libitum-fed animals. The list from Table 3.6 shows the 18 most significantly 
regulated GO biological processes in dietary restricted muscle with associated p-value. Although 
functions known to be affected by CR (including glucose and lipid metabolism) are not among the 
top 18 most-regulated ontologies, several other metabolic ontologies were found to be significantly 
regulated (p < 0.05) such as glycogen metabolism, aspartate metabolism, protein metabolism, 
nucleoside metabolism, adipose tissue differentiation and mitochondrial biogenesis.           
    Additionally, I observed a significant regulation of cell cycle, growth and 
apoptosis-related ontologies in CR samples. I noticed for example that caloric restriction reduced 
the expression of many genes associated with cell death such as cell death effectors (caspase-1,-3,-
4 and -9), apoptosis mediators (BAX, PDCD4, DIDO1, TRAF2, TRAF3, DAP, TMBIM1, RELT), 
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DNA fragmentation effectors (DFFA, CIDEA) and signalling regulators (RIPK2, DAPK2). Other 
known negative mediators of apoptosis such as BCL6 and tumor suppressors such as BCoR-L1 
were upregulated. This reduction in expression of pro-apoptotic genes could explain the reduced 
the atrophy and sarcopennia seen in the muscle of animals and human volunteers placed upon 
caloric restricted conditions (Colman et al., 2008).  
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                 Fig. 3.7 Hierarchical clustering of CR-sensitive gene probes.       
          The 478 gene probes significantly differentially regulated in skeletal muscle 
samples from CR compared to ad libitum-fed animals were subjected to gene cluster analysis using 
a Pearson correlation. A heatmap was generated where each row represents one of 478 probe sets 
and each column represents one skeletal muscle sample from an individual animal. The intensity of 
colour in a cell represents the normalized expression of the probe, where green and red depicts low 
and high expression, respectively, compared to the average expression of each probe across all 
samples. n = 6 animals in each group. 
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Table 3.6   Top 18 significantly CR-regulated ontologies and associated p-values. 
 
                  Ontology                                                   p-value 
GO:48589: developmental growth                   3.11E-06 
GO:6952:   defence response         9.57E-06 
GO:9607:   response to biotic stimulus       2.56E-05 
GO:6955:   immune response                   2.95E-05 
GO:6878:   copper ion homeostasis        3.05E-05 
GO:7517:   muscle development        8.58E-05 
GO:6936:   muscle contraction                   0.000104 
GO:19882: antigen presentation        0.000131 
GO:42535: positive regulation of tumour necrosis factor-alpha biosynthesis           0.000142 
GO:42534: regulation of tumour necrosis factor-alpha biosynthesis                         0.000142 
GO:42533: tumour necrosis factor-alpha biosynthesis    0.000142 
GO:48668: collateral sprouting        0.000264 
GO:48669: collateral sprouting in the absence of injury     0.000264 
GO:48738: cardiac muscle development       0.000264 
GO:48739: cardiac muscle fibre development      0.000264 
GO:45736: negative regulation of cyclin-dependent protein kinase activity             0.000333 
   GO:30333: antigen processing        0.000397 
GO:9611:   response to wounding        0.00044 
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                             3.5    Caloric restriction changes the genomic profile of networks regulating 
glucose and lipid metabolism in skeletal muscle and liver               
                     As seen from Table 3.7,  some of the crucial genes involved in glycolysis such as 
phosphofructokinase (PFKL), ketohexokinase (KHK), phosphoglycerate mutase 1 (PGAM1) and 
hexokinase 1 (HK1) were downregulated  (-1.69,  -2.04, -1.51 and - 1.77 times, respectively)  and 
this fits with the already accepted and established paradigm that caloric restriction inhibits the 
process of glycolysis and consequently reduces the toxic metabolic by-products such as 
methylglyoxal and ROS (Hipkiss, 2006, 2007). I noticed also that the expression of insulin receptor 
substrate 2 (IRS2) was increased 1.52 times in the skeletal muscle of caloric restricted animals. 
This change in expression is similar to the results of other independent experiments where 
laboratory animals that were subjected to exercise showed an improved glucose metabolism and 
reduction in the production of free radicals, process that was partially mediated by the signalling 
pathway acting downstream of  IRS2 (Park et al., 2007). Glycerol-3-phosphate dehydrogenase 1 
(GPD1), which is a key NAD-dependent enzyme involved in glycerol biosynthesis, was also 
increased 1.76 times and this correlates with the discovery that deletion of the gene in mutant 
yeasts showing increased lifespan cancelled the anti-ageing effect (Du et al., 2005), suggesting that 
it is positively associated with delayed ageing.  Previously it was shown that caloric restriction 
improved insulin sensitivity and I also discovered that many mediators that are associated with 
insulin resistance and diabetes such as insulin-like growth factor binding protein 4 (IGFBP4) and 
insulin-like growth factor binding protein 5 (IGFBP5) were reduced  too (-1.6 and -2.2 times). It is 
known already that caloric restriction increases mitochondrial biogenesis, subsequently reducing 
the oxygen consumption and the free radicals produced  (Lambert and Merry, 2004), but less is 
known about peroxisomal biogenesis and the role of peroxisomal enzymes in reducing ROS levels 
upon caloric restriction in ageing models. I discovered for example that hydratase/3-hydroxyacyl 
Coenzyme A dehydrogenase (EHHADH) which is a critical enzyme for peroxisomal fatty acid 
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beta-oxidation was increased 1.624 times in the skeletal muscle of caloric restricted animals. I 
detected also increased expression of many transporters localized at both mitochondria and plasma 
membrane such as mitochondrial transporters of ADP: ATP (SLC25A30 + 2.6 times, SLC25A25 + 
3.14 times and similar to mitochondrial carrier protein MGC4399 +1.52 times) or aminoacids 
transporters (SLC38A3, SLC35C2 and SLC43A1 + 1.5 times). I further noticed a reduced 
expression of genes critical for fatty acid biosynthesis and transport such as fatty acid desaturase 3 
(FADS3, -1.6 times), fatty acid binding protein 3, (FABP3, -1.7 times) and fatty acid binding 
protein 5 (FABP5, -1.9 times). These changes could explain the reduced accumulation of lipid 
droplets in the skeletal muscle of obese human patients undergoing fasting or losing weight 
(Goodpaster et al., 2000). Therefore the above mentioned genomic changes of networks regulating 
glucose and lipid metabolism correlate with previous reports detailing the improved metabolic 
flexibility and reduced oxidative stress in CR models. 
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     Table 3.7 Expression of critical genes regulating lipid and glucose metabolism altered by caloric 
restriction as revealed by microarray analysis   
 
         GeneBank                   Symbol                Common name                                                array fold-change  
 
L25387                       PFK-C                 phosphofructokinase             -1.69 
NM_031855               KHK                    ketohexokinase                                -2.04 
NM_053290               PGAM1               phosphoglycerate mutase 1                          -1.51 
NM_012734            HK1      hexokinase 1         -1.77 
XM_001076309         IRS2                    insulin receptor substrate 2                  1.53 
NM_022215               GPD1                  glycerol-3-phosphate dehydrogenase 1     1.77 
NM_001004274         IGFBP4               insulin-like growth factor binding protein 4              -1.6 
AW917764                 IGFBP5               insulin-like growth factor binding protein 5    -2.2          
NM_133606               EHHADH            enoyl-Coenzyme A, hydratase        1.62 
NM_173137               FASD3                fatty acid desaturase 3       -1.6 
NM_024162               FABP3                fatty acid binding protein 3                  -1.7 
NM_145878               FABP5                fatty acid binding protein 5                  -1.9 
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                  Table 3.8 The expression of previously known NR4A2 regulated genes and interacting 
partners in CR-samples as revealed by microarray  
 
             GeneBank                   Symbol                Common name                                            array fold-change  
 
NM_012740                TH                     tyrosine hydroxylase                                                   - 1.53 
NM_022548                WIG1                 wild-type p53-induced gene 1                   - 1.5 
XM_215812                TP53BP1           transformation related protein 53 binding protein 1    - 2.3 
NM_030989                p53                    tumor protein p53                     - 1.5 
NM_001008349          NFkB2               NFkB light polypeptide gene enhancer 2                  - 1.6 
NM_171992                CCND1             cyclin D1                                 - 2.3 
 
 
 
 
 
 
 
 
 
 
 
70 
 
                                 3.6   Validation of arrays results by using RT-PCR                                  
                      In order to validate the results obtained by using microarrays I arbitrarily 
selected 17 genes and assessed mRNA expression by RT-PCR. Table 3.9 compares CR-regulated 
gene expression in skeletal muscle by gene array and RT-PCR.  All 17 genes selected for validation 
demonstrated similar expression patterns for the microarray and real-time RT-PCR measurements, 
yet with different magnitudes, validating array results.  I detected in our microarray experiments a 
reduced expression of many nuclear receptors and transcription factors associated with cancer such 
as ARNTL (aryl hydrocarbon receptor nuclear translocator-like, -6.5 times), RUNX1 (runt related 
transcription factor 1, -5.34 times) and NR1D1 (nuclear receptor subfamily 1 group D member 1, -
2.88 times). In addition, the expression levels of many receptors involved in inflammation such as 
Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4)  were reduced, which could explain 
the reduced inflammatory process noticed independently in caloric restricted models (Lee et al., 
2010).   Also, genes involved in the development of sarcopenic phenotype such as caspase-3, 
ubiquitin carboxy-terminal hydrolase L1, calsequestrin 2 and proteasomal subunits 8 and 9 were 
downregulated by CR, suggesting a possible involvement.   Another gene involved in insulin 
sensitivity regulation such as apelin was downregulated too, with an unknown role in this case.      
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                    Table 3.9 Comparison of CR-regulated genes in skeletal muscle by microarray and 
RT-PCR.  
                     Gene identifier, symbol, common name, fold-change in microarray experiment 
observed in CR-rats compared to ad lib, fold-change in RT-PCR experiment observed in CR-rats 
compared to ad lib (p < 0.05) 
 
          GeneBank            Symbol      Common name                                          microarray   RT-PCR 
 
NM_024362            ARNTL     aryl hydrocarbon receptor nuclear translocator-like            -6.58      -6.13 
NM_017325             RUNX1     runt related transcription factor 1                                       -5.35      -9.20 
NM_145775             NR1D1      nuclear receptor subfamily 1, group D, member 1            -2.88       -3.05 
NM_198769             TLR2        Toll-like receptor 2                                                             -2.86       -1.20 
NM_012861             MGMT      O-6-methylguanine-DNA methyltransferase                     -2.76       -2.42 
NM_017237             UCHL1     ubiquitin carboxy-terminal hydrolase L1                           -3.70       -2.30 
NM_001024791       EPN3        epsin 3                                                                                 -3.22       -8.83 
NM_001013247       SLN          sarcolipin                         -6.54       -3.03 
NM_017131             CASQ2     calsequestrin 2                  -3.13       -1.50 
NM_031612             APLN       apelin, AGTRL1 ligand                 -2.54       -3.15 
NM_080767             PSMB8     proteosome (prosome, macropain) subunit, beta type 8      -2.25       -3.00 
NM_012708             PSMB9     proteosome (prosome, macropain) subunit, beta type 9      -2.15       -3.25 
NM_012922             CASP3      caspase 3, apoptosis related cysteine protease                    -2.42       -3.80 
NM_001007713       TMBIM1   transmembrane BAX inhibitor motif containing 1              -3.90       -1.33 
NM_024388              NR4A1     nuclear receptor subfamily 4, group A, member 1               2.2          2.6 
NM_019328              NR4A2     nuclear receptor subfamily 4, group A, member 2               3.02         1.8 
NM_017352              NR4A3     nuclear receptor subfamily 4, group A, member 3                3.7           2.1 
 
 
 
 
                           
72 
 
                           3.7   Altered expression of NR4A family in skeletal muscle, liver and brain of 
CR animals             
                        Included in the transcripts found to be differentially regulated in skeletal 
muscle by CR were three functionally related genes: NR4A1, NR4A2 and NR4A3. The nuclear 
receptor subfamily 4 group A (NR4A) family of nuclear receptors was initially included in the class 
of the early responsive genes for growth factors (Milbrandt, 1988) and has since been implicated in 
regulating the response to insulin (Fu et al., 2007). In order to determine if these receptors were 
differentially expressed in a tissue-specific manner following CR, I further assessed their gene 
expression by RT-PCR in skeletal muscle, liver and whole brain of CR- and ad libitum-fed animals. 
In muscle and liver the upregulation of all three NR4A receptors (NR4A1, NR4A2 and NR4A3) 
was observed in dietary restricted animals compared to the control (Fig. 3.8A). In contrast, in brain 
the dietary restriction did not significantly alter expression of any NR4A receptor. These data 
highlight the complex regulation of these receptors and suggest that each NR4A receptor may 
perform diverse functions in different tissues in different developmental stages or physiological 
conditions (Pei et al. 2006). 
 
 
 
 
 
 
 
     Fig. 3.8 RT-PCR assay of gene expression of NR4As and PPARs nuclear receptor 
families in multiple tissues from CR
  Animals were grouped into CR and 
expression in each group was determined by RT
liver and brain of CR animals compared to 
and brain of CR animals compared to 
the control rat genes β-actin to control for differences in amount of starting material (n = 6 animals 
per group; +/- SEM; *P < 0.05 by ANOVA;
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-animals compared to control.                   
ad libitum conditions and relative mRNA 
-PCR; 8A: Relative expression of NR4As in muscle, 
ad lib; 8B: Relative expression of PPARs in muscle, liver 
ad lib. All samples were run in triplicate with test probes and 
 *** P < 0.001 by ANOVA; NS 
 
   
= not significant.).  
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                              3.8     Altered expression of genes belonging to NR4A-associated signaling 
pathways 
                                Similar to other steroid receptors each NR4A receptor contains a DNA-binding 
domain, a transactivation domain and a putative ligand-binding domain. Initially classified as 
orphan receptors due to the lack of a known ligand, it now seems probable that they do not require 
ligand binding for their physiological function. It was already shown that NR4A members interact 
with RXRs (Calgaro et al., 2007) and that RXR ligands increase NR4As activity (Wallen-
Mackenzie et al., 2003). In addition, it was shown that caloric restriction decreased the expression 
values of RXRs in skeletal muscle of mice models. Therefore, I hypothesized that RXR expression 
might be upregulated by caloric restriction, thereby allowing the possibility of an increased 
transcriptional activation of target genes. However, microarray analysis identified no significant 
effects of CR on any RXR isoform (-α, -β, -γ). I next investigated by RT-PCR (Fig. 3.8B) whether 
CR affected expression of an important class of RXR-interacting proteins that have previously been 
shown to be altered as a consequence of CR, namely the peroxisome proliferator-activated 
receptors (PPARs) (Masternak and Bartke, 2007). CR resulted in downregulation of PPAR-α in 
muscle and up-regulation in liver compared to control. In contrast, PPAR-β/δ was downregulated in 
both liver and brain but not in muscle. No significant change in PPAR-γ expression was observed 
in any of the three tissues investigated. In previous studies it was also shown that caloric restriction 
changed PPARs expression but had no effect on RXRs (Masternak et al., 2005a; Masternak et al., 
2005b).  Additionally, in liver and heart PPARs expression was found to be both increased or 
decreased, depending on the isoform and tissue investigated (Masternak et al., 2004), suggesting 
that regulation of these nuclear hormone receptors by CR is complex and occurs in a tissue-specific 
and isoform-specific manner. In order to better understand the significance of altered NR4A 
expression in muscle of CR rats, I further investigated known transcriptional targets of NR4A 
receptors (Fig. 3.9). To date, very few NR4A transcriptional targets are known. Attenuation of 
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NR4A1 expression in muscle results in decreased expression of genes important for glucose and 
lipid metabolism such as including uncoupling protein-3 (UCP-3), glucose transporter 4 (GLUT4), 
CD36, caveolin 3 (CAV3) and AMP-activated protein kinase γ3 subunit (AMPK-γ3) (Maxwell et 
al., 2005). Two recent reports have also described NR4A3 transcriptional targets in muscle. These 
include fatty acid binding protein-4 (FABP-4), PPAR gamma-coactivators alpha and beta (PGC-1α 
and β), lipin1a and pyruvate dehydrogenase phosphatase 1 (PDHP1) (Pearen, Ryall et al. 2006). I 
next investigated muscle-specific expression of these targets by RT-PCR. Fig. 3.9 shows relative 
gene expression of two NR4A1 targets (UCP-3 and AMPK-γ3) and three NR4A3 targets (PGC-1α, 
-1β and FABP-4) in muscle from animals fed ad libitum or with the CR diet. I observed significant 
upregulation of UCP-3, AMPK-γ3, PGC-1α and PGC1-β, but no change in expression of FABP-4 
following CR. These data are consistent with increased transcriptional activity of NR4A1 and 
NR4A3.  Since PPAR-α was downregulated and PPAR-β/δ not changed upon CR in muscle, it is 
likely that the increase in UCP-3, AMPK-γ3, PGC-1α and PGC1-β expression values was caused 
by NR4As, not by PPARs. Previously it was also shown that NR4A1 overexpression is able to 
repress the expression levels of many genes involved in mitochondrial metabolism of lipids 
belonging to sterol regulatory element binding protein-1c (SREBP1C)-pathway such as glycerol-3-
phosphate acyltransferase 1 (GPAM), SCD-1 and fatty acid synthase (FASN) (Pols et al., 2008). I 
performed RT-PCR for these target genes and noticed that GPAM and SCD-1 expression levels 
were significantly downregulated in the skeletal muscle of caloric restricted rats (Fig. 3.10), 
suggesting a possible NR4A1 involvement.   Consequently, I used Ingenuity Pathway AnalysisTM 
(IPA) to investigate whether additional NR4A-interacting proteins were regulated by CR. IPA 
identified one network in which all three NR4A receptors are depicted together with interacting 
proteins (Fig. 3.11). Coloured genes were identified by microarray analysis as differentially 
upregulated or downregulated by CR (red and green colouring, respectively). IPA analysis of the 
genes affected by CR identified one homodimeric protein, platelet-derived growth factor-B (PDGF-
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B) that directly stimulates expression of all three NR4A receptors. PDGF-B is a potent mitogen for 
vascular smooth muscle cells and was found to inhibit the induction of nitric oxide synthase 
activity in vascular smooth muscle cells (Schini et al., 1992). Interestingly,  NR4A3 is induced by 
platelet-derived growth factor and mediates vascular smooth muscle cell proliferation (Nomiyama 
et al., 2006), a role for NR4As in modulating the protection against vascular diseases being recently 
been hypothesized (Pols et al., 2007).  Microarray analysis revealed a trend towards decreased 
expression of PDGF-B in the CR condition (1.2-fold compared to ad libitum), but this was not 
statistically significant (p = 0.20), suggesting that the up-regulation of NR4A receptors following 
long-term CR is independent of PDGF-B activity. Taken together, pathway analysis identified 
multiple potential mechanisms of regulation of NR4A expression which may contribute to the 
pleiotropic effects of CR. 
 
 
 
 
 
 
 
 
 
 
                  Fig. 3.9 CR changes the expression of genes regulated by NR4A1 and NR4A3 in skeletal 
muscle of CR rats                  
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                              3C. Discussion 
                        1.  Hindlimb suspension (HLS) as a model of accelerated ageing      
   During ageing human skeletal muscle is characterized by reduced mass, 
impaired functionality and altered metabolic flexibility. The phenotype of the aged muscle is 
partially similar, but not completely identical, to the phenotype acquired by skeletal muscle after 
short-term or long-term inactivity (bed rest), or after an impaired level of activity (spaceflight) 
(Dorrens and Rennie, 2003; Harridge, 2003; Hebuterne et al., 2001). Hindlimb suspension (HLS) is 
a useful method to model in rodents the effects of such inactivity on human skeletal muscle 
metabolism and in recent years several groups have used this approach to study especially the 
changes in gene expression induced by long-term, chronic suspension (Knox et al., 2004; 
Matsushima et al., 2006). The results of these studies conclusively proved that muscle unloading is 
characterized by a reduced rate of fatty acid oxidation and decreased transcription of genes 
involved in lipid metabolism, simultaneously with increased levels of expression of genes involved 
in glycolysis and glycogen synthesis. Such perturbation will lead to an increased reliance on 
glucose as a preferred energy source, signifying in fact a loss of metabolic flexibility (Grichko et 
al., 2000; Henriksen and Tischler, 1988; Langfort et al., 1997). The effects of acute, short-term 
HLS on global genome expression have not been previously explored in detail. Therefore, in the 
present chapter I presented the conclusions of the microarray assay which identified the changes 
induced by such a short-term suspension on skeletal muscle genomic expression profile, followed 
by RT-PCR and western blot for confirmation.       
   In my study I focused on identifying the early-responding signaling and 
regulatory genes that might explain the loss of metabolic flexibility in muscle.  A changed profile 
of genes regulating lipid and glucose metabolism was observed which indicates that such metabolic 
inflexibility develops in the acute phase of the unloading (Fig. 3.2).  The chronic exposure to 
unloading was shown already to increase the expression of genes involved in glycolytic pathway 
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such as hexokinase, phosphofructokinase, and pyruvate kinase (Stein et al., 2002). As shown in 
Table 3.3, I detected in the acute HLS-samples (24 hours) from soleus an increased expression of 
genes regulating glycolysis and gluconeogenesis (FBP2, GPD1 and H6PD), an unexpected reduced 
expression of other crucial genes (HK2, PGAM1 and GYS2) and no change for other important 
genes such as phosphofructokinase and pyruvate kinase. I also noticed that many other genes 
involved in lipid metabolism showed surprisingly increased levels of expression such as ACOT1, 
FDFT1, BCKDHA, ACSL3, only SCD-2 having a reduced expression.  These seemingly 
contradictory data show first of all that during the acute phase it is discernable a perturbed glucose 
metabolism as suggested by the changed genomic profile of some of the rate-limiting genes.  
Nevertheless, since not every gene involved in glucose metabolism had an increased expression 
upon acute HLS and since some crucial genes had even a decreased expression, I can conclude that 
the process of adaptation is still in an incipient form during the first 24 hours.                                            
  Moreover, since some of the genes crucial for lipid metabolism are increased it is 
possible that the lipid metabolism process is in fact accelerated during the early phase. This could 
indicate that unlike in the chronic phase when the genes relevant for lipid oxidation are 
downregulated, the acute phase might develop a very early type of compensatory adaptation to 
acute unloading-induced metabolic deregulation, via an increased rate of lipid metabolism. Such 
possible adaptation will be nevertheless overwhelmed during the chronic phase characterized by an 
enhanced reliance on glucose utilization concomitant with increased lipid accumulation, leading to 
the loss of metabolic flexibility. 
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                      2. The role of PPARs-dependent signalling during acute HLS     
           Microarray and RT-PCR assays showed a significant reduction in PPAR-α and 
PPAR-γ and an increase in PPAR-β/δ expression levels (Fig. 3.4A), simultaneously with a decrease 
in PGC-1α and PGC-1β expression (Fig. 3.4B). The increase in UCP-3 expression in soleus 
suggests that the acute upregulation of PPAR-β/δ following short-term HLS may represent an 
active response of skeletal muscle in order to reduce the deleterious impact on its physiology. It is 
therefore possible that the loss of PPAR-β/δ expression after 12 days may explain the noticed 
inflexibility during chronic stage of immobility. This means that activation of PPAR-β/δ could 
have clinical beneficial effects in the case of muscle diseases during ageing.   Gene arrays 
demonstrated no significant change in pyruvate dehydrogenase kinase isozyme 4 (PDK4) or 
FABP3 expression in soleus or gastrocnemius muscle after 24-h HLS. However, I did observe a 
significant increase in expression of CPT-1b and CPT-2 in soleus muscle after unloading, in 
contrast to the observations made in the models of long-term exposure to HLS (Fig. 3.4B and 
3.4C).              
             In the present study I observed in the soleus muscle after acute HLS a significant 
increase in the expression of the known PPAR-β/δ target gene UCP-3, but not in the 
gastrocnemius. On the basis of its homology with other members of uncoupling proteins family 
UCP-3 has been implicated mainly in the regulation of energy expenditure (Jia et al., 2009). So far 
UCP-3 was shown to have at least three main roles: facilitating the fatty acid oxidation; removing 
LCFA and translocating lipid peroxide anions; and activating a proton leak (MacLellan et al., 
2005). As a consequence UCP-3 reduces the levels of oxidative stress and lowers the mitochondrial 
membrane potential, thereby maximizing the oxidation state of mitochondrial respiratory chain 
carriers. This results in decreased ROS production and protection of the mitochondria from 
damage.  UCP-3 transgenic mice tended to have lower body weight, increased oxygen consumption 
and decreased mitochondrial proton motive force than the control mice (Clapham et al., 2000). In 
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addition, they have lower fasting plasma glucose level and insulin levels and increased glucose 
clearance rate. Several reports have reported that fatty acids induce UCP-3 gene expression in 
skeletal muscle (Boss et al., 1998). UCP-3 expression is correlated with the levels of free fatty 
acids and with lipid peroxidation markers, suggesting a switch toward fat oxidation. UCP-3 was 
also shown to protect against lipotoxicity in a cachexia model (Minnaard et al., 2006). The 
cachectic state is often accompanied by increased rates of adipose tissue lipolysis, reduced 
mitochondrial volume and changes in mitochondrial protein synthesis rate. Therefore it was 
proposed that increased expression of UCP-3 protects mitochondria against the oxidative damage 
induced by nonesterified fatty acids (Schrauwen et al., 2001). In addition, recently it was 
demonstrated the role for UCPs in the adaptive response to long-term overfeeding by regulating 
substrate oxidation (Ukkola et al., 2001).         
   Several investigations linked upregulated PPAR-β/δ with high levels of UCP-3 
expression (de Lange et al., 2007; Fritz et al., 2006; Son et al., 2001).  The UCP-3 gene promoter 
contains a PPAR response element (Riquet et al., 2003) and specific PPAR-β/δ agonist treatment 
resulted in upregulation of UCP-3. The same study reported that modulation of UCP-3 by targeting 
PPARs appeared specific to PPAR-β/δ because neither PPAR-α nor PPAR-γ were able to 
transcriptionally regulate UCP-3. Moreover, it was also shown that low-intensity exercise increased 
skeletal muscle protein expression of PPAR-β/δ and UCP-3 in type 2 diabetic patients, suggesting 
that regulation of these two serve to improve clinical outcome (Fritz, Kramer et al. 2006). I 
hypothesized that UCP-3 functions may be polyvalent and differ in the context of acute and chronic 
activation of the protein. Although the loss of UCP-3 function appears not to be involved in the 
pathogenesis of obesity-related conditions, it is possible that upregulation of UCP-3 may improve 
metabolic flexibility.            
          It was also recently demonstrated that the effects of caloric restriction on 
metabolic responses including regulation of glucose and lipid utilization may involve AMPK or 
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ACC and it is important to stress that PPAR-β/δ directly interacts with AMPK (Kramer et al., 
2007). In the present study both ACC-β and AMPK-α1 subunits were upregulated in the soleus 
muscle by HLS.  AMPK is a major player in the regulation of energy homeostasis, being mainly, 
but not exclusively, activated by changes in AMP: ATP ratio due either to a reduction in ATP 
synthesis or to an increase in ATP consumption. Described initially as a “fuel gauge” or as a 
“guardian of energy status” by Hardie, AMPK acts as a metabolic master switch, being a main 
regulator of oxidative capacity and mitochondrial biogenesis by activating the catabolic ATP-
producing pathways and by inhibiting the anabolic ATP-consuming processes (Hardie and Carling, 
1997). The AMPK-α subunit is coded by two different genes: α1, expressed mainly in the 
oxidative/glycolytic type IIa and oxidative type I fibers; and α2 type, expressed in all types. In my 
experiments I detected an increased expression of AMPK- α2 expression only. AMPK-α2 but not 
AMPK-α1 KO mice are resistant to aminoimidazole carboxamide ribonucleotide (AICAR)-induced 
hypoglycaemic effects and whole body α2 deletion results in a mild insulin-resistant phenotype and 
impaired glucose tolerance test (Towler and Hardie, 2007). The differential role of the two genes is 
further supported by other transgenic experiments that showed that the mice expressing an inactive 
AMPK-α2 subunit have a lower endurance exercise (Koh et al., 2008; Park et al., 2008).  AMPK is 
activated by many stimuli like nutrient depletion, oxidative stress, hypoxia, heat shock, ischemia or 
prolonged exercise by the action of upstream kinases such as LKB1, CamKKIIβ and possibly Tak1. 
Once activated AMPK will phosphorylate many of its targets such as ACC-2, mTOR, e2FK and 
HMG-CoA reductase modifying in short-term their function or changing the genomic expression 
profile of its target genes in long-term. AMPK activation was also correlated with increased 
glucose metabolism mediated not only by translocation of GLUT4 through the plasma membrane 
in an AMPK-dependent and phosphoinositide 3-kinase (PI3K)-independent fashion, but also by its 
increased expression as a consequence of AMPK-mediated effects on gene expression (Song et al., 
2010). I did not find nevertheless a change in expression of GLUT4 in the microarray experiment. 
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Moreover, since PGC-1α is required for this global AMPK-dependent effect on gene expression 
(Thomson and Winder, 2009), and since in my case I noticed a significant reduction in PGC-1α 
expression level, I could speculate that AMPK has no significant effect on transcription in hindlimb 
suspended mice.  AMPK activation will lead to an increased rate of fatty acid oxidation, glucose 
uptake and mitochondrial biogenesis. Switching between glucose and lipids as fuel of choice is a 
constant property of normal healthy muscle, but this ability is reduced during ageing and after 
chronic inactivity. The hindlimb suspension reduces in long-term the metabolic flexibility 
characterizing the normal muscle by preferentially using glucose as a fuel of choice and not lipids. I 
did not measure the levels of fatty acid oxidation in my model of suspended mice, therefore I can 
only speculate about a possible change in its rate. Nevertheless, a possible increased activation of 
AMPK in the acute stage could reflect a genuine increased rate of fatty acid oxidation and this is 
contrasting with the long-term phenotype of unloading.         
                  Another important question is whether AMPK acts upstream or downstream of 
UCP-3. An increase in UCP-3 expression will also lead to an increase in ATP: AMP ratio that 
regulate AMPK activity, which could occur via mitochondrial uncoupling (Dokladda et al., 2005), 
suggesting that AMPK could act downstream of UCP-3. Since PPAR-β/δ agonist treatment also 
activated AMPK signalling through an unknown still mechanism, it is possible that AMPK acts 
downstream of UCP-3 and PPAR-β/δ (Kramer et al., 2007).   Nevertheless, AMPK activation was 
also shown to lead to increased expression of UCP-3 as proved by AICAR stimulation (Putman et 
al., 2003). This issue is a matter of future studies, my data being insufficient to draw a clear and 
final conclusion in this respect at this point.                
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                             3. The role of NR4A family in mediating the multiple effects of caloric 
restriction on skeletal muscle physiology in rats        
                  Caloric restriction is the only dietary intervention that increases the lifespan of 
any experimental model used so far and prevents or delays the development of ageing–associated 
diseases (Masoro, 2005). During ageing skeletal muscle is characterized by loss of muscle mass 
and inervation, reduced muscle strength and impaired metabolic flexibility (Bautmans et al., 2009; 
Hebuterne et al., 2001; Narici et al., 2008; Ryall et al., 2008). These changes are associated with 
increased oxidative stress (Droge, 2005) and insulin resistance (Serrano et al., 2009; Ye et al., 
2006), accumulation of intramuscular ectopic lipids (Slawik and Vidal-Puig, 2006) and reduced 
regenerative capabilities of satellite cells (Renault et al., 2002), partially due to an increased 
occurrence of inflammation or cell death (Kayo et al., 2001). Caloric restriction was shown to 
improve the ageing phenotype by reducing the levels of oxidative and nitric stress, by increasing 
insulin sensitivity and mitochondrial biogenesis, by inhibiting pro-inflammatory and pro-apoptotic 
signals and by improving metabolic flexibility (Carmeli et al., 2002; Lal et al., 2001; 
Leeuwenburgh et al., 1997; Marzetti et al., 2009b).        
                       By using microarray and RT-PCR assays I noticed an increase in expression 
of the family of NR4A receptors upon caloric restriction in rats. It is likely that NR4A subgroup 
has no natural ligand because there is no defined ligand pocket due to the presence of bulky 
hydrophobic amino acids in the ligand binding domain. This conclusion is supported further by the 
fact that DHR38, the only known orthologue of NR4A3 in Drosophila, presents similar 
characteristics. The lack of a ligand-dependent mechanism of regulation of activation suggests that 
NR4As are constitutively active and that there are other mechanisms regulating their activity such 
as post-translational modifications, binding of other mediators to AF-1 transactivation domain, 
different subcellular localizations and changes in expression (Maxwell and Muscat, 2006). The 
most important post-translational modification proved to regulate NR4A subgroup functions is 
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phosphorylation, and so far it was shown that NR4A receptors are phosphorylated at multiple sites 
by many protein kinases such as RSK, ERK, Akt and MSK1. In addition, even if there are no 
known ligands it was discovered nevertheless that NR4A subgroup activity is increased by diverse 
stimuli such as 6-mercaptopurine that binds to AF-1 domain of NR4A3, PGA2 that binds to the 
ligand-binding domain of NR4A3 and the compound DIM-C-pPhCl (1,1-bis(3¶-indolyl)-1-(p-
chlorophenyl)-methane) that activates NR4A1  activity through the binding to the C-terminus. 
Another mechanism of control of NR4A function is differential localization. For example NR4A1 
can be localized not only in the nucleus but also in cytosol and mitochondria, and such extranuclear 
localization is involved in the induction of apoptosis.  It is now well established that NR4A 
subgroup expression levels are modified by the action of diverse stimuli such as free fatty acids, 
oxidative stress, prostaglandins, growth factors, cytokines, peptide hormones, phorbol esters and 
neurotransmitters through the phosphorylation of many transcriptional factors such as AP-1, 
CREB, NFkB and Sp1 (Maxwell and Muscat, 2006). Therefore, the increased expression noticed 
can be directly correlated with an increased level of activity.      
            The nuclear hormone receptor 4A (NR4A) subgroup comprises three different 
receptors: neuron-derived clone 77 (NR4A1, Nurr 77, NGFI-B), nuclear receptor related 1 
(NR4A2, Nurr1) and neuron-derived orphan receptor 1 (NR4A3, NOR-1). The typical NR4As 
DNA binding motif sequence is known as NGFI-B response element (NBRE) and is defined by two 
adenines followed by the classical NR sequence AGGTCA. NR4A can bind to the specific DNA 
sequences either as monomers, either as dimers. Interestingly enough, NR4A1 and NR4A3 can 
heterodimerize with RXR and this interaction confers the ability to bind not only to NBRE but also 
to DR5 elements.  The initial studies demonstrated that NR4A receptors are important in cell 
survival and apoptosis and recent reports have linked them to the regulation of DNA repair (Pols 
and de Vries, 2008).  
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             Since the roles of NR4A family members in regulating metabolism and energy 
expenditure are relatively a recent discovery and since systematic reports about their specific 
function in aged skeletal muscle are scarce, I will present below a short summary of the current 
knowledge of their functional profiles in order to better decipher and integrate the potential 
relevance of my data in the previous corpus of information. 
 
                                3.1 NR4A1               
                     There are multiple independent reports indicating that NR4A1 has a critical 
role in regulating glucose and lipid metabolism in skeletal muscle (Kanzleiter et al., 2009). In 
addition, the experimental mice lacking NR4A1 develop insulin resistance and obesity upon a high-
fat diet showing reduced oxygen consumption, increased accumulation of intracellular lipids in 
myocytes and impaired insulin receptor phosphorylation compared to the wild-type mice fed on the 
same type of diet (Chao et al., 2009). The silencing of NR4A1 in C2C12 myogenic cell line 
resulted in the subsequent decrease in expression of many genes involved in lipid transport (CD36, 
caveolin 3), glucose uptake (GLUT4),  fatty acid oxidation (UCP-2, UCP-3, AMPK-γ3) and 
signalling (adiponectin receptor 2) (Maxwell et al., 2005). To confirm the changes identified by 
microarray an RT-PCR assay was performed for some of the NR4A1 known targets, noticing that 
the expression levels of UCP-3 and AMPK-γ3 were upregulated in the skeletal muscle of the 
caloric restricted rats (Fig. 3.9). This result is in agreement with the silencing experiment 
performed in C2C12 cells mentioned above, suggesting a possible involvement of NR4A1 in my 
model’s phenotype. In addition, it was reported that in liver NR4A1 blocks SREBP1 activity (Pols 
et al., 2008) and reduces the expression of SREBP1 target genes such as SCD-1, GPAM and 
FASN. I also noticed by RT-PCR that while the expression of SREBP1 was not significantly 
decreased, the expression values of SCD-1 and GPAM were reduced in skeletal muscle of CR 
models (Fig. 3.10). In another independent report the overexpression of NR4A1 in C2C12 cells 
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increased also the expression of genes relevant for glucose transport (GLUT4), glycolysis (BPGM, 
PGAM2, ENO3, PFKM) glycerophosphate shuttle (GPD1 and SLC37A2), glycogenolysis (PYGM, 
PHKA1 and PHKG1) and glycogen storage (GYS3 and PPP1R3C) (Chao et al., 2007), but it did 
not affect the genes involved in lipid metabolism. In my microarray experiment an increased 
expression it was detected only for GPD1 and PGAM1, the rest of the genes from the list being 
unchanged (Table 3.8).  Furthermore, in another report it was shown that whilst the overexpression 
of the gene in L6 in vitro had no effect on lipid oxidation, it had nevertheless a significant effect on 
the rate of glucose uptake in both basal and insulin-stimulated conditions due to an increased 
expression of GLUT4 and glycogenin (Kanzleiter et al.). Nevertheless, in my microarray 
experiment I did not see a significant change in the skeletal muscle of the caloric restricted rats in 
the expression of the above mentioned target genes.                                                                                                                                
                       NR4A1 was proved also to have a powerful effect on cell death and oncogenesis, 
events affecting the skeletal muscle during ageing. For example, in pancreatic beta-cell lines its 
expression was induced by free fatty acids and this correlates with the degree of apoptosis in vivo 
(Kuang et al., 1999). Moreover, in stimulated T-cells the silencing of the gene prevented apoptosis 
(Liu et al., 1994). Another possibility is that NR4A1 is involved in blocking the inflammatory 
signals in aged caloric restricted animals since it was shown that it is an inhibitor of NFkB-
dependent signalling (Evans, 2009) through the interaction with IkBa, the inhibitor of p65 subunit 
of NFkB (You et al., 2009). Therefore it can be concluded that NR4A1 might be a crucial mediator 
in modulation of the changes induced by caloric restriction in skeletal muscle in the expression of 
many genes that regulate glucose and lipid metabolism. Nevertheless, since there are no published 
reports about the effects of acute caloric restriction on NR4A1 expression, I can not speculate if 
such an effect is an early or late-stage event. 
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                                     3.2 NR4A2 
                                      The data analysis of the microarray experiment followed by RT-PCR 
showed an increased expression of NR4A2 in the skeletal muscle samples taken from caloric 
restricted rats. In different tissues NR4A2 has different functions and changes in its expression 
have been correlated with diverse pathological conditions characterized by oxidative stress and 
inflammation. Reduced expression of NR4A2 was reported in the neuronal samples from patients 
with Parkinson disease (Le et al., 2008) and mutations affecting the NR4A2 gene were further 
associated with familial forms of this neurodegenerative disease (Federoff, 2009; Sleiman et al., 
2009; Sutherland et al., 2009). One possible explanation was suggested by the discovery that the 
silencing of NR4A2 resulted in a significant increase in α-synuclein gene expression due to a 
reduced inhibitory binding of the nuclear receptor to the gene promoter (Yang and Latchman, 
2008). Since α-synuclein is also important in the pathogenesis of many protein aggregation 
disorders affecting skeletal muscle during ageing (Askanas et al., 2000), I verified its expression in 
my microarray experiment but noticed that it was nevertheless unchanged.  
                              Less is known about the role of NR4A2 in skeletal muscle physiology besides 
the fact that its expression is moderately increased in skeletal muscle after exercise (Mahoney et al., 
2005) and beta-adrenergic treatment (Myers et al., 2009).  I verified in my microarray experiment 
data set any change in expression values of previously reported NR4A2 target genes in other 
tissues. I detected a reduced expression of genes involved in lipid metabolism such as FABP3 and 
FABP5 previously reported to be positively regulated by NR4A2 (Volakakis et al., 2009). Another 
gene that has been reported to be increased by NR4A2 activation (Li and Tai, 2009) such as cyclin 
D1 was also decreased. It was noticed in the same set of data a decreased expression of many 
growth factors associated with skeletal muscle mass, atrophy and differentiation such as FGF2, 
FGF9 and FGF7, but not FGF20 and FGF8, reported previously to be regulated by NR4A2 (Grothe 
et al., 2004; Kim et al., 2003). 
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                            NR4A2 was shown also to have complex effects on cellular stress and 
inflammation in different tissues. In the case of cell death affecting the dopaminergic neurons 
NR4A2 proved to act  as a neuroprotective agent by blocking the gene expression of many 
inflammatory mediators in astrocytes and microglia (Bensinger and Tontonoz, 2009). The 
overexpression of the receptor in neural stem cells improved also the resistance against oxidative 
stress (Sousa et al., 2007).  The precise mechanisms are still unclear but it was already discovered 
that NR4A2 is interacting with astrocytal CoREST complex, blocking the expression of many 
inflammatory mediators that once released by astrocytes could have neurotoxic effects (Saijo et al., 
2009). The overexpression of NR4A2 in macrophage cell line THP-1 reduced further the levels of 
oxidized lipids and inflammatory mediators possibly through the transrepression of NFkB 
signalling pathway (Pei et al., 2005). A similar conclusion was also suggested by recent 
experiments using neuronal models (Sousa et al., 2007). This protective effect in the case of 
astrocytes, neurons and macrophages is nevertheless contradictory to the effect shown by the 
overexpression of the receptor in a model of a immortalized synoviocyte cell line that presented 
increased expression of many pro-inflammatory mediators such as IL-8, amphiregulin and kit 
ligand (Davies et al., 2005; O'Kane et al., 2006), genes that were nevertheless unchanged in my 
microarray experiment. A similar conclusion was derived from independent studies of NR4A2 
overexpression in cartilage (Mix et al., 2007). In addition, in the T-cells from the CNS of the mouse 
models of multiple sclerosis (EAE) NR4A2 had a higher level of expression compared to the wild-
type animals and the overexpression of NR4A2 in vitro resulted in an increased expression of pro-
inflammatory cytokines such as IL-17 and IFN-γ. In the skin of psoriatic patients NR4A2 
expression level is increased significantly in both cytosol and nucleus, and blocking of TNF-α 
signalling by treatment with the drug infliximab was able to reduce NR4A2 expression level to the 
normal values and restore the predominant cytosolic localization seen in the skin of healthy patients 
(O'Kane et al., 2008). I did not detect nevertheless any change in expression levels of the above 
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mentioned target genes in my experiment with caloric restricted rats, therefore the possible role of 
NR4A2 in reducing inflammation in my experimental caloric restricted model is a matter to be 
explored further in the future. In NR4A2 heterozygous mice the striatal levels of nNOS were 
increased and the neuropathy seen in the dopaminergic neurons was dependent on nitric oxide 
production (Imam et al., 2005).  I did not detect nevertheless a reduced expression of nNOS in the 
caloric restricted mice. 
                      NR4A2 was also reported to be regulated in some tissues by NFkB (McEvoy et al., 
2002).  The interplay between NR4A2 and the regulation of cell cycle was also proved by the fact 
that in the same type of neurons it is interacting with p53 and has a negative effect by repressing its 
transcriptional activity with anti-apoptotic effects (Zhang et al., 2009). In my microarray 
experiment p53 was downregulated simultaneously with some of its binding proteins such as 
TP53BP1 and some of its target genes such as WIG1.  The discovery that glucocorticoid receptor is 
interacting with then N-terminus of NR4A2 increasing its transcriptional activity (Carpentier et al., 
2008) is contrasting nevertheless with the fact that caloric restriction is reported to downregulate 
the GR expression in some tissues (Gursoy et al., 2001).  
                            Therefore the downstream gene targets for NR4A2-dependent signalling in the 
case of skeletal muscle are still undeciphered, but it is probable that an increase in its expression 
might be involved in the repression of pro-inflammatory mediators upon caloric restriction 
conditions.  
 
                              3.3    NR4A3 
                              In my experiment it was noticed also an increased NR4A3 expression in the 
skeletal muscle of caloric restricted rats, receptor that was cloned in 1994 (Ohkura et al., 1994) and 
has different splice variants with different functional properties (Ohkura et al., 1998).  The specific 
role of NR4A3 in skeletal muscle was recently explored and it was proved for example that in 
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C2C12 murine cultured myotubes its expression was increased by beta-adrenergic treatment in 
PKA-dependent manner (Kanzleiter et al., 2009; Pearen et al., 2006). The silencing of NR4A3 gene 
reduced the expression level of UCP-2 and increased the expression level of UCP-3. Since UCP-3 
was found to be upregulated in caloric restricted samples it is likely that this is due to NR4A3-
independent regulatory mechanisms. Silencing of NR4A3 expression in myogenic C2C12 cell line 
reduced palmitate oxidation, increased lactate concentration and shifted the metabolism toward a 
more anaerobic process due to a lower expression of genes involved in lipid oxidation and pyruvate 
use (Pearen et al., 2008) such as PGC1-α and PGC-1β. This correlates with my discoveries that in 
the skeletal muscle of the caloric restricted rats the expression levels of PGC1-α and PGC-1β genes 
were increased while lactate dehydrogenase was decreased (Fig. 3.9). Nevertheless, other target 
genes regulating lipid oxidation reported to be reduced in the NR4A3-silenced C2C12 cells such as 
PDK4, FOXO1 and lipin1a were not changed in my experiment.  
                              An increase in expression of NR4A3 could also affect glucose metabolism, since 
some of NR4A3 polymorphisms are associated with a better insulin secretion in non-diabetic 
patients (Weyrich et al., 2009). The overexpression of NR4A3 in 3T3-L1 adipocytes increased the 
rate of glucose transport (Fu et al., 2007) upon insulin treatment though an increased GLUT4 
translocation to the plasma membrane in a manner dependent on PI3K/Akt-associated signalling, 
and the silencing of the gene generated the opposite phenotype. NR4A3 has also clear effects on 
the hormonal regulation of food intake since it was shown before to be expressed at lower values in 
the hypothalamus of leptin-deficient obese animal models compared to controls, independently of 
5-HT2C signalling. The injection of NR4A3 siRNA in animal models suppressed the daily food 
intake (Nonogaki et al., 2009) which might suggest a compensatory role in obese animals.  
                              NR4A3 has also an important but still not fully understood role in the regulation 
of cell death and oncogenesis. For example, it was reported that overexpression of NR4A3 
prevented endothelial cell death under hypoxia conditions and that silencing of the gene increased 
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the number of apoptotic cells (Martorell et al., 2009).  In T-cells the overexpression of NR4A3 
induced nevertheless apoptosis through the upregulation of CD25. In addition, the induction of 
apoptosis upon TCR activation is accompanied by upregulation of NR4A3 and NR4A1 (Cheng et 
al., 1997). The cell death of MCF7 cancer cell line induced by treatment with calcium ionophore 
A23187 (Ohkubo et al., 2000) increased the expression levels of NR4A3, and a similar event was 
also noticed in the early stage of rat liver resection-reperfusion injury (Ohkubo et al., 2002).  When 
spleen cells from NR4A3 transgenic mice were treated with prostaglandin A2 (PGA2), the number 
of the apoptotic cells tripled compared to control (Kagaya et al., 2005). By using cell-free systems 
the same authors showed that PGA2 is able to transactivate NR4A3 though binding to LBD. 
NR4A3 has therefore much more complex and intriguing relationships with the regulation of cell 
death and oncogenesis than the other two members of the family. For example, as a result of the 
t(9;22) translocation NR4A3 was reported to fuse with EWS (EWS/NOR1) and the new product 
was proved to have a role in the development of extraskeletal myxoid chondrosarcoma (EMC) 
(Antonescu et al., 1998). The mechanisms underlying this process of oncogenesis are still debated 
but it was shown so far that the fusion protein is able to modulate transcription by affecting pre-
mRNA splicing (Ohkura et al., 2002). Another reports showed that PARP-1 was able to bind to 
NR4A3 but not to EWS/NOR1, consequently inhibiting the NR4A3 transactivation properties and 
its interactions with the global transcriptional machinery (Ohkura et al., 2008).  
                            NR4A3 has also important effects on inflammatory mediators since it was shown 
that the administration of purine anti-metabolite 6-mercaptopurine, an antineoplastic and 
antiproliferative agent with additional anti-inflammatory properties, was able to transactivate 
NR4A3 in AF-1 dependent manner (Wansa et al., 2003). In addition, IL-1B treatment of human 
synovial and gingival fibroblasts increased both NR4A3 expression levels and its DNA binding 
activity (Borghaei et al., 1998). The list of upstream regulators and signalling pathways of NR4A3 
expression include so far CAM-KK cascade and the subsequent CREB signalling in neurons 
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(Inuzuka et al., 2002) and smooth muscle cells (Martinez-Gonzalez et al., 2003), and  PKA-
signalling in cultured osteoblasts upon  parathyroid hormone treatment (Pirih et al., 2003). In 
endothelial cells NR4A3 expression is increased by vascular endothelial growth factor (VEGF) in a 
CREB-dependent manner regulating further cell cycle, DNA synthesis and cell growth (Rius et al., 
2006). The role of NR4A3 in mediating vascular smooth muscle cells proliferation was shown by 
the fact that its increased expression upon statin treatment was inhibited by simvastatin by 
interfering with CREB phosphorylation through inhibition of RhoA/ROCK pathway (Crespo et al., 
2005).                         
          Therefore, based on these particular experiments performed already on the cultured 
myotubes I can speculate that the increase in NR4A3 expression in the skeletal muscle of caloric 
restricted rats might mediate an increase in the rates of lipid oxidation,  mitochondrial biogenesis 
and reduced oxidative stress, which could explain the improvements seen in skeletal muscle during 
CR (Nadeau et al., 2006) .     
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Chaptter  4--THE  EFFECTS  OF  VISFATIN  (( eNAMPT))   ON  OXIDATIVE  
STRESS  LEVELS  AND  INSULIN  RECEPTOR-- DEPENDENT  
SIGNALLING  IN  CULTURED  MYOTUBES  
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                             4A. Introduction 
                   Adipokines are cytokines secreted by the adipose tissue acting in autocrine (Karastergiou 
and Mohamed-Ali, 2009), paracrine (Vona-Davis and Rose, 2007) or endocrine fashion (Wozniak et 
al., 2009). Since adipokines can influence the metabolism of  other peripheral tissues such as skeletal 
muscle (Kim et al., 2009), myocardium (Schram and Sweeney, 2008), liver (Marra and Bertolani, 
2009),  pancreas (Stadler et al., 2009) or components of immune system (Curat et al., 2004), their 
endocrine effect has overall a major physiological impact. Any changes in adipokines expression, 
activity or localization play a significant role in the development of many pathological conditions 
such as obesity (Trayhurn and Wood, 2005), metabolic syndrome (Kobayashi, 2005), inflammation 
(Aldhahi and Hamdy, 2003) or lipodystrophy (Sweeney et al., 2007). As discussed in the previous 
chapter, during ageing skeletal muscle is characterized by progressive structural changes and 
decaying functionality (Rossi et al., 2008). These phenotypes are partially underlined by changes in 
expression profile of the networks regulating glucose and lipid metabolism, insulin sensitivity 
(Serrano et al., 2009; Ye et al., 2006) and antioxidant defence (Droge, 2005), the same type of 
processes that are affected in the pathological conditions associated with adipokines  mentioned 
above. In addition, a significant part of the published literature revealed the critical role of 
adipokines in modulating the signalling pathways regulating insulin sensitivity and antioxidant 
defence in peripheral tissues during ageing (Di Gregorio et al., 2004; Esposito et al., 2006; Fulop et 
al., 2006; Miles et al., 2008; Picard and Guarente, 2005; Schutte et al., 2007; Terlain et al., 2006).         
   Visfatin is a newly discovered member of adipokine family with the unique 
particularity within the group of having two variant forms, identical in sequence and coded by the 
same gene, but with different localizations: the first is intracellular (iNampt), and the second 
extracellular (eNampt). The intracellular form of visfatin is ubiquitously expressed and it was proved 
so far to synthesize NMN, an intermediate of NAD, through its phosphoribybosiltransferase activity 
(Wang T. et al., 2006). The extracellular form was found to be actively secreted through a non-
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classical and still obscure regulated pathway (Revollo et al., 2007) by both white adipocytes 
(Fukuhara et al., 2005) and brown  adipocytes (Wang et al., 2009), justifying its inclusion in the 
adipokine group. Recently, a more complex picture emerged since it was reported that visfatin is 
secreted also by many other types of cells such as macrophages (Curat et al., 2006) and hepatocytes 
(Garten et al., 2010). The discovery that intracellular visfatin (iNampt) is highly expressed in 
skeletal muscle inspired initially the speculation that it might act also as a myokine after the 
secretion from myocytes, similarly to interlukin-6 (IL-6) or inrerleukin-15 (IL-15) (Krzysik-Walker 
et al., 2008), and recently it was reported also that visfatin was detected in the culture medium of rat 
L6 differentiated myotubes (Wang et al., 2010).                        
      There are no definitive conclusions about the relationships between extracellular 
visfatin (eNampt) and the ageing process or the ageing phenotype, but there are multiple arguments 
to implicate the extracellular form of visfatin in the development of the pathological conditions 
associated with ageing. Measurements of the levels of plasma visfatin revealed significant 
differences between the healthy human subjects (control group) and diverse cohorts of patients 
suffering from a large variety of pathological conditions such as chronic kidney disease (Mu et al., 
2010), acute pyelonephritis (Mazaki-Tovi et al., 2010), diabetic nephropathy (Kang et al., 2010), 
inflammation (Chang et al., 2010b), thyroid dysfunctions (Ozkaya et al., 2009), ischemic stroke (Lu 
et al., 2009a), polycystic ovary syndrome (Panidis et al., 2008), coronary artery disease (Liu et al., 
2009a), arthritis (Jurcovicova et al., 2010), markers of increased oxidative stress (Bo et al., 2009), 
endothelial dysfunction (Takebayashi et al., 2007) and insulin sensitivity (Li et al., 2006). In almost 
all these pathological cases the level of plasma visfatin was found to be higher in the disease group 
compared to the healthy one, correlating moreover with the degree of the symptoms. Nevertheless, it 
is not clear yet whether such increased concentration of visfatin represents a cause of the disease, an 
accidental side effect or an indication of a protective/compensatory role (as discussed in the case of 
HLS and PPAR-β/δ before). For example, whilst overweight patients showing weight loss under a 
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hypocaloric diet had lower visfatin plasma levels (de Luis et al., 2008), in a different model of 
hemorrhagic shock/resuscitation the plasma concentration of visfatin correlated positively with the 
protective therapeutic hypothermia intervention (Beiser et al., 2010). Also, it was shown that visfatin 
expression is upregulated in skeletal muscle upon exercise in human patients (Costford et al., 2010).
    It is known already that adipokines or cytokines such as TNF-α (Lo et al., 2007), IL-6 
(Lihn et al., 2008), resistin (Junkin et al., 2009), omentin (Winkler and Cseh, 2009), vaspin (Rabe et 
al., 2008), leptin (Solinas et al., 2004) and adiponectin (Vu et al., 2007) have a major impact on 
skeletal myotubes survival and lifespan, stress responses, inflammation and insulin sensitivity.  As 
previously reported (Adya et al., 2008a,b; Xie et al., 2007; Lim et al., 2008), once secreted in the 
plasma by adipocytes, hepatocytes or macrophages the extracellular form of visfatin (eNampt) is 
able to bind to the insulin receptor expressed by endothelial cells, osteocytes and cardiomocytes and 
trigger the activation of PI3K/Akt signalling cascade, leading to an increase in the rate of glucose 
uptake. The possibility that visfatin could be used as an insulin-mimetic agent opened a new 
direction in the research dedicated to find new solutions for the treatment of insulin resistance, 
obesity and metabolic syndrome (Fukuhara et al., 2005). Previous in vitro or ex vivo research 
showed that the incubation of primary or immortalized cell lines originating from different tissues 
with different concentrations of visfatin (eNampt), changes in its intracellular expression levels 
(iNampt) by genetic interventions (transgenic or knock-out), or pharmacological-based inhibition of 
its phosphoribosyltransferase function can have different, even opposite effects on cellular viability, 
stress responses and inflammatory signals.                  
           For example, it was reported that incubation of macrophages (Li et al., 2008), 
cardiomyocytes (Lim et al., 2008) or amnion cells (Kendal-Wright et al., 2008) with visfatin 
(eNampt) improved the cellular viability and prevented apoptosis induced by various toxic agents. In 
addition, the blocking visfatin phosphoribosyltransferase function induced apoptosis of tumour cells 
(Khan et al., 2007; Khan et al., 2006). Nevertheless, it was also shown that silencing of the gene 
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reduced the levels of oxidative stress induced by IL-1β in lung endothelial cells (Zhang et al., 2008) 
and that incubation of human umbilical vein endothelial cells (HUVECs) with visfatin activated the 
NFkB-associated pathway in an ROS-dependent manner (Kim et al., 2008).   Although there are no 
reports about changes in visfatin plasma levels during ageing, it was reported nevertheless that 
overexpression of visfatin in endothelial cells increased their replicative lifespan and improved their 
resistance against cellular stress in a high glucose environment (Borradaille, N.M. et al. 2009). 
Skeletal muscle is the main system responsible for the removal of the circulating glucose and its 
physiology is modified by changes in the levels of plasma circulating adipokines, especially in the 
case of insulin sensitivity, inflammatory status and antioxidant defence  (Dyck et al., 2006). Since 
there were no previous reports about the effects of plasma visfatin on skeletal muscle stress 
responses and insulin sensitivity, I explored these questions in the present chapter whose main 
findings were published in the attached paper (Oita et al., 2010). In my research I used C2C12 cell 
line that it is an established, robust and stable cellular model (Kubo, 1991), being an attractive 
choice to study in vitro the effects of different adipokines on skeletal muscle physiology.  
   The first goal of the present chapter was to test by using fluorescent-based assays 
whether the incubation of C2C12 myotubes with exogenous visfatin induced a change in oxidative 
stress levels. The second was to test if exogenous visfatin activated insulin receptor-dependent 
signalling.  
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                        4B. Results 
                         4.1 Visfatin (eNampt) incubation increases the levels of oxidative stress in 
cultured and differentiated murine C2C12 skeletal myotubes        
    In order to study the effects of free, plasma circulatory, extracellular form of visfatin 
(eNampt) on skeletal muscle stress-responses a commercially available mouse visfatin recombinant 
protein (BioVision, Inc) has been used. To confirm the results and to remove any reasonable doubt 
about the validity of the protein chosen for my experiments, the main experimental conclusions have 
been further verified by using two other versions available on the market, reaching the same 
conclusions. One was purchased from MBL International and it was produced in bacteria, and the 
other was purchased from Axxora Ltd and it was  produced in mammalian HEK 293 cells, version 
that was already validated in a previously published paper (Li et al., 2008).                     
               To explore the possibility that extracellular visfatin (eNampt) could induce oxidative 
stress in a cultured model of skeletal muscle, I incubated fused and differentiated murine C2C12 
myotubes with different concentrations of visfatin (0-200 ng/ml) for a variable range of time (0-24 
hours). The levels of ROS generated intracellularly were measured by using the fluorogenic specific 
probe carboxy-H2DCFDA. This probe is easily transported across the plasma membrane into the 
cytosol where it is deacetylated by nonspecific cellular esterases to the compound carboxy-DCFH. 
The free radicals generated intracellularly reduce the fluorescein further to the compound carboxy-
DCF that shows an increased bright green fluorescent emission upon UV excitation. This signal was 
detected by fluorescent microscopy and images were further processed by software-based analysis. 
In order to double-check the results, I also verified the imaging results by using an automatic 
microplate reader attached to a PC, reaching the same conclusions.                            
                 As seen from figure 4.1, the incubation of cells with different concentrations of 
visfatin for 24 hrs induced a significant increase in the level of free radicals from a starting value of 
20 ng/ml, and since the maximum signal detected was reached at 100 ng/ml of visfatin I decided to 
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use this value as the working concentration. This concentration is consistent also with previous 
published papers exploring the effects of visfatin on stress responses in other types of cells (Lovren 
et al., 2009; Moschen et al., 2007; Xie et al., 2007).   To identify the earliest time point of a 
significant ROS detection I incubated cultured myotubes with 100 ng/ml of visfatin for a different 
range of time (1- 24 hours), and as seen from figure 4.2 by using the fluorescent microscopy 
imaging I discovered a significant increase in ROS production between 4 and 6 hours of incubation, 
with a maximum signal value reached after 18 hours. Longer incubation time failed to further 
increase the production of the free radicals. In conclusion, for the rest of experiments performed in 
this chapter I used the concentration of 100 ng/ml of visfatin and an incubation period of 18 hours as 
optimal conditions for inducing and measuring oxidative stress levels.                 
               To certify that the signal is genuine, I pre-incubated the C2C12 cells with 1mM 
NAC (N-acetyl-l-cysteine, a gluthatione precursor that is widely used as a scavenger for free 
radicals) for 1 hour before visfatin treatment and repeated the carboxy-H2DCFDA fluorescent-based 
assays. As seen from figure 4.3, the signal from cells pre-treated with NAC before visfatin challenge 
was reduced with cca. 40% compared to signal detected from cells incubated only with visfatin. 
Since carboxy-H2DCFDA-based microscopy is not discriminating efficiently between different 
species of oxygen free radicals, I further explored the detection of individual species like superoxide 
and hydrogen peroxide by using type-specific probes. To detect the presence of hydrogen peroxide I 
used the probe pentafluorobenzenesulfonyl fluorescein (Fig. 4.4A) that becomes fluorescent upon 
perhydrolysis of the sulfonyl linkage and to detect the generation of superoxide I used the 
mitochondrial-specific probe MitoSOXTM Red (Fig. 4.4B). The fluorescent-based assays 
experiments using the probes listed above proved that after 18 hours of incubation of the cells with 
100 ng/ml of visfatin both types of free radical species were detected.                      
    
 
                      Fig. 4.1 Chronic incubation of differentiated myocytes with various concentrations of 
visfatin induces oxidative stress 
          Differentiated C2C12 myotubes were incubated for 
of recombinant visfatin (0-200 ng/ml). After 
H2DCFDA for 25 min to detect 
µM Hoechst 33342 to stain the nuclei. Relative expression compared to negative control data is 
shown. Data shown are the average of quadruplicate samples per experiment, from three 
independent experiments +/− SEM. *Denotes p<0.05 compared to control. **Denotes p<0.01 
compared to control.  
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24 hrs with different concentrations 
24 hrs cells were incubated with 25 
the levels of intracellular ROS, followed by 5 min incubation with 1 
 
 
 
 
 
 
 
 
 
 
 
 
   
µM carboxy-
  
           Fig. 4.2 Incubation of differentiated myocytes with a high concentration of visfatin induces 
oxidative stress after 6 hrs                    
             Differentiated C2C12 myotubes were incubated for a different range of time (0
hrs) with 100 ng/ml recombinant visfatin. Cells were incubated with 25 
25 min to detect ROS followed by 5 
Relative expression compared to control data is shown. Data shown are the average of quadruplicate 
samples per experiment, from three independent experiments +/
to control. **Denotes p<0.01 compared to control. NS denotes no difference between treatment and 
control.  
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µM carboxy
min incubation with 1 µM Hoechst 33342 to stain the nuclei. 
− SEM. *Denotes p<0.05 compared 
   
-24 
-H2DCFDA for 
             Fig. 4.3 The oxidative stress induced by the treatment of cultured myocytes with visfatin is 
reduced by the pre-treatment with
               Differentiated C2C12 myotubes were incubated for 18 hrs with 100 ng/ml recombinant 
visfatin after the pre-treatment in the presence or absence of 1 mM NAC for 1 hr to scavenge the 
free radicals. Cells were incubated with 25 
followed by 5 min incubation with 1 
compared to control data is shown. Data shown are the average of quadruplicate samples per 
experiment, from three indepe
and between visfatin treatment plus NAC
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 antioxidants  
µM carboxy-H2DCFDA for 25 min to detect ROS 
µM Hoechst 33342 to stain the nuclei. Relative expression 
ndent experiments +/− SEM. **Denotes p<0.01 compared to control 
 compared to visfatin alone.  
             Fig. 4.4 Visfatin treatment of cultured myocytes generates both superoxide and hydrogen 
peroxide reactive oxygen species. 
  C2C12 differentiated myotubes were incubated for 18 hrs with 100 ng/ml of visfatin as 
shown before. A. Production of hydrogen peroxide was detected by incubating myoblasts with 1 
µg/ml of pentafluorobenzenesulfonyl fluorescein for 25 min followed by 5 min incubation with 1 
µM Hoechst 33342 (to stain the nuclei);
differentiated cells with 5 µM MitoSOX
Hoechst 33342 (to stain the nuclei). Relative expression compared to control is shown. Each data 
point is the average of quadruplicate samples per experiment from three independent experiments. 
+/− SEM. **Denotes p<0.01 compared to control.
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C2C12 differentiated myotubes were incubated for 18 hrs with 100 ng/ml of visfatin as 
. Production of hydrogen peroxide was detected by incubating myoblasts with 1 
benzenesulfonyl fluorescein for 25 min followed by 5 min incubation with 1 
hst 33342 (to stain the nuclei); B. Superoxide generation was detected by incubating 
µM MitoSOXTM Red for 15 min followed by 5 min incubation with
Hoechst 33342 (to stain the nuclei). Relative expression compared to control is shown. Each data 
point is the average of quadruplicate samples per experiment from three independent experiments. 
− SEM. **Denotes p<0.01 compared to control. 
        
 
 
 1 µM 
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              4.2   Visfatin (eNampt) treatment is not increasing the levels of oxidized proteins and 
lipids and it is not changing the myocytes global antioxidant capability     
    Oxidation can change the structure and the function of proteins (le-Donne et al., 2006), 
DNA/RNA (Radak et al., 1999) or lipids (Rosenfeld, 1998) and an increased level of ROS can 
affect the proper metabolism of skeletal muscle (Singh et al., 2008). Therefore I further verified if I 
could detect a change in the levels of the oxidized forms of lipids and proteins upon incubation with 
visfatin. To detect and quantify the levels of the oxidized forms of the proteins I used the OxyblotTM 
assay method that detects the levels of carbonylated residues introduced in the side-chains of the 
proteins by the action of oxygen free radicals. Briefly, the denatured and reduced cell lysates 
extracted were treated with 2,4-dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups to 
2,4-dinitrophenylhydrozone (2,4-DNP) residues. Such derivatized 2,4-DNP residues were 
recognized by a specific antibody through a typical western blot assay and the levels of oxidation 
were further quantified by densitometric analysis. As seen from figure 4.5, there were no significant 
differences between the levels of oxidized proteins from cell lysates extracted from the wells 
incubated with visfatin for 16, 24 or 48 hours compared to cell lysates extracted from control, 
untreated cells. The specificity of the assay was proved by the lack of chemiluminescent signal in 
the samples treated only with the derivatization-control solution (buffer) instead of DNPH.                      
   I tested also the possibility that the free radicals induced by visfatin could increase 
the levels of oxidized lipids. To test this hypothesis I used an LPO assay kit that is based on the 
capability of thiocyanate ions (the chromogen) to recognize the ferric ions produced by the reaction 
of lipid hydroperoxides with the ferrous ions from the assay solution. As seen in figure 4.6, I did not 
detect any significant increase in the levels of oxidized lipids in the samples taken from the cells 
treated with visfatin for 16, 24 or 48 hours compared with to control.           
             Because these two sets of results concerning the levels of oxidized products were 
apparently contradictory with the results presented in the subchapter 4.1, I hypothesized that visfatin 
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could increase simultaneously not only the production of ROS but also the global cellular 
antioxidant defence capacity that might prevent such free radicals to have any significant oxidizing 
effect on proteins and lipids. To test this possibility I measured colorimetrically the global 
capability of the cell lysates to prevent the oxidation of the compound ABTS® by metmyoglobin, 
and as seen from figure 4.7 visfatin treatment for 24-48 hours failed to change the global 
antioxidant capacity compared to control, unlike hydrogen peroxide that reduced it.                   
          These experiments proved that the free radicals produced by incubation with visfatin 
did not increase significantly the levels of oxidized lipids and proteins. Additionally, the lack of a 
general simultaneous increase in global cellular antioxidant defence upon incubation with visfatin 
might suggest the possibility of a partial or localized increase in such antioxidant defence. This 
subject will be explored in detail in the following chapters.   
 
        
 
 
 
 
 
 
 
 
                  Fig. 4.5 Visfatin treatment 
        C2C12 differentiated myotubes were incubated for 16, 24 and 48 hrs with 100 ng/ml of 
visfatin. The denatured and reduced cell lysates extracted were treated with 2,4
dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups to 2,4
(2,4-DNP) residues, or only with buffer as a negative control. The cell lysates were resolved by
using a standard western blot procedure by using an antibody against the derivatized 2,4
residues. Quantization of the expression was performed by densitometric analysis and the values 
were further to the untreated cells. 
experiments +/− SEM. NS denotes no significant difference between visfatin treatment and control.
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             Fig. 4.6    Visfatin treatment 
 C2C12 differentiated myotubes we
visfatin as shown before. The lipids were extracted and the levels of lipid hydroperoxides were 
quantified based on the capability of thiocyanate ions (the chromogen) to recognize the ferric ions 
produced by the reaction of lipid hydroperoxides with the ferrous ions from the assay solution. 
Quantization of the expression was performed by colorimetric analysis and the values were further 
normalized to the negative control. 
experiment from three independent experiments +/
between visfatin and control. 
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Each data point is the average of duplicates samples per 
− SEM. NS denotes no significant difference 
                                                                                                                             
                 
                   Fig. 4.7    Visfatin treatment 
capability                   
        C2C12 differentiated myotubes were incubated for 24 
visfatin as shown before or with hydrogen peroxide as a positive control for 30 minutes. Cells were 
scraped and the cell lysates extracted were used to block the oxidation of ABTS compound by 
metmyoglobin. The levels of oxidati
point is the average of duplicates samples per experiment from three independent experiments +/
SEM. ***Denotes p<0.001 compared to control. NS denotes no significant difference between 
visfatin treatment and control.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
does not increase the myocytes global cellular antioxidant 
      
and 48 hrs with 100 ng/ml of 
on were assayed by colorimetry, relative to control. Each data 
 
   
− 
111 
 
         4.3 Visfatin (eNampt) treatment is not affecting the cellular viability and is not 
increasing the levels of nitrosylated proteins                                
     A sustained oxidative stress in cultured skeletal myocytes can also have cytotoxic 
effects that could lead to a reduced cellular viability (Liao et al., 2006). In order to measure the 
cellular viability after visfatin treatment I used a commercially available assay kit (BioVision, Inc) 
that is measuring the activity of the enzyme lactate dehydrogenase which is released from the cells 
in the supernatant if the integrity of the plasma membrane is compromised, generating NADH 
following lactate oxidation. The kit quantifies the levels of NADH generated by using the specific 
compound WST. Visfatin treatment for 24-48 hours did not change significantly the levels of 
NADH in the supernatant unlike hydrogen peroxide, proving that the oxidative stress generated by 
visfatin had no significant effect on cellular viability (Fig. 4.8). This fact correlated with the 
previous finding that there was no significant increase in the levels of oxidized products, offering a 
limited ground to the hypothesis that a partial and localized increase in the mechanisms regulating 
antioxidant defence might explain the lack of effects of the detected free radicals on cellular 
integrity and physiology.                      
           An increase in the levels of  ROS is accompanied usually by a higher production of 
nitric oxide that can modify cell physiology through a further generation of oxygen free radicals 
mediated by increased production of peroxynitrate (Supinski and Callahan, 2007), through an 
increase in cyclic GMP (cGMP) levels (Drenning et al., 2009), or through the post-translational 
modifications of proteins like nitrosylation of specific residues (Nogueira et al., 2009;Sharov et al., 
2006). The process of protein nitrosylation represents a significant challenge to the proper 
functionality of the cells (Riederer et al., 2009) and it was reported already to be involved in the 
development of the ageing phenotypes (Butterfield et al., 2007; Murdaugh et al., 2010; Musci et al., 
2006). Therefore I looked by western blot at the levels of nitrotyrosine residues, which unlike S-
nitrosylation modifications are irreversible changes induced by nitric oxide (Stamler et al., 2008), 
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targeting for example proteins associated with calcium signalling in skeletal muscle (Viner et al., 
1996). As seen from figure 4.9, there was no significant increase in the levels of nitrotyrosines 
residues (YT) by the incubation with visfatin for 1-48 hours.                              
      This paragraph proved that the oxygen free radicals induced by visfatin did not affect the 
cellular viability and that the nitric oxide potentially produced by such ROS did not increase the 
levels of nitrosylated proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         Fig. 4.8   Visfatin treatment 
  C2C12 differentiated myotubes were incubated for 24 and 48 hrs with 100 ng/ml of 
visfatin or with hydrogen peroxide as a positive control for 1hr. 
supernatant was performed by colorimetric analysis. NADH is produced by the oxidation of lactate 
by the enzyme lactate dehydrogenase that is released in the supernatant if the plasma membrane is 
damaged. To quantify NADH levels 
to the negative control. Each data point is the average of duplicates samples per experiment from 
three independent experiments +/
significant difference between visfatin challe
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− SEM. ***Denotes p<0.001 compared to control. NS denotes no 
nge and control. 
        
further normalized 
           Fig. 4.9      Visfatin treatment 
proteins                  
        C2C12 differentiated myotubes were incubated between 1
visfatin as shown before. Protein lysates were resolved by a typical western blot to detect the 
presence of nitrotyrosines (YT)
analysis and the values were further normalized t
average from three independent experiments +/
between visfatin challenges and control.
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                        4.4   Acute or chronic visfatin (eNampt) treatment is not activating the insulin 
receptor–dependent PI3K/Akt signalling                              
     As previously reported, exogenous visfatin (eNampt) binds to insulin receptor 
expressed by many types of cells like HUVECs (Adya et al., 2008a), osteoblasts (Xie et al., 2007), 
mesangial cells (Song et al., 2008) and cardiomyocytes (Lim et al., 2008)  and increases the glucose 
uptake rate through the activation of phosphoinositide 3-kinase (PI3K/Akt) signalling, acting 
therefore as an insulin mimetic agent. It appears nevertheless that visfatin does not compete with 
insulin since it binds to a different site of the insulin receptor (Fukuhara et al., 2005). To test if the 
same effect can be identified in the case of the cultured skeletal myocytes I incubated differentiated 
C2C12 cells with 100 ng/ml of visfatin for 5, 10, and 15 minutes and verified the possible activation 
of the Akt pathway by western blot followed by densitometric analysis. I tested in this respect the 
levels of the phosphorylated forms of Akt (at Ser473 and Thr308 residues), the phosphorylated forms 
of Akt-upstream positive and negative regulators (PTEN and PDK1) and the phosphorylated forms 
of Akt-downstream targets (GSK-3β and c-Raf).  While 100 nM insulin was able to induce a 
significant increase in phospho-AktSer473 levels after 5 minutes of treatment (figure 4.10A), visfatin 
failed to change in the first 15 minutes the levels of phospho-AktSer473 and phospho-AktThr08, the 
levels of phosphorylated forms of Akt upstream activator (PDK1) and inhibitor (PTEN), as well as 
the levels of phosphorylated forms of Akt downstream targets like GSK-3β and c-Raf (figure 
4.10B). In addition, as seen from figure 4.10A, the chronic incubation with visfatin for 18 hrs did 
not change the levels of phospho-Akt at Ser473
 
residue and neither the ability of insulin to activate 
PI3K/Akt pathway after 5 minutes. These experiments proved that the incubation of C2C12 cells 
with extracellular visfatin did not activate the PI3K/Akt pathway and did not interfere with the 
activation of the same pathway by insulin. This proves that in the case of cultured myocytes visfatin 
is not acting as an insulin-mimetic agent.  
 
               Fig. 4.10    Visfatin treatment 
signalling                     
  A. Phosphorylation of Akt at Ser473 residue was detected at baseline, in the cells with 
chronic visfatin exposure (100 ng/ml) for 18 hrs, following 100 nM insulin stimulation for 5 min and 
in the cells showing treatment with visfatin for 18 hrs followed by insulin s
Quantization of Akt phosphorylation at Ser473 or Thr308 was performed by densitometric analysis 
compared to the negative control
raised against the phosphorylated forms of A
phosphorylated forms of Akt upstream regulators (PDK1 and PTEN) and of its downstream targets 
(c-Raf and GSK-3β) following visfatin treatment at 100 ng/ml (no treatment, 5, 10 and 15 min). 
Quantization of Akt phosphorylation at Ser473 or Thr308 was performed by densitometric analysis 
compared to the negative control. Each data point is the average from three independent experiments 
+/− SEM. ***Denotes p<0.001 compared to control. NS denotes no significant differe
visfatin and insulin treatment compared to insulin alone in chronic exposure, or between control and 
visfatin in both chronic and acute exposures.
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                           4.5. Blocking PI3K is not reducing the oxidative stress levels increased by 
visfatin (eNampt)                              
       As shown above in the present chapter, visfatin treatment did not activate 
PI3K/Akt pathway in the acute stage of incubation (1- 15 minutes), nor in the chronic stage (18 
hours). Nevertheless, PI3K/Akt pathway could be activated by visfatin treatment in an interval 
between these two time points and such activation could be missed by my western blot experiment.  
It was already shown that the chronic activation of Akt signalling characterizing early oncogenesis 
increased the aerobic glycolysis rate (the Warburg effect) (Robey and Hay, 2009) leading to an 
increase in the levels of free radicals (van Gorp et al., 2006). Therefore, to test the possibility that an 
eventual Akt activation upon visfatin challenge could mediate the increase in ROS levels detected 
previously, I blocked PI3K by its specific inhibitor LY294002 (50 µM) for 1 hour before the 
incubation with 100 ng/ml of visfatin for another 18 hours. As seen from figure 4.11 there was no 
change in the signal detected by fluorescent assays in the cells with blocked PI3K/Akt signalling 
before visfatin challenge compared to the signal detected from cells incubated only with visfatin. 
This experiment proved that the ROS production is independent of PI3K/Akt signalling pathway. 
 
 
   Fig. 4.11    The oxidative stress induced by visfatin is not mediated by PI3K/Akt signalli
            Differentiated C2C12 cells were pre
inhibitor of PI3K, before being subjected to another 18 hrs of challenge with 100 ng/ml of visfatin. 
Cells were incubated with 25 µ
incubation with 1 µM Hoechst 33342 to stain the nuclei. Relative expression compared to control is 
shown. Each data point is the average of quadruplicate samples per experiment from three 
independent experiments +/− SEM. **Denotes p<0.01 comp
significant difference between the treatment of visfatin plus PI3K inhibitor compared to visfatin 
alone.  
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                        4C. Discussion           
  
                Visfatin is a new member of adipokine family with one form but with two different 
localizations, one being intracellular (iNampt) and another extracellular (eNampt) (Garten et al., 
2010). The intracellular form was proved so far to be involved in the NAD synthesis pathway 
through its phosphoribosyltransferase activity (Wang T. et al., 2006),  and the extracellular form was 
discovered to be actively secreted by diverse types of cells such as macrophages, adipocytes and 
hepatocytes (Fukuhara et al., 2005;Wang et al., 2009;Curat et al., 2006). Initially considered to be an 
insulin minetic agent, visfatin proved to be also an inducer of oxidative stress and inflammation.                                        
       Because there were no previous reports about the effects of an increased levels of 
plasma visfatin on the stress responses of skeletal muscle in vivo (both animal models or human 
patients), and since skeletal muscle is a target for the rest of adipokines with a major influence on 
insulin sensitivity, stress markers and inflammatory status, I explored such possible effects of an 
increased concentration of plasma visfatin on skeletal muscle by using an in vitro approach.         
                  
                   1.   The relationships between exogenous visfatin (eNampt) and the levels of 
oxidative stress                            
             I showed in the present chapter that incubating murine C2C12 fused and 
differentiated myotubes with different concentrations of exogenous murine visfatin (eNampt) (<200 
ng/ml) induced oxidative stress as monitored by fluorescent-based assays (Figs.4.1-4.3). This event 
occurred in the chronic stage, after a minimum of 5 hours, not in the acute stage as shown to happen 
in the case of stimulation of endothelial cells (Kim et al., 2008). While visfatin treatment increased 
free radicals, it did not affect the cellular viability that indicates that such a stress is not impairing 
significantly the myotubes survival (Fig. 4.8). Visfatin did not induce an increase in the levels of 
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oxidized lipids or oxidized proteins either. The detection of an increase in ROS levels without an 
increase in the levels of oxidized products or impaired viability after visfatin challenge suggested an 
existence of a simultaneous improvement of the antioxidant capacity of the cells to resist such a 
stress. The measurement of this global cellular ability to protect against oxidative stress was 
performed by using the ABTS assay that did not show any global change in the antioxidant potential 
of C2C12 cells after the treatment with visfatin compared to control (Fig. 4.7).                    
       The additional metabolic consequences and the upstream mediators of the increased 
levels of free radicals are still unknown, therefore the main questions still to be answered in the 
following chapters are: 
1. What pathways mediate the increased levels of ROS induced by visfatin? 
2. What pathways could mediate the protection against such oxidative stress that might explain 
the lack of oxidized products or loss of viability? 
3. What consequences such increased ROS levels could have on the signalling pathways 
relevant for glucose metabolism? 
 
                             2.  Visfatin (eNampt) and insulin-dependent signalling pathway              
                 Previously it was shown that visfatin can act as an insulin mimetic agent, but the 
issue is still controversial and debated (Fukuhara et al., 2005). Since there were no previous reports 
about the effects of exogenous visfatin on skeletal muscle, which is a main target for adipokines and 
the main organ responsible for the removal of the glucose from the plasma, I tested whether visfatin 
can activate the PI3K/Akt signalling pathway that mediates the effects of insulin on the rate of 
glucose uptake. The stimulation of C2C12 cells with 100 ng/ml  visfatin did not induce the 
phosphorylation of Akt at Ser473 or at Thr308 residues in the first 15 minutes (Fig. 4.10B), unlike the 
insulin challenge that triggered a robust response after 5 minutes at the AktSer473 (Fig. 4.10A). 
Visfatin did not change either the phosphorylated levels of Akt upstream activator (PDK1), upstream 
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inhibitor (PTEN) or of Akt downstream targets like GSK-3β and c-Raf (Fig.4.10B).  The pre-
incubation of C2C12 cells with visfatin for 18 hrs did not impair or augment the ability of insulin to 
activate PI3K/Akt after 5 minutes and the incubation of cells with visfatin alone for 18 hrs did not 
change either the levels of phosphorylated Akt at Ser473 residues (Fig. 4.10A). This showed that in 
C2C12 cells visfatin did not activate PI3K/Akt signalling pathway, indicating that in the case of 
cultured skeletal myocytes it is not an insulin-mimetic agent.                  
         The possibility of an increase in the rate of glucose uptake by visfatin, independently of 
PI3K/Akt signalling, will be explored in the future chapters.  Nevertheless, such activation of Akt 
pathway could occur later through mechanisms independent of insulin receptor phosphorylation 
status and such eventual activation could mediate a subsequent oxidative stress response.  For 
example, chronic activation of Akt observed in the early stages of oncogenesis can increase the 
levels of aerobic glycolysis (the Warburg effect) and an increased glycolysis rate is associated with a 
higher production rate of free radicals (van Gorp et al., 2006).  Therefore I blocked PI3K activity by 
its specific inhibitor before visfatin treatment and repeated the fluorescent-based measurement of 
ROS levels that did not show any changed values comparing to visfatin-only treated cells (Fig. 
4.11).  This proved that the observed ROS production induced by visfatin treatment in C2C12 cells 
is independent of Akt signalling.                           
            Because the long-term incubation of cultured myotubes with visfatin (>24 hours) 
might still modify the rate of glucose uptake or glucose metabolism independently of Akt signalling, 
possibly through the modulation of other physiological processes like a robust NAD metabolism as 
shown before (Revollo et al., 2007), the next question to be raised and answered in the following 
chapter is the following:                                                                            
               What is the effect of exogenous visfatin on glucose uptake rate? And if I will see 
such an effect, what are the pathways mediating it? 
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                      Chaptt er  5--   THE  DIFFERENTIAL  EFFECTS  OF  VISFATIN  
(( eNAMPT))   AND  TRIGLYCERIDES  ON  THE  EXPRESSION  OF  ROS--
REGULATORY  GENES,,   GLUCOSE  UPTAKE  AND  INSULIN  
SENSITIVITY    
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                       5A. Introduction 
                             In the previous chapter it was showed that exposure of C2C12 cells to exogenous 
visfatin (eNampt) increased intracellular ROS levels after 18 hours. Nevertheless, the cellular 
viability was not impaired. Furthermore, no significant increase in the levels of oxidized proteins or 
oxidized lipids was detected, usually generated by a sustained, chronic production of reactive 
oxygen species (Nader-Djalal et al., 1998). To explain this initial apparent discrepancy a provisional 
hypothesis was proposed, based on the theoretical possibility that visfatin could increase 
simultaneously not only the levels of intracellular ROS but also the cellular antioxidant defence 
status. It was shown for example that physical exercise increased in skeletal muscle not only the 
levels of ROS but also the antioxidant defence status  (Bejma and Ji, 1999). This hypothesised 
improved antioxidant defence could block any significant oxidizing effects on cellular constituents 
such as proteins and lipids by the simultaneously produced ROS.  Since such an antioxidant 
response was not observed at the pancellular level by using the ABTS assay, the first goal of the 
present chapter was to inquire whether visfatin might induce a transient or localized antioxidant 
response. This potential localized increase in antioxidant capability by visfatin, undetectable at the 
global, pancellular level, could explain the lack of oxidized products. The identity and the 
mechanisms of such transient or localized responses have been already explored in macrophages 
(Flesch et al., 1994), placenta (Ejima et al., 1999) and plant-pathogen interactions (Piterkova et al., 
2009). To explore the possibility of such localized responses, an RT-PCR assay was performed to 
quantify the expression levels of certain selected genes already known to be involved in ROS 
production or antioxidant defence.  
                   To establish a reliable control in order to compare possible expression changes 
induced by visfatin within an ageing context, a lipid-based challenge was used. Intramyocellular 
triglycerides are an important source of energy for normal, healthy skeletal muscle especially in the 
case of chronic, low level exercise (Gorski, 1992). Nevertheless, during ageing the human skeletal 
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muscle is characterized by an accelerated accumulation of intramyocellular lipids depots that are 
associated with a progressive increase in the level of oxidative stress, generalized insulin resistance 
and chronic inflammation (Franklin and Kanaley, 2009; Crane et al., 2010; Machann et al., 2005). 
These intracellular events are also involved in the development of ageing-associated diseases 
involving skeletal muscle such as metabolic syndrome  (Georg and Ludvik, 2001), sarcopennia 
(Borst, 2004; Fulle et al., 2004) and frailty (Lang et al., 2009; Faulkner et al., 2007). Interestingly, it 
appears that skeletal muscle contains lipid droplets in the extracellular, interstitial space (Russell et 
al., 1998), with unknown origin and unclear function. Skeletal muscle can use different types of 
lipids from circulation for energy purposes, such as the free fatty acids released by adipocytes in 
plasma (Martin et al., 1993) or triglycerides. The plasma triglycerides are structured as chylomicrons 
or as very-low-density lipoproteins (VLDLs) (Voshol et al., 2009). The established method 
previously used to model in vitro the lipid-related toxicity seen in ageing and ageing-associated 
diseases was the incubation of primary or immortalized muscle cells with BSA-bound free fatty 
acids such as palmitate or oleate (Garcia-Martinez et al., 2005; Lu et al., 2000). This method 
presents nevertheless multiple technical pitfalls, increasing the dangers of non-specific results 
(Wang X. et al., 2010) or artefacts (Bickerton et al., 2007). In addition,  less it is known about the 
effects on skeletal muscle of lipids stored as triglycerides (VLDL or chylomicrons), and not as free 
fatty acids (Kraegen et al., 2001). Consequently, in order to avoid the problems seen in the 
experiments using free fatty acids bound to BSA and to further explore the effects of lipids stored as 
triglycerides, I used a new alternative method, namely the incubation of cultured myocytes with the 
commercially available fat emulsion StructolipidTM. This 20% fat emulsion is composed of 
equimolar amounts of long chain triglycerides (LCT) from refined soy oil and medium chain 
triglycerides (MCT) from coconut oil in the ratio of 64% (w/w) and 36% (w/w) respectively, the 
fatty acids being randomly distributed within the same triglyceride molecule. StructolipidTM  is 
currently used in clinical practice as a parenteral nutrition regimen choice by intravenous 
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administration in order to supply energy and essential fatty acids (1-1.5 g/kg body weight/day) 
(Ellborg et al., 2010), but it was also successfully used to model in vitro the effects of 
intramyocellular accumulation of lipid depots seen in aged or dysfunctional skeletal muscle.  For 
example, it was shown already that incubation with StructolipidTM at high concentrations (0.2 
mg/ml) induced oxidative stress in cultured cells (Delaigle AM, 2006; Delaigle et al., 2004). 
Therefore I used this fat emulsion to induce a lipid-based challenge in C2C12 cells.                       
                     The first goal of the present chapter was to confirm that this new type of lipid challenge 
(StructolipidTM) is a genuine model of lipid overload of C2C12 cells by testing its transport and 
accumulation in cytosol, followed by measurements of oxidative stress markers as performed in 
previous chapter. After these preliminary experiments the existence of any possible changes in the 
expression of some of the genes relevant for oxidative stress and antioxidant defence induced by 
visfatin or fat emulsion are to be explored by using RT-PCR.  
                       It was shown before that the treatment with exogenous visfatin increased the rate of 
glucose uptake in many types of cells such as pancreatic β cells (Brown et al., 2010) and osteoblasts 
(Xie et al., 2007), similarly to insulin. This effect was dependent on activation of Akt signalling that 
was not detected in the experiments presented in previous chapter. The chronic treatment with 
exogenous visfatin could nevertheless modify the glucose uptake rate indirectly, through the 
regulation of other signalling pathways. For example, it is known that glucose metabolism and 
uptake can be modified by changes in NAD metabolism that are known to be regulated by the 
activity of the intracellular form of visfatin, iNampt (Revollo et al., 2007). It was also shown that 
incubation of smooth muscle cells with exogenous visfatin increased the intracellular NAD levels 
and subsequently activated the NFkB signalling pathway, but the upstream mechanisms are still 
unclear (Romacho et al., 2009). I tested therefore the possibility that chronic exogenous visfatin 
(eNampt) treatment could change the rate of glucose uptake in cultured myotubes by using a new 
fluorescent method based on measurements of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
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deoxyglucose (2-NBDG). This method was developed recently (O'Neil et al., 2005; Zou et al., 2005) 
and it was already proved to be an efficient, reliable and safer alternative to the classical radioactive  
(2-DG) method both in vitro (Zou et al., 2005; Ball et al., 2002) and in vivo (Ye et al., 2008). The 
second goal of the present chapter was therefore testing whether the incubation of C2C12 cells with 
exogenous visfatin or triglycerides can change the glucose uptake rate in both basal and insulin-
stimulated conditions by using 2-NBDG. 
                     Previously it was shown that the physiological effects induced by lipids on the rate of 
glucose uptake are partially mediated by an impaired activation of PI3K/Akt pathway (Nogueira et 
al., 2008) and by changes in expression of transporters such as glucose transporter 1 (GLUT1) and 
glucose transporter 4 (GLUT4) (Bloch-Damti and Bashan, 2005). The third goal of the present 
chapter was therefore to test whether the triglyceride challenge can interfere with the PI3K/Akt 
signalling pathway by using the western blot method to quantify the levels of phosphorylated forms 
of Akt, as performed in the previous chapter in the case of visfatin treatment. In addition, RT-PCR 
was used to quantify the possible change induced by visfatin or triglycerides in the expression of 
GLUT1, which is involved in the basal glucose uptake, and GLUT4, that is mediating the insulin-
stimulated glucose uptake process.              
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                        5B. Results 
                             5.1 Triglyceride treatment is an accurate and efficient method to model the 
effects of lipids in skeletal muscle                            
                  StructolipidTM  was previously proven to induce oxidative stress in cultured 
skeletal myocytes (Delaigle et al., 2006; Delaigle et al., 2004), and I used it as an alternative to the 
free fatty acids method to model the effects induced by lipids on skeletal muscle physiology 
characterizing the ageing-associated diseases such as obesity and metabolic syndrome (Samuel et al., 
2010). C2C12 cultured and differentiated myotubes were incubated with the fat emulsion that was 
diluted 1/100 in serum-free DMEM to a final concentration of 0.2 mg/ml of triglycerides (TG). To 
confirm the transport and accumulation of the triglycerides in C2C12 cells I performed fluorescent-
based assays by using the specific dye Nile Red (1 µg/ml). A marked increase in lipid depots was 
detected by Nile Red staining after 6 hours of treatment with 0.2 mg/ml of triglycerides (Fig. 5.1). 
This shows that triglycerides are transported into the cytosol of cultured myotubes.  
 
 
 
 
 
 
 
 
                     Fig. 5.1 StructolipidTM triglycerides are transported into the cytosol of C2C12 
differentiated myotubes                    
         C2C12 cells were incubated for 6 hrs with 0.2 mg/ml of 
was diluted 1/100 in serum-free DMEM to a final concentration of 0.2 mg/ml of triglycerides (TG). 
Cells were further incubated with 1 µg/ml Nile Red diluted i
min incubation with 1 µM Hoechst 33342 to stain the nuclei. 
performed at 560 nm for Nile Red and at 460 nm for 
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                              5.2 The incubation with triglycerides induces oxidative stress in cultured 
C2C12 cells after 24 hours                                     
                               To test whether 0.2 mg/ml of triglycerides treatment can generate oxidative stress 
in C2C12 cells after 24 hours of incubation I used the carboxy-H2DCFDA fluorescent-based assay 
as described in previous chapter and noticed a significant increase in oxidative stress levels, as seen 
from figure 5.2. This showed that triglyceride challenge induced oxidative stress. In order to 
investigate in detail the effects of incubation with triglycerides on the skeletal myocytes physiology, 
I explored also the possible detection of oxidized forms of proteins by using the OxyblotTM system 
followed by densitometric analysis, as performed in the previous chapter for visfatin challenge. 
Figure 5.3 shows that the incubation of C2C12 cells with 0.2 mg/ml triglycerides increased with 
almost 80% the global levels of carbonylated proteins after a minimum incubation time of 24 hours, 
with a significant increase of a band around 30 kDa. This proved that the cellular stress pattern 
induced by triglyceride treatment is different from the one generated by exogenous visfatin 
(eNampt). The pattern of carbonylated proteins triggered by triglyceride challenge in C2C12 cells is 
different also from the pattern seen in the skeletal muscle from diabetic animal models (Oh-Ishi et 
al., 2003) and from the pattern shown by  aged skeletal muscle  (Griffin et al., 2008). This shows 
that triglyceride treatment is an acceptable model of the effects of ageing on skeletal muscle when an 
accumulation of intramyocellular lipids occurs.  
 
 
 
 
 
             Fig. 5.2 Incubation of differentiated myocytes with 
after 24 hours              
    C2C12 cultured and differentiated myotubes were incubated for 24 hrs with 
fat emulsion that was diluted 1/100 in serum
triglycerides. Cells were incubated with 25 
followed by 5 min incubation with 1 
was performed at 520 nm for carboxy
quantification was further done by using software
negative control is shown. Each data point is the average of quadruplicate samples per experiment 
from three independent experiments +/
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                             Fig. 5.3 Incubation of differentiated myocytes with 
of oxidized proteins after 24 hours
  C2C12 differentiated myotubes were incubated for 16, 24 a
triglycerides in serum-free DMEM.
with 2,4-dinitrophenylhydrazine (DNPH) to derivatize the carbonyl groups to 2,4
dinitrophenylhydrozone (2,4-DNP) residues. The cell 
ECL western blot procedure by using an antibody against the derivatized 2,4
Quantization of the expression was performed by densitometric analysis and the values were further 
normalized to negative control. 
+/− SEM. NS denotes no significant difference between treatment and control. **Denotes p<0.01 
compared to control.  
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          5.3      The incubation of cultured C2C12 cells with triglycerides changes the expression 
of genes involved in oxidative stress and antioxidant defence in a different manner compared 
to visfatin challenge 
                     In order to decipher the mechanisms involved in ROS production and antioxidant 
defence changed by visfatin or triglycerides in cultured myocytes I performed RT-PCR for a number 
of genes already known to be involved in the process. As seen from figure 5.4, the incubation of 
C2C12 cells for 24 hours (but not for 6 hours) with 0.2 mg/ml of triglycerides was able to increase 
significantly the expression levels of many genes involved in antioxidant defence such as catalase 
(CAT), superoxide dismutase 1 (SOD1), superoxide dismutase 2 (SOD2) and of transcriptional 
factors required for antioxidant defence or ischemic response such as hypoxia-inducible factor 1A 
(HIF1A), nuclear respiratory factor 1 (NRF1) and nuclear respiratory factor 2 (NRF2). Triglyceride 
treatment did not change the expression levels of other genes responsible for free radical production 
such as NADPH oxidase 4 (NOX4), a subunit of NADPH oxidase complex. In comparison, as seen 
from figure 5.5, incubation of C2C12 cells with 100 ng/ml of visfatin for 24 hours increased the 
expression level of SOD1 and NOX4 genes only, leaving the rest of the genes mentioned above 
unchanged.  The incubation of skeletal myocytes with triglycerides, but not with visfatin, was also 
able to reduce after 24 hours the expression of glutathione peroxidase-3 (GPX3), a powerful 
antioxidant factor (Fig. 5.6). This could indicate a possible reduction in the general antioxidant 
defence ability by triglycerides as proved already for skeletal muscle from diabetic patients or from 
the animal models of metabolic syndrome (Chung et al., 2009).                      
         In conclusion, the pattern induced by visfatin treatment was different compared to the 
pattern shown by lipid emulsion. The fact that the levels of expression of transcriptional factors such 
as NRF1, NRF2 and HIF1A and antioxidant proteins such as GPX3 were not changed after visfatin 
treatment corroborates with the finding from previous chapter that visfatin did not oxidize proteins 
nor lipids.  
                   Fig. 5.4 Incubation of differe
levels of some of the ROS-regulatory genes 
C2C12 differentiated myotubes were incubated for 6 or 24 hrs with 0.2 mg/ml of 
serum-free DMEM. After RN
samples were run in triplicate and fold change in expression was calculated by normalizing the test 
gene crossing threshold (Ct) with the control (beta
challenged samples to the values from untreated cells. 
NS denotes no significant difference between treatment and control. Each data point is the average 
from three independent experiments +/
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                     Fig. 5.5 Incubation of differentiated myocytes with visfatin increases the expression 
levels of some of the ROS-related genes differently compared to triglyceride challenge
         C2C12 differentiated myotubes were incubated for 24 hrs with 
serum-free DMEM. After RNA extraction and cDNA synthes
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 Fig. 5.6     Incubation of differentiated myocytes with 
the expression levels of GPX3, a powerful antioxidant gene 
   C2C12 differentiated myotubes were incubated for 24 hrs with 
with 0.2 mg/ml triglycerides in serum
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     5.4 Incubation of cultured myotubes with triglycerides, but not with visfatin, 
changes the rate of glucose uptake in cultured myocytes                       
           Previously it was shown that long term changes in the expression level or in the 
enzymatic activity of intracellular form of visfatin (iNampt) could affect the levels of glucose uptake 
and glucose metabolism through the modulation of NAD levels (Revollo, 2008), independently of 
PI3K/Akt signalling. I explored this possibility of indirect effects of glucose uptake rate also in the 
case of chronic exogenous visfatin (eNampt) challenge that failed to activate PI3K/Akt pathway, as 
shown in previous chapter.  In order to test this hypothesis I used a new available method, recently 
developed, that is based on fluorescent microscopy measurements of the compound 2-NBDG (Ye et 
al., 2008; Fukushima et al., 2007; Zou et al., 2005; Ball et al., 2002; Yamada et al., 2000).   
C2C12 cultured cells, treated or not with visfatin for 24 hours, were incubated with the compound 2-
NBDG (0.1 mg/ml) diluted in PBS for 30 minutes followed by f1uorescent microscopy imaging 
(Fig.5.7B). As seen from figure 5.7C, there were no differences in the recorded values between 
visfatin–treated and control cells, indicating that visfatin has no effect on the rate of glucose uptake 
in the case of cultured myotubes. This correlates with the fact that only in the cellular types that 
presented an activation of PI3K/Akt signalling pathway by visfatin such as osteocytes and 
endothelial cells it was also noticeable an increased rate of glucose uptake (Xie et al., 2007). In 
contrast, the incubation of C2C12 cells with triglycerides (0.2 mg/ml) for 24 hours increased the 
levels of basal transport of glucose by approximately 40%. This discovery correlates with previous 
independent experiments elucidating the mechanisms of insulin resistance in skeletal muscle. For 
example, it was already shown by 2-DG method that palmitate treatment of cultured myotubes is 
increasing the rate of glucose uptake in the basal state (Montell et al., 2001), confirming the 
usefulness of StructolipidTM in obesity research.   
                    To study the effects of triglycerides or visfatin on the insulin-stimulated glucose 
uptake I incubated C2C12 cells with 100 ng/ml of visfatin or with 0.2 mg/ml of triglycerides for 24 
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hours, followed by the incubation with 100 nM insulin diluted in PBS for 30 minutes (Fig. 5.8A). To 
quantify the rate of glucose uptake I repeated the 2-NBDG assay as described above. The fluorescent 
microscopy measurements of  2-NBDG signal showed that insulin treatment alone increased the 
levels of glucose uptake in C2C12 cells more than 2.5 times compared with non-treated cells 
(Fig.5.8B), confirming the usefulness of the 2-NBDG assay for glucose measurements in C2C12 
cells (del Aguila et al., 1999).   While the pre-incubation with visfatin for 24 hours did not affect the 
insulin-dependent glucose uptake, triglyceride treatment nevertheless was able to reduce it by a 
third. This shows that extracellular form of visfatin did not change the rate of glucose uptake in both 
basal and insulin-stimulated states, unlike the modulation of its intracellular form (iNampt) that 
increased the rate of NAD synthesis and indirectly the rates of glucose uptake and glucose 
metabolism (Revollo, 2008). The decrease in glucose uptake by triglycerides in insulin-stimulated 
condition correlates also with the fact that palmitate treatment of cultured myotubes reduced the 
glucose uptake rate in the insulin-stimulated state as shown by 2-DG method (Ragheb et al., 2009).         
            The increase in the glucose uptake in basal state and reduction in the insulin-
stimulated state upon triglyceride challenge can be explained by changes in PI3K/Akt signalling that 
regulates the translocation of glucose transporters at the plasma membrane (Nakamura et al., 2009; 
Nogueira et al., 2008; Kelly et al., 2008), and by changes in the expression levels of glucose 
transporters such as GLUT1 (Dimopoulos et al., 2006; MacLaren et al., 2008) and GLUT4 (Armoni 
et al., 2007), aspects that were approached  next.   
 
 
 
 
                       Fig. 5.7 Incubation
increases the rate of the basal glucose uptake 
  C2C12 differentiated myotubes were incubated for 24 hrs with 
or with 0.2 mg/ml of triglycerides
glucose uptake cells were incubated with 0.1 mg/ml of 2
5 min incubation with 1 µM Hoechst 33342 to stain the nuclei (
performed at 520 nm for 2-NBDG and at 460 nm for 
done by using software-based analysis (C).
Data shown are the average of quadruplicate samples per experiment, from three independent 
experiments +/− SEM. **Denotes p<0.01 compared to control. NS
between treatment and control. 
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                               Fig. 5.8 Incubation of differentiated myocytes with 
decreases the rate of the insulin
         C2C12 differentiated myotubes were incubated for 24 hrs with 
with 0.2 mg/ml of triglycerides.
for 30 minutes before the incubation with 0.1 mg/ml of 
30 min, followed by 5 min incubation with 1 
microscopy was performed at 520 nm for 
quantification was further done by using software
control data is shown (B). Data shown are the average of quadruplicate samples per experiment, 
from three independent experiments +/
denotes no significant differen
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                                 5.5. Triglyceride treatment impairs the insulin-stimulated activation of 
PI3K/Akt signalling                                   
             As shown in the third chapter exogenous visfatin treatment did not change the levels 
of phosphorylated Akt and this correlates with the unchanged rate of glucose uptake shown above.  
It was reported before that the incubation of cultured cells with free fatty acids can induce insulin 
resistance partially by interfering with insulin-dependent PI3K/Akt pathway activation (Nakamura et 
al., 2009; Nogueira et al., 2008; Kelly et al., 2008) that regulates GLUT4 translocation at the plasma 
membrane (Storz et al., 1999). I further verified by western blot the phosphorylated levels of Akt at 
Thr308 and of GSK-3β, which once phosphorylated by Akt at Ser9 residue upon insulin challenge 
has reduced activity (Hajduch et al., 2001). As seen in figure 5.9A, the incubation of cells with 0.2 
mg/ml triglycerides for a minimum of 24 hours reduced the levels of phospho-AktThr308 in the 
insulin-treated cells, but did not change the levels of phospho-AktThr308   in the basal state. Also, as 
seen from figure 5.9B, while triglycerides treatment for a minimum of 24 hours did not affect the 
basal level of phospho-GSK-3βSer9, it reduced nevertheless the increase in its levels induced by the 
stimulation with insulin. This correlates also with previous data about the effects of free fatty acids 
such as palmitate on Akt activation (Dimopoulos et al., 2006). The fact that triglycerides treatment 
impaired the activation of Akt pathway by insulin could explain the decrease in the rate of glucose 
uptake in the insulin-stimulated conditions shown above since this might impair the translocation of 
GLUT4 transporter to the plasma membrane. The lack of any significant change in phospho-
AktThr308 or phospho-GSK-3βSer9 levels in the basal condition after triglyceride challenge shows that 
the increase in glucose uptake noticed before is not mediated by the PI3K/Akt signalling pathway.  
 
 
 
                   Fig. 5.9 Incubation
PI3K/Akt pathway by the insulin
       C2C12 differentiated myotubes were incubated for 3, 16, 24 and 48 hrs with 0.2 mg/ml 
of triglycerides in serum-free DMEM.
minutes (A) or for 15 minutes (B). Cells extracts were used to detect by ECL western blot the levels 
of phospho-AktThr308 (A) and phospho
GAPDH was used. Quantization of phosphorylation was performed by densitometric analysis 
compared to the loading control, followed by normalization of values to the negative control. Each 
data point is the average from three independent experiments +/
compared to control. NS denotes no significant difference between treatment and control.
 
144 
 of differentiated myocytes with triglycerides
                       
 Cells were further treated or not with 100 nM insulin for 10 
-GSK-3βSer9 (B). As loading control an antibody against 
− SEM. ***Denotes p<0.001 
 impairs the activation of 
   
 
  
 
 
 
   
 
 
 
 
 
 
 
 
145 
146 
 
                         5.6 Incubation with triglycerides, but not visfatin, changes the expression levels 
of glucose transporters                                 
              Because in the experiments presented above triglyceride treatment increased the 
level of basal glucose uptake but decreased the level of insulin-stimulated glucose uptake, I verified 
by RT-PCR the expression levels of GLUT1 and GLUT4 transporters that are responsible for the 
above mentioned processes. Figure 5.10A-B shows that while visfatin treatment for 24 hours had no 
effect on the expression levels of both transporters, the treatment of cells with 0.2 mg/ml of 
triglycerides significantly increased the gene expression levels of GLUT1 after a minimum 
incubation time of 6 hours and reduced the expression levels of GLUT4 after 24 hours. The fact that 
GLUT1 gene expression is upregulated might explain the increase in the rate of glucose uptake by 
triglycerides in the basal state as detected by 2-NBDG assay. Also, this suggests that the increase in 
GLUT1 expression is not regulated by PI3K/Akt-dependent downstream events since there was no 
change in phospho-AktThr308 level in the basal state. The fact that GLUT4 is decreased upon 
triglyceride challenge correlates also with my previous findings of the effects of triglycerides on the 
rate of glucose uptake in the insulin-stimulated state and with the effects of triglycerides on 
phospho-AktThr308 or phospho-GSK-3βSer9 levels in the insulin-stimulated state. The lack of effect of 
exogenous visfatin on the expression levels of glucose transporters correlates also with the lack of 
effect on the PI3K/Akt signalling pathway and the unchanged rate of glucose uptake, proving that 
visfatin is NOT an insulin mimetic agent in the case of cultured myocytes.   
 
                       Fig. 5.10 Incubation
changes the expression levels of glucose tra
         C2C12 differentiated myotubes were incubated for 24 hrs with 
with 0.2 mg/ml triglycerides in serum
synthesis, an RT-PCR assay was
in triplicate and fold change in expression was calculated by normalizing the test gene crossing 
threshold (Ct) with the control (beta
**Denotes p<0.01 compared to control. ***Denotes p<0.001 compared to control. NS
significant difference between treatment and control. 
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Table 5. 1 Composition of StructolipidTM 
Oil source (% by wt)   Coconut (36%), soybean (64%)    
Ratio of n–6 to n–3 PUFAs   7:1    
Fat content (g/L)   200    
Molecular weight   683    
Phospholipids (g/L)   12    
Glycerol (g/L)   22.5    
pH   8.0    
Osmolarity (mOsmol/L)   350    
Energy (kcal/L)   1960    
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                          5C. Discussion 
                             1.  Triglycerides treatment induces oxidative stress in a different manner 
compared with visfatin                                          
       StructolipidTM is a commercially available fat emulsion extensively used in the 
parenteral medicine (Weigt et al., 2002). It was also employed in molecular biology experiments as 
an alternative to the established BSA-bound free fatty acids method  in order to model the lipid-
induced oxidative stress in cultured cells (Delaigle et al., 2004; Delaigle et al., 2006). By diluting the 
fat emulsion to a final concentration of 0.2 mg/ml of triglycerides in serum-free medium I was able 
to model in an accurate way the physiology of skeletal muscle seen during lipid-induced stress in 
obesity and ageing. This emulsion is an accelerated and robust method for delivery and transport of 
triglycerides in C2C12 cells (Fig. 5.1) that avoids the technical difficulties  or the artefacts 
characterizing the free fatty acids treatment previously used (Bickerton et al., 2007). In addition, this 
lipid form models the effects of lipids stored in the blood as triglycerides and not as free fatty acids, 
aspect that has been not extensively studied previously.                        
       The treatment of C2C12 cells with 0.2 mg/ml triglycerides for 24 hours induced 
oxidative stress as measured by fluorescent microscopy (Fig. 5.2).  I noticed an increase in the level 
of oxidized proteins by 80% compared with the negative control after a minimum incubation time of 
24 hours (Fig. 5.3), a band localized around 30 kDa showing a significant increase in the 
carbonylated form. The identity of such a band is still unexplored and this question will not be 
covered in the present thesis. So far I did not identify another independent report to confirm or 
support my particular finding. The pattern is also different from the one noticed in the skeletal 
muscle of diabetic animal models presenting increased depots of intracellular lipids in skeletal 
muscle  (Oh-Ishi et al., 2003), the one seen in the skeletal muscle of mice fed with a high-fat diet 
(Bonnard et al., 2008) or in the aged skeletal muscle  (Feng et al., 2008).  Some of the bands from 
the lanes with control and with 16 hrs of triglycerides treatment samples are decreasing after 24 hrs 
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and 48 hrs of TG treatment. This could signify that the big band seen around 30 kDa after a 
minimum of 24 hrs of treatment is an aggregation of carbonylated proteins undigested by the 
proteasome. Nevertheless, it could be argued with equal strength that since triglycerides treatment 
will likely decrease the expression values of some of proteins expressed in C2C12 cells, than their 
basal levels of oxidation upon the derivatization step will also be decreased (assuming that they are 
not oxidized by triglycerides-induced oxidative stress), therefore the bands present a decreased 
signal. For example, the triglycerides treatment reduced the expression of GPX3 and GLUT4 at 
transcription level as seen in chapter 5. Whether this is a single band or an aggregation of undigested 
proteins is still to be determined.         
  By using an RT-PCR assay I also showed that visfatin had a different effect on genes 
regulating ROS production or antioxidant defence compared to lipid-based challenge. For example, 
triglycerides increased expression values of crucial genes such as SOD1, CAT and SOD2 and of 
transcription factors such as NRF1, NRF2 and HIF1A (Fig. 5.5), reducing simultaneously expression 
of GPX3, an important antioxidant factor. Visfatin increased nevertheless only expression of NOX4, 
a member of NOX family, and of SOD1. NOX4 is a member of NADPH oxidase family with 7 
members that present a core structure of 6 transmembrane domains and a long cytosolic domain 
containing FAD and NADPH binding domains (Bedard and Krause, 2007). The oxidation 
mechanism is based on the transfer of one electron from the NADPH to the molecular oxygen 
generating superoxide. The first described member of the family (NOX2) was identified more than 
20 years ago (Harper et al., 1984) as a member of an enzymatic complex involved in the generation 
of ROS in the human neutrophils during phagocytosis. The phagocytic NADPH complex is formed 
of a membrane-bound cytochrome b558, three cytosolic factors named p47phox, p67phox, p40phox and 
the small GTPase Rac2 that has a regulatory role. During the activation of the phagocyte NADPH 
oxidase complex the cytosolic proteins translocate to the plasma membrane initiating the production 
of superoxide (Geiszt, 2006). In the recent years it was shown that NADPH family members are 
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expressed also in non-immune cells and fulfil multiple functions. NOX4 was identified initially in 
the kidney (Cheng et al., 2001) and is the most elusive member of the family, its functions being 
only partially understood. Besides kidney, NOX4 is widely expressed in a large variety of tissues 
such as foetal liver, smooth muscle cells, adipocytes, vascular endothelial cells, osteoclasts, 
hematopoietic stem cells and skeletal muscle. The fact that its overexpression alone increased to the 
production of superoxide indicated that it is constitutively activated (Ambasta et al., 2004), unlike 
other NOX members. The subcellular localization of NOX4 is also diverse. In HUVECs cells NOX4 
was localized in the nucleus (Kuroda et al., 2005), in smooth muscle cells in nucleus and ER 
(Hilenski et al., 2004) and in the skeletal myocytes it was localized in cytosol and close to plasma 
membrane. Nevertheless, in an independent report the production of superoxide by NADPH 
oxidases in cultured myocytes was identified only in the sarcoplasmic reticulum (SR) fraction (Xia 
et al., 2003). Dysregulations in the NOX4 activity or changes in its expression levels have been 
reported in the development of diabetic nephropathy (Gorin et al., 2005) and cardiovascular diseases 
(Sorescu et al., 2002).  Of interest, recently it was also reported that NOX4 mediates the production 
of ROS in cultured 3T3-L1 adipocytes after insulin challenge (Mahadev et al., 2004), partially by 
inhibiting the action of tyrosine phosphatases (PTPases). In addition, it was shown that exogenous 
visfatin treatment of vascular endothelial cells stimulated the accumulation and aggregation of gp91 
and p47 phox subunits of NADPH oxidase complex in the membrane rafts domains, leading to an 
increase in the production of superoxide (Xia et al., 2010). The specific role of NOX4 in skeletal 
muscle is still unexplored, besides the fact that it is an important regulator of proliferation and 
differentiation (Mofarrahi et al., 2008). Therefore, the increased expression of NOX4 by visfatin 
treatment could partially explain the increased levels of ROS detected by the H2DCFDA fluorescent 
method. Nevertheless, since MitoSOXTM probe used in the previous chapter is specific only for the 
superoxide produced by mitochondria, and since NOX4 was reported so far to be present only in 
cytosol, around the plasma membrane, in the SR but not in mitochondria, it is likely that the 
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increased superoxide production upon visfatin challenge did not reflect a direct involvement of 
NOX4, suggesting independent mechanisms. Nevertheless, the measurement of NOX4 activity is not 
covered in the present thesis and whether the increase in NOX4 expression by visfatin indicates that 
the production of ROS by visfatin occurs though its activation is a subject for future studies. 
Interestingly, NOX4 was not increased by the triglyceride treatment, although it was shown 
independently that high-fat diet was able to induce in mice models an increase in its expression and 
that palmitate-treated endothelial cells silenced with a NOX4-specific construct had a reduced level 
of activation of NFkB signalling (Maloney et al., 2009). The upstream regulators for such increase in 
NOX4 levels upon visfatin challenge are unknown so far. The relevance of this discovery was 
further reinforced by other recent independent reports showing that exogenous visfatin challenge 
induced also changes in localization and/or activity of other members of NADPH oxidases family 
increasing the levels of ROS produced, with a potential relevance for the development of many 
pathological conditions affecting ageing such as metabolic syndrome, inflammation and arthritis 
(Boini et al., 2010; Malam et al., 2011; Xia et al., 2011).       
   Therefore, the next question to be approached in the coming chapter is the following: 
                 What signalling pathways are regulating the ROS production and the underlying 
changed genomic profile upon visfatin treatment in C2C12 cells?                   
 
 
                         2. Triglyceride incubation induced insulin resistance in C2C12 cells by 
affecting PI3K/Akt signalling               
   As already known, once activated by insulin challenge the PI3K-dependent 
signalling induces the translocation of GLUT4 transporter to the plasma membrane within the 
first hour of incubation (Valverde et al., 2005). I reported in this chapter an increased rate of 
glucose uptake in skeletal myocytes after 30 minutes of incubation with insulin (Fig. 5.7), likely a 
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consequence of the increased translocation of GLUT4 to the plasma membrane. As shown in the 
previous chapter, short- or long-term treatment of cultured myocytes with exogenous visfatin 
alone did not change the phosphorylated levels of PI3K/Akt-associated signalling pathway. 
Furthermore, the pre-incubation of C2C12 cells with visfatin for 24 hours did not influence the 
subsequent activation of Akt by the acute insulin stimulation as shown in the previous chapter. In 
the present chapter I showed also that the incubation of C2C12 cells with visfatin for 24 hours did 
not change gene expression levels of glucose transporters such as GLUT1 and GLUT4 (Fig. 
5.10A,B). In addition, visfatin had no effect on the rate of glucose uptake in both basal (Fig. 
5.7C) and insulin-stimulated conditions (Fig. 5.8B), as measured by 2-NBDG assay. This proved 
that in the case of cultured skeletal myocytes visfatin is not an insulin mimetic agent, which is 
also a strong argument to dismiss the possibility of an insulin mimetic effect on skeletal muscle in 
vivo too. 2-NBDG is a fluorescent derivative of glucose that is taken up from the extracellular 
space into the cytosol of cultured myotubes by glucose transporters and consequently can be 
visualized by fluorescent microscopy. This alternative method is also applicable for automatic 
microplate readings. In addition, unlike the radioactive assay, 2-NBDG approach is also useful 
for the identification of localization patterns and it is applicable for live, real-time imaging 
(Gaudreault et al., 2008). Previously, by using 2-DG method it was shown that skeletal muscle 
from obese rats had an impaired glucose uptake response compared to the skeletal muscle from 
wild-type animals (Jacob et al., 1996), and the same effect was shown also in the case of L6 rat 
cultured skeletal myotubes treated with palmitate (Kelly et al., 2008). My findings correlate with 
previous data that indicated that the increase in the rate of glucose uptake upon the challenge with 
the exogenous visfatin (eNampt) was noticed only in those cells that also presented an activation 
of PI3K/Akt signalling pathway (Lim et al., 2008), event missing in my experiments.              
                   I also showed that the chronic triglyceride treatment reduced the levels of 
phosphorylated forms of Akt and GSK-3β (one of Akt substrates) only in the insulin-stimulated 
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state, but not in the basal state (Fig. 5.9A,B). In the same time, as shown by 2-NBDG assay, the 
triglyceride challenge increased the rate of glucose uptake in basal state (Fig. 5.7C), but reduced 
it in the insulin stimulated state (Fig. 5.8B). These findings correlate with the reduced insulin-
stimulated activation of Akt signalling by triglycerides. Triglycerides reduced also the expression 
level of GLUT4 after 24 hours (Fig. 5.10B), possibly contributing to the reduced glucose uptake 
seen in the insulin-stimulated state. The fluorescent-based assays showed also that triglycerides 
treatment increased the glucose uptake in basal state and this correlates with the increased 
expression of GLUT1 transporter (Fig. 5.10A). The lack of reduction in phospho-Akt levels after 
triglycerides treatment in the basal state showed that PI3K/Akt signalling pathway is not involved 
in the increased GLUT1 expression.                     
   The relevance of the increase in GLUT1 expression upon triglyceride treatment is 
still debated. It was shown for example that GLUT1 translocation at the plasma membrane is 
higher in the human patients with diabetes and obesity and that the metabolic inflexibility seen 
during diet-induced obesity is partially dependent on an increased, unregulated level of glucose 
uptake in basal state (Miele et al., 1997).  Alternatively, the increase in GLUT1 expression and in 
the rate of basal glucose uptake in C2C12 cells upon TG treatment might act as a compensatory 
mechanism to counteract the reduced expression of GLUT4 and the impairment of PI3K/Akt-
signalling pathway that mediates the translocation of GLUT4 at the plasma membrane upon 
insulin challenge in order to assure a steady supply level of glucose. For example, an increase in 
GLUT1 expression was shown already to have a positive, compensatory effect on 
cardiomyocytes upon the in vivo pressure-load-induced hypertrophy (Morissette et al., 2003).        
     Therefore, the next question to be asked is this:                    
        What are the effects of visfatin on inflammatory signalling pathways?  
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                               6A. Introduction 
                                     In the fourth chapter it was shown that exogenous visfatin (eNampt) 
treatment increased ROS levels in C2C12 cells (Fig. 4.1), but independently of insulin receptor-
dependent signalling and of PI3K/Akt-associated pathway (Fig. 4.10-11). One possible explanation 
for this ROS increase could be the binding of extracellular visfatin (eNampt) to another as yet 
unidentified receptor. The hypothetical existence of such a membrane receptor was already 
proposed in the literature (Li et al., 2008), but there are no published reports of attempts to identify 
it. The screening of such putative visfatin-specific membrane receptor was also beyond the scope of 
the present thesis, being a subject for future studies. Another hypothesis to explain the increase in 
ROS levels is based on the possibility of exogenous visfatin (eNampt) transport from extracellular 
space across plasma membrane and the accumulation in the intracellular compartments of C2C12 
cells. An active transport across membrane structures was reported previously for other cytokines 
like leptin (Bouret, 2008), leukaemia inhibitory factor (Pan et al., 2008) and TNF-α (Pan et al., 
2002). It is reasonable to assume that an active transport of exogenous visfatin (eNampt) from 
extracellular space across plasma membrane will result in an intracellular increase of visfatin 
expression (as iNampt) in C2C12 cells, assuming the absence of a simultaneous process of 
proteasomal degradation or additional re-secretion. Nevertheless, since the precise subcellular 
localization of intracellular form of visfatin is still debated (Kitani et al., 2003), the possible 
destination of such a transport is also unclear. In the testes of prepubertal chickens the intracellular 
form of visfatin (iNampt) was localized mainly in the nucleus of Sertoli and Leydig cells, but in the 
testes of adult chickens the pattern was cytosolic in both cell types (Ocon-Grove et al., 2010). 
Similarly, visfatin was localized mainly in the cytosol of proliferating PC-12 and 3T3-L1 cells, but 
in the differentiated state of both cell lines the pattern was nuclear (Kitani et al., 2003). An increase 
in the expression of intracellular form of visfatin (iNampt) could lead to higher levels of ROS as a 
consequence of the modulation of cellular processes such as to nicotinamide adenine dinucleotide 
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(NAD) synthesis (Pilz et al., 2007), independently of its putative binding to a membrane receptor.  
Nicotinamide mononucleotide (NMN) is synthesized by intracellular form of visfatin (iNampt) 
from nicotinamide through its phosphoribybosiltransferase activity (Wang T. et al., 2006), and 
NAD will be synthesized from NMN by the activity of another enzyme, mononucleotide 
adenylyltransferase (NMNAT1) (Garavaglia et al., 2002). Increased expression of iNampt 
correlates with higher levels of NAD in cultured fibroblasts (Imai, 2009a) and visfatin 
heterozygous+/-  females mice further presented reduced levels of NAD in pancreatic islets (Revollo 
et al., 2007). The fact that NMNAT1 is localized also in nucleus (Berger et al., 2005) further 
suggests the possible existence of different functions for intracellular form of visfatin (iNampt) if 
localized in cytosol or in nucleus, unknown yet. Nevertheless, an increase in ROS levels as a direct, 
immediate effect of higher levels of NAD is improbable. A reduction in NAD levels increased the 
levels of oxidative stress in C. elegans (Vrablik et al., 2009) and nicotinamide supplementation 
prevented mitochondrial dysfunctionalities reducing ROS levels (Jia et al., 2008). Such effect could 
be nevertheless indirect, such as an inflammatory response. For example it was shown that 
incubation of smooth muscle cells with exogenous visfatin (eNampt) activated NFkB-signalling 
through its phosphoribybosiltransferase activity, independently of PI3K/Akt-signalling pathway 
(Romacho et al., 2009).                                 
   It is also likely that intracellular form of visfatin (iNampt) might fulfil other 
functions besides NMN synthesis which could induce a sustained ROS production, as suggested 
already (Li et al., 2008). For example, it was shown that overexpression of visfatin gene in primary 
human endothelial cells increased ROS levels, the process being blocked by the inhibition of 
mitochondrial NADH oxidase complex I function (Zhang et al., 2008). Furthermore, the silencing 
of the visfatin/PBEF gene by siRNA was able to reduce ROS levels induced by the incubation of 
the same type of cells with the cytokine IL-1β. A possible explanation proposed by the authors for 
this increase in ROS levels was the fact that visfatin was shown to directly interact with other 
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proteins already proved to be involved in oxidative stress production and inflammation like NADH 
dehydrogenase subunit 1 (ND1) and ferritin light chain and interferon induced transmembrane 3 
(IFITM3). Therefore, the first goal of the present chapter was testing whether incubation of C2C12 
cells with exogenous visfatin between 1-24 hours was followed by its active transport from 
extracellular space into the cytosol by using western blot method.     
          The second aspect to be investigated in the present chapter was the possible activation 
of intracellular signalling pathways (other than PI3K/Akt) that could explain the increase in ROS 
levels. For example, it was reported that acute exogenous visfatin treatment (<30 min) activated 
mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated kinase 1 
(ERK1/2) in ventricular cardiomyocytes (Lim et al., 2008) and p38 in HUVECs cells (Liu et al., 
2009b). It is already known that MAPKs, also known as stress-activated kinases (SAPKs), are 
important mediators of oxidative and nitric stress responses (Cao et al., 2004).  Interestingly, so far 
there are no reports about the possible activation of c-Jun terminal kinase (JNK) by visfatin 
treatment, another member of MAPK family which is critically involved in ROS production (Shen 
and Liu, 2006), and this possibility will not be tested in the present thesis either. It was previously 
shown that exogenous visfatin challenge (eNampt) induced the activation of NFkB pathway in the 
first hour of treatment in endothelial cells (Lee et al., 2009) and after 4 hours in smooth muscle 
cells (Romacho et al., 2009). It is also well known that an activation of NFkB signalling could 
induce an increase in ROS production by activating the transcription of some of its pro-
inflammatory target genes that subsequently can mediate a chronic and sustained stress response 
like TNF-α (Munhoz et al., 2004),  COX-2 (Munhoz et al., 2008), IL-6 (Paule et al., 2007), IFN-γ 
(Briscoe et al., 2006) and iNOS (Pinlaor et al., 2008). Recently it was also discovered that MAPKs-
induced effects can be independent of transcriptional regulation through the direct phosphorylation 
of cellular targets, other than regulators of gene expression.  For example, it was reported that JNK, 
another member of MAPK family, can phosphorylate proteins regulating axodendritic growth in 
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neurons such as microtubule-associated protein 2 (MAP2) (Bjorkblom et al., 2005) and superior 
cervical ganglion-10 protein (SCG10) (Tararuk et al., 2006), affecting neurogenesis.  Therefore, it 
would be possible also for p38 and ERK to directly phosphorylate proteins involved in antioxidant 
defence and oxygen metabolism and modify their enzymatic properties, eventually leading to 
increased levels of ROS.  There are also multiple reports about the relationships between visfatin 
expression or function and the levels of circulating NFkB-regulated cytokines associated with 
oxidative stress. For example, it was shown that cultured human monocytes treated with exogenous 
visfatin expressed higher levels of TNF-α (Moschen et al., 2007). Similarly, human monocytes or 
synovial fibroblasts transfected or stimulated with exogenous visfatin showed increased TNF-α 
expression values via NFkB and AP-1 signalling (Brentano et al., 2007).  In other report, the 
experimental mice of collagen-induced arthritis presented increased visfatin and TNF-α plasma 
levels, and the pharmacological inhibition of phosphoribybosiltransferase activity of visfatin 
reduced circulating TNF-α levels (Busso et al., 2008). Furthermore, decreased visfatin expression 
values correlated with decreased levels of plasma circulating interferon-γ (IFN-γ) upon caloric 
restriction in human volunteers (Lee et al., 2010). Also, exogenous visfatin (eNampt) treatment of 
cultured macrophages increased not only the gene expression but also the secretion values of an 
important cytokine such as IL-6 in endothelial cells (Kim et al., 2009). To test the possible 
activation of MAPKs (ERK and p38) and NFkB signalling pathways in C2C12 cells by exogenous 
visfatin (eNampt), western blot was performed for the phosphorylated forms of MAPKs (p38, ERK 
½) and NFkB pathway (p65, IKKα/β and IkBa).  Such pathways could be nevertheless activated 
during chronic stages of incubation with visfatin (eNampt), events that might not be detected by my 
western blot experiment. Therefore, ERK, p38 and NFkB activations were blocked by using their 
specific inhibitors prior visfatin challenge, and intracellular ROS levels were measured by 
fluorescent-based assays, as performed in previous chapters.  
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                       6B. Results 
                            6.1 Visfatin (eNampt) was not transported from the extracellular space across 
plasma membrane into the cytosol of C2C12 cells                               
    To test the possibility that visfatin was transported across the plasma membrane, 
C2C12 cells were incubated with 100 ng/ml visfatin for an interval between 1-24 hours followed by 
western blot assay by using cell lysates. Since the commercially available visfatin chosen for this 
particular experiment had a FLAG-tag at the N-terminus, two different antibodies have been used to 
perform western blot. The first antibody was raised against the tag, and the second was raised against 
the visfatin, recognizing both intracellular (iNampt) and extracellular (eNampt) forms. As positive 
control 10 ng of tagged exogenous visfatin diluted in PBS was used (10% of the input). This value 
reflects approximately the same concentration which should have been detected in the amount of 
protein lysates loaded in each well (60 ng) if the membrane transport efficiency for exogenous visfatin 
had been at maximum levels (100%), assuming the absence of a simultaneous proteasomal degradation 
process.                                            
             As seen from figure 6.1, when the antibody specific for FLAG-tag has been used no 
band was detected in cell lysates from the samples treated with visfatin for 1-24 hrs. Moreover, the 
western blot using the antibody specific for visfatin did not detect either any extra band of the size 
predicted for the exogenously added extracellular form (eNampt) which, due to the attached tag, is 
approximately 1 kDa bigger than the intracellular form (iNampt) endogenously expressed by C2C12 
myotubes and also recognized by the antibody. Had exogenous visfatin (eNampt) been transported 
from the culture medium into the cytosol of C2C12 cells two distinct bands should have been detected 
by using the second antibody: one for the intracellular form of visfatin expressed endogenously by 
C2C12 cells (iNampt) of 56 kDa, and another corresponding to the extracellular version (eNampt-
FLAG) transported across plasma membrane of cca. 57 kDa. Therefore, this blotting experiment shows 
that visfatin is not transported from the extracellular space into the cytosol of C2C12 cells. This allows 
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the speculation that the effects of visfatin on myocytes cellular stress responses are likely the 
consequences of its binding to a membrane-bound receptor, other than insulin receptor. Once bound to 
this putative receptor visfatin (eNampt) could activate/repress different intracellular signalling 
pathways other than PI3K/Akt, leading to increased levels of ROS through still unknown mechanisms. 
The identity of this putative receptor is still unexplored in the literature, its existence only theoretically 
proposed (Li et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
                      Fig.  6.1 Visfatin is not transported from the extracellular space into the cytosol of 
C2C12 myocytes              
                   C2C12 differentiated myocytes were incubated with visfatin (100ng/ml)
diluted in serum-free medium for 1
positive control. Protein lysates were resolved by a typical western blot and probed by using the 
antibody raised against the FLAG
against GAPDH was used (below). Each data point is the average from three independent 
experiments +/− SEM. NS denotes no significant difference between treatment and control.  
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-24 hrs and 10% of the initial input has been used (10ng) as 
-tag (above) or visfatin (middle). As a control an antibody 
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                         6.2 Acute visfatin (eNampt) treatment did not activate MAPKs such as p38 and 
ERK                      
              Previously it was reported that exogenous visfatin challenge can modulate intracellular 
signalling pathways by increasing the phosphorylated levels of mitogen-activated kinases (MAPKs) 
like ERK and p38 in the first 30 minutes of treatment, in an Akt-dependent manner (Adya et al., 
2008a; Kim et al., 2008; Lim et al., 2008). It is already known that activation of MAPKs such as p38 
(Cao et al., 2004) and ERK  (Ding et al., 2007) can further mediate an increased production of oxygen 
free radicals. As seen in figure 6.2, western blot experiments showed that visfatin treatment did not 
induce any increase in the phosphorylated forms of p38 and ERK in the first 30 minutes of incubation. 
Since there were no previous reports of JNK activation by exogenous visfatin (eNampt), this 
possibility was not explored in the present thesis either.        
       Nevertheless, MAPKs could be activated in the later, chronic stages of visfatin 
treatment independently of Akt-signalling pathway, leading potentially to higher levels of ROS (Perry 
et al., 1999). Therefore, C2C12 cells were  pre-incubated for 1 hour with the inhibitor U0126 that 
blocks MEK 1/2 activation (ERK 1/2 upstream activators) or with InSolutionTM p38 MAP kinase 
inhibitor III that blocks p38α activity, followed by exogenous visfatin treatment (100 ng/ml) for 
another 18 hours. The measurement of free radicals by using carboxy-H2DCFDA-based assays 
showed no differences in ROS levels between the samples pre-treated with MAPKs inhibitors followed 
by visfatin challenge compared to the signal detected from visfatin-only treated cells (Fig. 6.3). This 
proved that the oxidative stress induced by exogenous visfatin is independent of p38 and ERK 
signalling pathways.  
 
 
 
                  Fig. 6.2       Visfatin is not activating the MAPKs (p38 and ERK 
minutes of incubation               
     C2C12 differentiated myocytes were incubated with visfatin (100ng/ml) diluted in 
serum-free medium for the indicated times (0, 10, 20 and 30 minutes). 
resolved by a typical western blot and probed by using the antibodies raised against the 
phosphorylated forms of p38 (above) or ERK ½ (middle).  As a control an antibody against 
GAPDH was used (below). Quantization of phospho
to the negative control was done 
three independent experiments +/
treatment and control.  
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Protein lysates were 
-p38 and phopsho-ERK1/2 levels, compared 
by densitometric analysis. Each data point is the average from 
− SEM. NS denotes no significant difference between visfatin 
1/2) in the first 30 
   
 
 Fig. 6.3      The oxidative stress induced by 
      Differentiated C2C12 cells were pre
of ERK activation, or with 10 
specifically p38 activation, before being subjected to another 18 hrs of challenge with 100 ng/ml 
of visfatin. Cells were incubated with 25 
followed by 5 min incubation with 1 
compared to control is shown. Each data point is the average of quadruplicate samples per 
experiment from three independent experiments +/
control. NS denotes no significant difference between inhibitors
compared to visfatin alone.    
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visfatin is independent of MAPKs signalling pathway  
-treated for 1 hr with 10 µM 
µg/ml InSolutionTM p38 MAP kinase inhibitor III
µM carboxy-H2DCFDA for 25 min to detect ROS, 
µM Hoechst 33342 to stain the nuclei. Re
− SEM. **Denotes p<0.01 compared to 
 followed by visfatin treatment 
                
U0126, an inhibitor 
 that blocks 
lative expression 
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                 6.3    Chronic visfatin (eNampt) treatment activated NFkB signalling                  
      Previously it was reported that exogenous visfatin treatment activated NFkB-signalling after 
1 hour of incubation of cultured synovial fibroblasts (Brentano et al., 2007) and after 4 hours in smooth 
muscle cells (Romacho et al., 2009). Such an activation of NFkB-signalling could induce an increase 
in the expression of many of its targets that could act as pro-inflammatory mediators, increasing further 
the production of ROS. For example, visfatin challenge increased in non-skeletal muscle cells the 
expression levels of  pro-inflammatory mediators such as iNOS (Romacho et al., 2009), eNOS (Lovren 
et al., 2009) and TNF-α (Luk et al., 2008; Moschen et al., 2007), genes that are associated with 
sustained nitric and oxidative stress responses. The quantification by western blot and densitometric 
analysis of phosphorylated levels of NFkB (p65) showed a significant increase in its activation after 4 
hours of incubation of C2C12 cells with extracellular visfatin (100 ng/ml) (Fig. 6.4). The activation of 
NFkB pathway was also confirmed by the increased phosphorylation level of the upstream activator of 
p65 subunit (IKK α/β) and of IkBα, the p65 inhibitor that once phosphorylated by IKK α/β is degraded 
by proteasome. The activation of NFkB did not occur in the acute stage of incubation with visfatin 
(within the first hour) as previously reported in synovial fibroblasts, macrophages or endothelial cells, 
but in the chronic stage (cca. 4-5 hours), approximately at the same time point when increased ROS 
production was detected. Because it was previously reported that NFkB signalling could increase the 
expression levels of many cytokines that can further mediate an additional oxidative stress response 
(Kanitkar et al., 2008), C2C12 cells were pre-incubated for 1 hour with 50 µg/ml IκB Kinase Inhibitor 
Peptide, a specific blocker of IKK activation, followed by the treatment with exogenous visfatin for an 
additional 18 hours. As seen from figure 6.5, a significant reduction in the levels of ROS produced 
(cca. 30%) was noticed by a fluorescent-based assay in C2C12 cells pre-treated with the IKK inhibitor 
followed by visfatin challenge compared to cells treated only with visfatin. This showed that the 
oxidative stress induced by visfatin is partially mediated by NFkB-dependent signalling.   
 
                      Fig. 6.4 Visfatin 
                       C2C12 differentiated myocytes were incubated with visfatin (100ng/ml) diluted in 
serum-free medium for the indica
western blot and probed by using the antibody raised against the phosphorylated form of p65 
subunit of NFkB (above), the phosphorylated form
control an antibody against GAPDH was used (bottom). Quantization of p65 
levels compared to negative control was done 
average from three independent experiments +/
between visfatin and control. **Denotes p<0.01 compared to control. 
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is activating the NFkB signalling pathway after 4 hrs of incubation 
ted times (0-6 hrs). Protein lysates were resolved by a typical 
s of IKKα/β (middle) and IkBa (below).  As a 
by densitometric analysis. Each data point is the 
− SEM. NS denotes no significant d
 
 
phosphorylation 
ifference 
                      Fig. 6.5     Blocking the activation of the NFkB signalling pathway is reducing the 
oxidative stress levels induced by visfatin with cca. 40%
          Differentiated C2C12 cells were pre
Inhibitor Peptide, an inhibitor of NFkB activation, before being subjected to another 18 hrs of 
challenge with 100 ng/ml of visfatin. Cells were incubated 
25 min to detect ROS, followed by 5 min incubation with 1 
nuclei. Relative expression compared to control is shown. Each data point is the average of 
quadruplicate samples per experiment from thr
p<0.01 compared to visfatin. **Denotes p<0.0
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                       6.4    Activation of NFkB by visfatin (eNampt) treatment changed the expression 
level of many of its regulated genes involved in oxidative stress production or antioxidant defence             
           NFkB signalling regulates the transcription levels of many genes that were already 
reported to be positively or negatively associated with oxidative stress like TNF-α, IFN-γ, IL-6, 
inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS), neuronal nitric oxide 
synthase (nNOS) and VEGFa (Bowie and O'Neill, 2000). To test the possibility that visfatin incubation 
of C2C12 cells could change their expression levels an RT-PCR assay was performed by using 
different time points (0-24 hours).  As seen in figure 6.6A, NFkB target genes known to be involved in 
the regulation of inflammatory signals such as TNF receptor-associated factor 1 (TRAF1) (Lee and 
Choi, 2007) and TNF receptor-associated factor 6 (TRAF6) (Wu and Arron, 2003) were not changed 
by visfatin treatment. VEGFa, a NFkB target gene proved to be upregulated upon visfatin treatment in 
non-skeletal muscle cells (Adya et al., 2008), showed only a moderate increased expression. Visfatin 
treatment further moderately increased the expression of nitric oxide synthase 1 (NOS1), named also 
the neuronal nitric oxide synthase (nNOS), enzyme involved in nitric oxide synthesis (Keser et al., 
2011).    Visfatin challenge increased also the level of expression of IL-6 and IL-15 (Fig. 6.6B) after 24 
hours of treatment, myokines regulated by NFkB that have a major role in skeletal muscle energy 
metabolism and stress responses (Chan et al., 2004). Exogenous visfatin challenge of C2C12 cells 
surprisingly decreased expression levels of other cytokines such as TNF-α and IFN-γ, previously 
reported to mediate a stress response (Kim et al., 2005). In the previous chapter it was shown a 
significant increase in NOX4 expression levels after 24 hours of visfatin treatment (Fig. 5.6). 
Previously it was discovered that NOX4 gene expression is regulated by NFkB pathway (Manea et al., 
2010). Therefore, the activation of IKK pathway was blocked by using the same inhibitor as before 
prior visfatin treatment for 24 hrs and the expression level of NOX4 was verified by RT-PCR. As seen 
from figure 6.7, the inhibition of NFkB activation reduced the expression level of NOX4 induced by 
visfatin by almost 50%. This shows that NOX4 expression is only partially regulated by NFkB.  
          Fig. 6.6  Visfatin treatment changes the expression levels of some of NFkB
genes                  
           C2C12 differentiated myocytes were incubated with visfatin (100ng/ml) di
serum-free medium for 0-24 hrs. After RNA extraction and cDNA synthesis RT
performed. All samples were run in triplicate and fold change in expression was calculated by 
normalizing the test gene crossing threshold (C
comparing to gene expression in untreated cells. 
**Denotes p<0.01 compared to 
significant difference between visfatin and control
          A. 
           
 
 
 
 
 
 
 
          B. 
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t) with the control (beta-actin) and then 
***Denotes p<0.001 compared to control. 
control. *Denotes p<0.05 compared to control
.  
-regulated target 
   
luted in 
-PCR was 
.  NS denotes no 
 Fig. 6.7 Blocking 
NOX4 upregulated by visfatin challenge  
           Differentiated C2C12 cel
Inhibitor Peptide (an inhibitor of NFkB activation
challenge with 100 ng/ml of visfatin. 
performed. All samples were run in triplicate and fold change in expression was calculated by 
normalizing the test gene crossing threshold (C
comparing to gene expression in untreated cells. 
**Denotes p<0.01 compared to visfatin.
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                 6.5 Blocking transcription and translation reduced the ROS levels increased by visfatin 
(eNampt)                                       
         Because the inhibition of NFkB activation reduced ROS levels increased by visfatin the 
logical conclusion was that ROS production is dependent on de novo synthesis of a new genomic 
profile. To investigate this possibility transcription or translation were blocked by using their specific 
inhibitors (Actinomycin D and Cycloheximide, respectively) for 1 hour prior the treatment with 
exogenous visfatin for another 18 hours, and fluorescent-based assays to measure ROS levels were 
repeated as described before. As seen from figure 6.8, a reduction of almost 70% in the levels of ROS 
was noticed in cells pre-treated with inhibitors followed by visfatin challenge compared to the cells 
treated only with visfatin. This suggests that there are other as yet unidentified pathways besides NFkB 
signalling that are mediating the stress response. The identity of these signalling pathways is a question 
unanswered yet, being a subject for future studies that will not be covered by the present thesis.  
 
 
 
 
 
 
 
 
 
              Fig. 6.8   ROS induced by visfatin is depende
of genes 
   Differentiated C2C12 cells were pre
(AD), an inhibitor of transcription, or with 
(CHX), an inhibitor of translation, 
ng/ml of visfatin. Cells were incubated with 25 
ROS, followed by 5 min incubation with 1 
expression compared to control is shown. Each data point is the average of quadruplicate 
samples per experiment from three independent experiments +/
compared to visfatin. **Denotes p<0.01 compared to 
control. 
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                        6C. Discussion          
                         1. Visfatin (eNampt) transport hypothesis vs. visfatin (eNampt) receptor-binding 
hypothesis                                      
     The fact that circulating pro-inflammatory cytokines such as leptin, TNF-α, IL-1α or 
LIF are actively transported across membrane structures such as blood-brain barrier is already known 
(Bouret, 2008;Pan et al., 2008;Pan et al., 2002), but the transporters and the regulatory mechanisms 
involved are still elusive. An active transport of exogenous visfatin (eNampt) from extracellular space 
into the cytosol of C2C12 cells could result in an intracellular accumulation as iNampt.  Nevertheless, 
the possible destination compartment for such a transport is not clear because the subcellular 
localization of intracellular form of visfatin is diverse, as detailed in introduction. A higher expression 
of visfatin as iNampt in the intracellular compartments of C2C12 cells could increase ROS levels, as it 
was shown already in endothelial cells (Zhang et al., 2008). There were no previous reports about the 
possible transport of visfatin (eNampt) from extracellular space across the plasma membrane into the 
cytosol of any mammalian cells. Therefore, this hypothesis was tested in C2C12 cells by using the 
western blot method (Fig.6.1). In conclusion, the experiments showed that there was no proof of a 
transport of exogenous visfatin (eNampt) into the cytosol of C2C12 cells in the first 24 hours of 
incubation. The western blot experiment using the antibody raised against FLAG-tag did not detect 
any band in the cell lysates taken from the samples treated with exogenous visfatin (eNampt). 
Furthermore, the western blot experiment using the antibody raised against visfatin did not detect any 
extra band corresponding to the size of the exogenous form that is almost 1kDa bigger in size than the 
intracellular form of visfatin (56 kDa), due to the attached tag. The incubation of C2C12 cells with 
exogenous visfatin (eNampt) did not change further the protein levels of endogenous, intracellular 
form of visfatin (iNampt), suggesting further no change in intracellular NAD levels. Since in the 
fourth chapter it was shown that visfatin treatment did not activate the insulin receptor-dependent 
PI3K/Akt signalling (Fig.4.10), it is likely that the stress responses induced by visfatin are generated 
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by the binding to an unknown membrane receptor. This putative receptor could induce an increase in 
the intracellular ROS levels only in the tissues or cells where it is expressed or functional by 
activating/repressing yet to be defined downstream intracellular signalling pathways. The same 
speculative conclusion about the possibility of a visfatin-specific receptor, other than insulin receptor, 
was reached by another independent report that also failed to prove an insulin mimetic property for 
extracellular form of visfatin (Li et al., 2008). One possible candidate for such a putative receptor for 
visfatin could be for example the insulin-like growth factor receptor (IGF-IR) which once activated 
can increase the levels of glucose uptake (Shefi-Friedman et al., 2001). Previously it was shown that 
in HUVECs cells exogenous visfatin challenge induced the activation of Akt/PI3K-signalling 
pathway, similarly to insulin. Since it was also proved that in HUVECs cells IGF-IR is expressed at 
higher values than insulin receptor (Nitert et al., 2005), it is possible therefore that visfatin insulin-
mimetic effects on HUVECs are mediated in fact by IGF-IR, not by insulin receptor. This issue is 
nevertheless a subject for future studies.  
              
                             2.    Visfatin (eNampt) treatment and signalling pathways activation            
               Visfatin did not activate MAPKs such as ERK and p38 in the acute stage of 
treatment, as shown before in non-muscle cells (Lim et al., 2008; Adya et al., 2008; Kim et al., 2007).  
The lack of activation of MAPKs like p38 and ERK in C2C12 cells in the acute phase of treatment 
correlates with previous findings that this activation by visfatin is dependent on the upstream Akt-
signalling (Lovren et al., 2009) event undetected in my case as shown in chapter 4 (Fig. 4.10). It is 
still possible nevertheless that such MAPKs activations might occur later, but since blocking of 
MAPKs had no effect on ROS levels induced by visfatin this issue was not pursued further. Also, it is 
possible that visfatin could activate JNK, the other member of MAPK family, but this is a subject for 
future studies.                  
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                      Visfatin activation of NFkB in the first 6 hours of treatment opened the 
possibility that it could mediate the ROS production induced. The blocking of p65 activation showed a 
significant reduction in ROS levels upon subsequent visfatin challenge. The IC50 of NFkB inhibitor is 
10 µM for the LPS-induced IkB degradation by IkB kinases (IKK) in RAW 264.7 cells. NFkB is an 
important mediator of cellular responses to oxidative stress and inflammation (Schmid et al., 2006). 
Nevertheless, I did not notice by RT-PCR an increase in NFkB-target genes such as TNF-α and IFN-γ, 
proved before to mediate a chronic inflammation and oxidative stress. The blocking of transcription 
and translation reduced the ROS levels by almost 70%, showing that there other pathways besides 
NFkB mediating such increase. The potential role of NOX4 in visfatin-induced effects deserves 
additional studies since blocking of NFkB reduced the increase in NOX4 expression triggered by 
visfatin challenge for 24 hrs.      
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                     7A. Introduction  
                               As discussed in the third chapter, the experimental animal models of skeletal 
muscle accelerated ageing (hindlimb suspension) and of skeletal muscle delayed ageing (caloric 
restriction) presented significant changes in expression profiles of nuclear receptors families, such 
as PPARs and NR4As.  During ageing it was noticed a progressive modification of adipose tissue 
mass and physiology accompanied by different expression and secretion profiles of adipokines 
(Esposito and Giugliano, 2004; Scrivo et al., 2010). Adipokines have a major endocrine impact on 
other peripheral tissues by modulating gene networks regulating insulin sensitivity, antioxidant 
defence and inflammation (Esposito and Giugliano, 2004). The known experimental models of 
ageing mentioned above are characterized by changes in expression or function of adipokines 
(Crisostomo et al., 2010). For example, caloric restriction reduced not only the body weight and 
adipose tissue mass but also plasma levels of circulating visfatin in obese women subjects (Lee et 
al., 2010). In addition, it is established that caloric restriction has anti-ageing effects (Niemann et 
al., 2010). These effects were shown to be partially dependent on the activation of sirtuin family 
which use as a substrate NAD previously synthesized from NMN generated by intracellular form of 
visfatin (iNampt) (Picard and Guarente, 2005), as discussed in detail in previous chapters. This 
conclusion was further reinforced by the discovery that transgenic mice models of sirtuin1 gene 
presented a phenotype similar to the experimental animals subjected to caloric restriction with a 
delayed ageing process (Bordone et al., 2007).                     
  The complex connections between expression levels of adipokines and nuclear 
receptor activation in an ageing context have been unravelled recently. For example, incubation of 
primary human trophoblast cells with adiponectin increased the expression of PPAR-α (Jones et al., 
2010), and the same phenotype was shown by the treatment of C2C12 cells with leptin (Bendinelli 
et al., 2005). Therefore, any changes in adipokines expression profiles, already certified to occur 
during progression of ageing and ageing-associated diseases (Esposito and Giugliano, 2004), could  
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have a significant impact on expression and function of skeletal muscle specific-PPARs. As such, a 
change in plasma visfatin levels during ageing could indirectly influence the outcome of a clinical 
therapy employing PPARs agonists/antagonists to manage the ageing-associated diseases affecting 
skeletal muscle. There are no reports published so far about the activation or repression of skeletal 
muscle-specific PPARs-associated signalling pathways or changes in expression of skeletal 
muscle-specific PPARs by exogenous form of visfatin (eNampt). It is known nevertheless that 
visfatin treatment (eNampt) increased the expression levels of PPAR-γ  in cultured preadipocytes, 
affecting adipogenesis (Yang et al., 2010). The first goal of the present chapter was to test whether 
the exposure of differentiated C2C12 myotubes to exogenous visfatin (eNampt) could change the 
expression levels of PPARs by using an RT-PCR assay.                  
    As discussed in the third chapter, PPAR-β/δ could be an important target in 
treating the metabolic dysfunctions in aged skeletal muscle. I further showed in the third chapter 
that expression of PPAR-β/δ was increased in acute phase of mice hindlimb suspension, possibly 
mediating a transient metabolic adaptation to the stress incurred. Significant progress has been 
recorded recently also in the development of specific and effective PPAR-β/δ agonists and 
antagonists. GW-501516 is a selective agonist for PPAR-β/δ that is currently employed in clinical 
trials at different stages to treat different pathological conditions such as dyslipidaemia (clinical 
trial NCT00158899), heart failure (clinical trial NCT00318617), obesity (clinical trial 
NCT00388180) and cardiovascular diseases (clinical trial NCT00841217) (Clinical Trials-NIH, 
2011). GW-501516 was used also successfully in reducing the phenotype of experimental animal 
models of brain inflammation and neurodegeneration (Defaux et al., 2009). At the cellular level, 
the treatment of myocytes with GW-501516 was shown to increase the rates of fatty acid oxidation 
through the upregulation of relevant genes (Sprecher, 2007) and changed the expression profile of 
genes involved in energy production and antioxidant defence (Dressel et al., 2003). As a 
consequence, GW-501516 treatment changed in skeletal muscle the fuel preference from glucose to 
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lipids (Brunmair et al., 2006) and improved overall the metabolic syndrome phenotype (Tanaka et 
al., 2003), although it did not change directly the rate of glucose uptake (Dimopoulos et al., 2007). 
This PPAR-β/δ agonist could be also used to target the underlying inflammatory mechanisms in 
skeletal muscle because it was already shown that it blocks the activation of NFkB pathway by 
palmitate in cultured myocytes (Coll et al., 2010). In conclusion, the second goal of the present 
chapter was to test whether the activation of PPAR-β/δ-dependent signalling by using the agonist 
GW-501516 can change oxidative stress levels and inflammatory signalling pathways induced by 
exogenous form of visfatin (eNampt). To test this possibility multiple fluorescent-based assays, 
western blot and RT-PCR methods were used.                    
                   The usefulness of PPAR agonists in modulating the expression, activity or 
secretion levels of adipokines in multiple tissues of possible clinical interest for ageing 
management has already been proven. For example, activation of PPAR-γ by the agonist BRL 
49653 reduced leptin levels in cultured adipocytes (De Vos et al., 1996). In addition, it was shown 
that PPARs-associate signalling pathways mediate the regulation of adiponectin expression levels 
induced by diet-derived fatty acids (Swarbrick and Havel, 2008). There are also multiple reports 
detailing the effects of PPARs activation or repression on visfatin expression or activity. For 
example, it was shown that administration of fenofibrate (a PPAR-α agonist) or rosiglitazone (a 
PPAR-γ agonist) increased visfatin gene expression in adipose depots of obese diabetic rats (Choi 
et al., 2005). In addition, PPAR-γ agonists such as GW1929 increased expression of visfatin in 
human, although not in murine macrophages (Mayi et al., 2010). Pioglitazone, another PPAR-γ 
agonist, decreased nevertheless the expression of visfatin in visceral adipose tissue of obese rats 
(Lv et al., 2009). The murine hepatic expression of visfatin was also decreased by administration of 
WY-14643, a PPAR-α agonist (Dahl et al., 2010). Furthemore, the effect was cancelled in a PPAR-
α null mice model, decrease which was proved to be important in the context of nonalcoholic fatty 
liver disease. The administration of L-165041, a PPAR-β/δ agonist, increased further visfatin 
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expression in adipose tissue from obese rats fed with a high-fat diet and in cultured 3T3-L1 
adipocytes (Choi et al., 2005). These reports suggest that there are tissue-specific mechanisms 
regulating visfatin expression by PPARs, unknown yet. Nevertheless, there are no reports published 
so far about the effects of PPARs agonists on skeletal muscle expression or function of intracellular 
form of visfatin (iNampt).                       
      PPAR agonists can change not only the intracellular expression levels but also 
secretion levels of circulating visfatin from different cellular types such as adipocytes and 
macrophages. For example, in vitro studies showed that incubation of human adipocytes or 
HUVEC cells with PPAR-γ agonists such as rosiglitazone, telmisartan or valsartan increased the 
extracellular secretion of visfatin as eNampt (Storka et al., 2008). The administration of GW1929, 
another PPAR-γ agonist, was also able to increase the expression and secretion of visfatin in 
murine macrophages (Mayi et al., 2010). In another study the administration of PPAR-γ agonist 
pioglitazone nevertheless reduced the circulating levels of visfatin in obese rats, not only the 
intracellular expression in adipocytes (Lv et al., 2009), and the administration of fenofibrate did not 
change the circulating levels of visfatin in human subjects with type 2 diabetes (Pfutzner et al., 
2008). Furthermore, it appears that in some tissues or physiological conditions PPARs and visfatin 
belong to similar functional signalling networks since the analysis of their expression values shows 
similar statistical patterns upon genetic-/pharmacological-based interventions. For example, 
treatment of bone marrow stromal cells (BMSCs) with tigogenin, a compound that inhibits 
adipocytic differentiation, reduced simultaneously the expression levels of PPAR-γ and the 
secretion level of visfatin (Zhou et al., 2007). The same conclusion was reached by the treatment of 
adipocyte 3T3-L1 cell line with LPS that impaired adipogenesis by reducing expression levels of 
both PPAR-γ and visfatin (Poulain-Godefroy and Froguel, 2007).  Whether visfatin is also a 
genuine myokine, as it was theoretically proposed based on its high level of expression in skeletal 
muscle (Krzysik-Walker et al., 2008), is an issue still highly debated. The recent discovery that 
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culture medium of rat L6 myocytes contains significant levels of visfatin is a pioneer discovery 
(Wang et al., 2010), but the result was not reproduced independently. Since PPARs agonists are 
effective in the treatment of insulin resistance and metabolic syndrome affecting skeletal muscle, 
and given the fact that exogenous visfatin (eNampt) induces oxidative stress and inflammation in 
cultured myotubes, it is therefore important to establish first of all whether visfatin is a genuine 
myokine in the basal, unstimulated conditions. Also, it is important to test whether such a possible 
secretion event of visfatin from skeletal muscle is changed by the activation of PPAR-β/δ signalling 
upon agonist treatment. Therefore, the third goal of the present chapter was to explore whether 
visfatin can be detected in the culture medium of differentiated and fused C2C12 myotubes and 
whether the incubation with GW-501516 can induce a change in such possible secreted values. To 
do this an ELISA assay was employed. Since the role of intracellular form of visfatin (iNampt) in 
regulating oxidative stress is not a particular focus issue of the present thesis, the possibility that 
GW-501516 can change only the intracellular expression of visfatin (iNampt) in C2C12 cells 
without a subsequent secretion was not tested, which is a subject for future studies.  
                 NR4A family of nuclear receptors is also an attractive target for the treatment of 
insulin resistance in skeletal muscle (Fu et al., 2007) as discussed in the third chapter, but so far 
there are no reports about any connection between NR4As expression and visfatin. In addition, 
there are no specific reliable agonists or antagonists developed yet targeting NR4As activity (Myers 
et al., 2009). Therefore, in the absence of a specific NR4As agonist or antagonist, the issue of 
possible connections between NR4As and visfatin was not explored in the present study, being a 
subject for future projects.   
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                     7B. Results 
                       7.1 Visfatin did not change significantly the expression levels of PPARs in 
C2C12 cells                                     
           To test whether the incubation of C2C12 cells with 100 ng/ml of exogenous visfatin 
(eNampt) for 24 hours changed the expression levels of PPAR family, an RT-PCR assay was 
performed. As seen from figure 7.1, no significant change was noticed in expression levels of 
PPAR-β/δ and PPAR-γ upon visfatin challenge for 24 hours. PPAR-α expression level in 
differentiated and fused C2C12 myotubes was too low to be detected by RT-PCR in the cDNA 
range used for the detection of the other two PPARs, and the identification of PPAR-α level was 
not further approached through western blot. This showed that unlike other adipokines that can 
modify PPARs expression levels in skeletal muscle (Jones et al., 2010),   exogenous visfatin had no 
significant effect in this aspect.  
 
                        
 
 
 
 
 
 
 
 
 
 
 
                 Fig. 7.1      Visfatin did not change significantly the gene expression levels of PPARs in 
C2C12 cells              
     C2C12 differentiated myo
serum-free DMEM medium for 24 hrs. After RNA extraction and cDNA synthesis, RT
performed. All samples were run in triplicate and fold change in gene expression was calculated by 
normalizing the test gene crossing threshold (C
the values to the gene expression in untreated cells.
visfatin and control. Each data point is the average of triplicate sam
independent experiments +/− SEM. 
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                         7.2.   Administration of GW-501516, a PPAR-β/δ agonist, reduced the 
oxidative stress induced by visfatin in C2C12 cells  
                         To explore the possibility that activation of PPAR-β/δ-dependent signalling can 
modify ROS levels induced by exogenous visfatin treatment, C2C12 cells have been incubated for 
24 hours with its specific agonist  GW-501516 (10nM) followed by the treatment with 100 ng/ml 
of exogenous visfatin (eNampt) for another 18 hours. The fluorescent microscopy experiment 
showed that the oxidative stress induced by exogenous visfatin was reduced almost in half in 
C2C12 cells pre-treated with GW-501516, compared to the cells treated only with visfatin (Fig. 
7.2A). This showed that PPAR-β/δ activation reduces the oxidative stress levels induced by 
visfatin.  Nevertheless, as seen in Fig. 7.2B, although the treatment of C2C12 cells with GW-
501516 for 24 hours had no significant effect on NOX4 expression levels, it did nevertheless 
reduce with cca. 30% the increase in NOX4 expression induced by visfatin challenge after 24 
hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 7. 2     Administration of GW
induced by visfatin in C2C12 cells 
  A. Differentiated C2C12 cells were pre
being later subjected to another 18 hrs of challenge with 100 ng/ml of visfatin
DMEM medium. Cells were incubated with 25 
followed by 5 min incubation with 1 
compared to control is shown. Each data point is the average of quadruplicate samples per 
experiment from three independent experiments +/
**Denotes p<0.01 compared to control
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             B.  C2C12 differentiated myocytes were pre-treated or not for 24 hrs with GW-501516 
(10nm), followed by the incubation with visfatin (100ng/ml) diluted in serum-free DMEM medium 
for another 24 hrs. After RNA extraction and cDNA synthesis, RT-PCR was performed. All 
samples were run in triplicate and fold change in expression was calculated by normalizing the test 
gene crossing threshold (Ct) with the control (beta-actin), and then comparing to the gene 
expression in untreated cells. NS denotes no significant difference between control and agonist 
alone.  **Denotes p<0.01 agonist plus visfatin compared to visfatin alone. **Denotes p<0.01 
visfatin plus or minus agonist compared to negative control. Each data point is the average of 
triplicate samples per experiment from three independent experiments +/− SEM. 
 
 
 
                             B.  
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    7.3   Administration of PPAR-β/δ agonist failed to reduce the activation of 
NFkB activation by visfatin  
                              As shown in a previous chapter, visfatin treatment increased the phosphorylated 
levels of NFkB (p65 subunit) after a minimum incubation time of 4 hours. To test whether the 
PPAR-β/δ agonist can reduce this activation, C2C12 cells have been incubated for 24 hours with its 
specific agonist GW-501516 (10nM) followed by the treatment with 100 ng/ml of exogenous 
visfatin (eNampt) for another 6 hours. The EC50 of this agonist is 1.1nM and has a specificity of 
almost 1000 times compared to the other two PPAR isoforms. To quantify activation of NFkB-
pathway a western blot for the phosphorylated form was performed. As shown by the Fig. 7.3, 
C2C12 cells pre-treated with the agonist GW-501516 before exogenous visfatin challenge for 6 
hours showed no difference in phospho-p65Ser536 and phospho-IKKα/βSer176/180 levels compared to 
cells treated only with visfatin. This showed that the reduction in ROS levels by GW-501516 is not 
mediated by an inhibition of NFkB-dependent signalling pathway and that the increase in 
antioxidant defence by agonist treatment did not affect the activation of NFkB. In addition, the 
blocking of NFkB activation by its specific inhibitor reduced almost completely the increase in 
phosphorylated p65 values induced by visfatin treatment, proving that the partial reduction in ROS 
levels shown in previous chapters was not due to a reduced efficiency of NFkB blocking. This 
further suggests that activation of NFkB is not mediated by an initial increase in ROS levels, as 
shown in other cases (Ho et al., 1999).   
 
 
 
 
 
 
                          Fig. 7. 3    Administration of PPAR
NFkB activation by visfatin                
    Differentiated C2C12 cells were pre
vehicle, the agonist GW-501516 diluted in DMSO (10nm) or with I
µg/ml) for 1 hr, before being subjected to another 6 hrs of challenge with 100 ng/ml of visfatin. 
Protein lysates were resolved by a typical
against the phosphorylated form of p65 subunit of NFkB (above), phosphorylated form of 
(middle) or an antibody against GAPDH as control (bottom). Quantization of p65 levels of 
phosphorylation, compared to the negative control was done 
point is the average from three independent experiments +/
compared to control. NS denotes no significant 
compared to visfatin alone. **Denotes p<0.01 
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                         7.4    Visfatin is not a myokine in the basal condition and the administration of 
PPAR-β/δ agonist did not induce a secretion of visfatin from C2C12 cells             
                            Previously it was discovered that visfatin can be detected in the supernatant of 
cultured L6 rat skeletal myotubes as a secreted myokine (Wang et al., 2010). It was shown also that 
visfatin secretion levels from diverse types of cells such as adipocytes or macrophages can be 
modified by PPAR agonists (Choi et al., 2005). Therefore, to test whether visfatin is a genuine 
myokine in my cellular model the serum-free DMEM supernatant of basal un-stimulated C2C12 
myotubes was taken after 24 hours of culture and the levels of circulating visfatin were determined 
by an ELISA assay. As seen from figure 7.4, visfatin was not detected in the basal state, proving 
that is not a myokine secreted under normal conditions in my murine model. To test whether 
PPAR-β/δ-dependent signalling can induce a secretion of visfatin as a myokine, C2C12 cells were 
treated with GW-501516 (10nm) for 24 hours or with DMSO as a vehicle, followed by collection 
of the supernatant that was subjected to the same ELISA assay. As seen from figure 7.4, visfatin 
was not detected either in the supernatant of C2C12 cells treated with PPAR-β/δ agonist. This 
experiment shows that in cultured C2C12 cells visfatin is not a genuine myokine and that any 
therapy targeting PPAR-β/δ will not induce a secretion of visfatin from skeletal muscle.  
 
 
 
 
 
 
 
 
 
 
      Fig. 7.4     Visfatin is not a myokine in the basal condition and the administration of 
did not induce a secretion of visfat
          Differentiated C2C12 cells were treated or not for 24 hrs with 
DMSO being also used as a vehicle. The medium was 
stimulated cells and subjected to a com
enzyme Immunoassay kit (RayBiotech Inc, VIS
with goat anti-rabbit secondary antibody has been incubated with rabbit anti
followed by the incubation with the supernatant 
mixed with biotinylated visfatin
and TMB substrate. The measurement of the signal was performed at 450 nm
the average from three independent experiments +/
compared to negative control. NS denotes no significant difference between treatment
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                        7C. Discussion 
                              Multiple human clinical trials and animal experiments using PPAR agonists had 
so far promising results in the treatment of insulin resistance and obesity (Erol, 2007). It was also 
shown previously that exogenous visfatin challenge changed the expression levels of PPARs in 
non-muscle cells (Zhou et al., 2007). This implies that a possible change of visfatin plasma levels 
during ageing could theoretically affect a clinical therapy targeting PPARs in order to treat skeletal 
muscle ageing-associated pathologies by changing their expression levels, such as a therapy for 
HLS. Therefore, an in-depth and detailed understanding of any possible relationships between 
plasma levels of extracellular form of visfatin (eNampt), nuclear receptors expression or activity in 
skeletal muscle and regulatory mechanisms of oxidative stress and inflammation in the context of 
ageing and ageing-associated diseases is a requirement for any clinical intervention strategy 
targeting PPARs or circulating visfatin (Sinclair, 2005; Yang et al., 2006). To explore the roles of 
any possible changes of visfatin plasma level on PPARs-associated signalling pathways in skeletal 
muscle, the same experimental conditions with exogenous visfatin (eNampt) treatment of cultured 
C2C12 myotubes have been used, as described in previous chapters.           
             The first goal of the present chapter was to test whether incubation of 
cultured C2C12 cells with exogenous visfatin changed the expression levels of PPAR family by 
using RT-PCR. As shown in figure 7.1, exogenous visfatin treatment (100 ng/ml) for 24 hours did 
not change significantly the expression of PPAR-β/δ and PPAR-γ. PPAR-α expression was too low 
to be detected in differentiated and fused C2C12 myotubes by RT-PCR, although it was detected 
previously in proliferating C2C12 myoblasts (Suzuki et al., 2007). This experiment indicated that a 
possible visfatin plasma increase during ageing or ageing-associated diseases did not affect at 
transcriptional level the targeting of PPAR-β/δ signalling by using specific agonists/antagonists to 
treat pathologic conditions affecting skeletal muscle (Kopelovich et al., 2002). Nevertheless, a 
possible visfatin plasma increase could affect the activity of PPARs independently of transcription, 
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but this is a subject for future studies that are not covered in the present thesis.           
        Also, it is important to know whether PPAR agonists are effective in reducing 
the oxidative stress and inflammatory responses induced by exogenous form of visfatin in cultured 
C2C12 cells. Additionally, it is also important to decipher through what mechanisms such putative 
process might occur. In the present chapter it was further showed that administration of a PPAR-β/δ 
agonist reduced the levels of oxidative stress induced by exogenous form of visfatin (Fig. 7.2A). It 
is unclear still if this reduction is due to a reduced expression of the genes that are involved in ROS 
production upon visfatin challenge, or due to a predictable increase in global antioxidant defence 
status after PPAR-β/δ activation as shown before (Dressel et al., 2003).The activation of PPAR-β/δ 
alone with the agonist GW-501516 did not change the gene expression level of NOX4 in C2C12 
cells after 24 hours (Fig.7.2B). Nevertheless, pre-treatment of C2C12 cells with the agonist GW-
501516 for 24 hours reduced with 30% the increase in NOX4 levels induced by the subsequent 
challenge of C2C12 cells with exogenous visfatin (eNampt) for another 24 hours. This proves that 
PPAR-β/δ interferes with visfatin action, but since GW-501516 did not change NOX4 gene 
expression levels in the basal state than it is likely that this effect is only indirect.    
     Whether visfatin is a genuine myokine as previously proposed (Krzysik-Walker et 
al., 2008) is an issue still debated, and it was shown already that it was detected in the supernatant 
of cultured L6 rat myotubes (Wang et al., 2010). A possible secretion of visfatin from skeletal 
muscle will add a new level of complexity to the issue discussed in this chapter. For example, 
interleukins such as IL-6, IL-8 and IL-15 are secreted by skeletal muscle in regulated fashion as 
genuine myokines too, having a crucial role in modulation of oxidative stress and inflammation 
levels in skeletal muscle through an autocrine and paracrine effect (Pedersen et al., 2007).  
Moreover, while as a cytokine IL-6 is a pro-inflammatory mediator, as a myokine IL-6 is secreted 
by skeletal muscle during contraction or physical exercise, having essentially protective and 
immunomodulatory properties.  For example, as a myokine IL-6 was shown to suppress the 
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production of TNF-α in skeletal muscle upon endotoxin challenge (Starkie et al., 2003). This 
suggests that as a myokine visfatin could fulfil different roles than visfatin secreted as an adipokine, 
possibly by acting in autocrine or paracrine fashion. Furthermore, visfatin secretion from skeletal 
muscle could (positively or negatively) interfere with an exogenous challenge of visfatin, as the one 
employed in my experiments. To test if visfatin is secreted by fused and differentiated C2C12 
myotubes in the supernatant an enzyme-linked immunosorbent assay (ELISA) assay has been used. 
As seen from figure 7.4, there were no differences between the negative control and the culture 
medium which was taken from C2C12 cells after 24 hours of culture. This shows that in this 
interval of time the exogenous form of visfatin (eNampt) is not secreted in the basal state from 
skeletal muscle differentiated myotubes.                          
      Furthermore, it was previously shown that the secreted values of visfatin can be 
modified by PPAR agonists in different cellular types (Choi et al., 2007; Choi et al., 2005; Pfutzner 
et al., 2008). Since PPAR-β/δ agonist treatment reduced the level of oxidative stress in cultured 
myocytes upon stimulation with exogenous visfatin, it was important to establish whether the 
treatment of C2C12 cells with GW-501516 can also modify the levels of visfatin secretion in the 
culture medium. Such event could interfere with exogenous visfatin (eNampt) challenge, positively 
or negatively. To test this possibility C2C12 cells have been treated for 24 hours with GW-501516 
and the levels of visfatin in supernatant were measured subsequently by using the same ELISA 
assay as above. As shown by the same figure, activation of PPAR-β/δ by GW-501516 did not 
induce a secretion of visfatin from C2C12 cells after 24 hours. This indicates that in the case of 
cultured C2C12 mouse cells visfatin is not a myokine upon the activation of PPAR-β/δ-signalling. 
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                             The healthy ageing strategy can be managed through diet, exercise and 
pharmacological-based interventions. As the 2009 Pharma R&D Annual Review report 
shows (Pharmaprojects, 2009), the global overall pipeline for all the drugs in active 
development grew by 5% in 2009 compared to 2008 (>9600) due to a significant increase of 
products in the preclinical stage, but the number of finally approved drugs reaching the 
market was still modest. Even more intriguing, while the last decade experienced a sustained 
biomedical revolution (in both theoretical and technological aspects), the number of 
applications submitted for approval to FDA in US decreased in the same period (Wood, 
2006). This gaps occurs because the rate of R&D success in phases II and III of drug 
development is still below 50% (Mervis, 2005) which makes the overall pre-approval average 
cost of any drug to 800 million USD (DiMasi et al., 2003). This makes the biomedical 
research for ageing management to be financially both risky and costly. Therefore, a solid in-
depth understanding of the complex connections between the progression of ageing, the 
effects of adipokines (such as visfatin) and the functional dynamics of nuclear receptors 
families (such as NR4As and PPARs) is a critical factor for the faster development of safer, 
more efficient and more affordable drugs for the treatment of ageing-associated diseases 
             In the present thesis I investigated the effects of exogenous added 
visfatin (eNampt) on in vitro cultured murine myotubes, with a special focus on oxidative 
stress, inflammation and insulin resistance parameters. The other major goal of the thesis was 
the identification of any significant changes in gene expression profiles of different families 
of nuclear receptors in two animals models of skeletal muscle ageing, since improving 
metabolic flexibility through the specific targeting of nuclear receptors-associated signalling 
may represent a novel intervention strategy to prevent the adverse physiological effects 
characterizing skeletal muscle during ageing. 
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                               8.1   The roles of nuclear receptors in ageing 
 
                             To model the effects of altered pace of ageing on skeletal muscle physiology in 
rodents two complimentary approaches have been used: one designed to accelerate it (hindlimb 
suspension, HLS) and one designed to decelerate it (caloric restriction, CR).   
 
                               8.1.1 The role of PPARs in the metabolic adaptation to HLS     
                   Acute HLS (24 hrs) induced a significant reduction in mouse PPAR-α and 
PPAR-γ and an increase in PPAR-β/δ expression levels (Fig. 3.4A), as summarized in our 
published paper (Mazzatti et al., 2008). The decrease in PPAR-α expression was simultaneously 
accompanied by a decrease in expression of its known targets PGC-1α and PGC-1β (Fig. 3.4B). 
Nevertheless, in the acute phase no significant decrease in expression of genes involved in fatty 
acid transport and oxidation was detected by microarray, suggesting that there are alternative 
pathways that compensate for the loss of PPAR-α and PPAR-γ. One possible candidate is PPAR-
β/δ, and it has already been shown that in some cases its increased expression or activation can 
compensate for the loss in PPAR-α expression (Muoio et al., 2002). In contrast to the other PPARs 
that were downregulated by HLS, PPAR-β/δ expression level was upregulated in both muscle types 
concomitantly with an increased UCP-3 expression in soleus as proved by both RT-PCR (Fig. 
3.4B) and western blot assays (Fig. 3.5). Uncoupling proteins like UCP-3 are known to be critical 
for the maintenance of ATP: AMP ratio and AMPK signalling, having a robust effect on the 
regulation of energy expenditure (Klip et al., 2005). Because of the proven role of PPAR-β/δ in 
regulating oxidative capacity and fuel switching it is possible that its increased expression 
following short-term HLS represents an adaptive, compensatory response to regulate the fuel 
utilization and to maintain the metabolic flexibility under stress. This hypothesis is further 
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supported by the finding that PPAR-β/δ expression is restored to the basal levels after 12 days of 
HLS (Fig. 3.6), approximately at the same time when muscle atrophy and loss of lipid oxidative 
capacity were observed. From these data it can be hypothesized that the loss of PPAR-β/δ 
expression may contribute to the metabolic inflexibility and adverse physiological alterations 
observed after long-term unloading. Improving metabolic flexibility through PPAR-β/δ regulation 
may represent a novel intervention strategy to prevent the adverse metabolic and physiological 
effects of muscle unloading.                      
    Several pieces of independent evidence suggested already that PPAR-β/δ may 
respond to such unloading events with a possible compensatory effect for the global metabolic 
deregulation. For example, PPAR-β/δ was shown to be involved in the remodelling of skeletal 
muscle by increasing type I oxidative fibers number which also reduced the body fat content (Wang 
et al., 2004). Increased PPAR-β/δ expression and activity has been previously implicated in the 
metabolic and structural adaptations to long-term fasting and endurance exercise, and increased 
expression was also an indicator of improvement in diabetic patients after training (Luquet et al., 
2004). In addition, previous investigations have demonstrated that transgenic mice expressing an 
activated form of PPAR-β/δ have enhanced fatty acid utilization and are protected against the high-
fat diet-induced obesity (Wang et al., 2003). Furthermore, PPAR-β/δ agonist treatment induced 
changes in muscle fuel metabolism as shown by increased lipid oxidation and decreased 
carbohydrate utilization (Constantin et al., 2007). PPAR-β/δ could therefore be a part of an 
adaptive, compensatory regulatory complex designed to protect against further metabolic 
complications. For example, it is already known that  PPAR-β/δ  can change the expression levels 
of genes involved in fatty acid oxidation and lipid homeostasis such as fatty acid binding protein 3 
(FABP3) which is involved in uptake and transport of fatty acids (Zimmerman and Veerkamp, 
2001), CPT-1 that is a rate-limiting enzyme in mitochondrial fatty acid oxidation and PDK4. 
Microarrays analysis demonstrated no significant change in PDK4 or FABP3 expression in soleus 
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or gastrocnemius muscle after acute HLS, but it was observed a significant increase in expression 
of CPT-1b and CPT-2 in soleus muscle after the acute stage of unloading.  In the models of long-
term exposure to HLS (12 days) the expression of these two genes were nevertheless decreased, 
further indicating that the adaptation during the acute stage is only transient. Hindlimb suspension 
has a major physiological impact by leading to a preferential use of glucose as a fuel of choice 
instead of lipids, therefore reducing in long-term the metabolic flexibility characterizing the healthy 
normal muscle. Such metabolic inflexibility is also a characteristic of aged skeletal muscle.  The 
increase in PPAR-β/δ expression during the acute phase and the subsequent reversal to the normal 
state in the chronic stage could signify that PPAR-β/δ is an important member of such metabolic 
switch. The return to the basal state in PPAR-β/δ expression during the chronic phase of unloading 
could be partially responsible for the loss in metabolic flexibility shown in later stages. This 
interpretation of PPAR-β/δ as a switch is also supported by its role in regulating Bcl-6 activation, as 
discussed in the introduction. Therefore, the changed expression level of several proteins such as 
PPAR-β/δ, UCP-3, AMPK and CPT-1/2 noticed in acute HLS might have a substantial role in the 
maintenance of metabolic flexibility and represent potential targets. Because of its interactions with 
the other putative targets PPAR-β/δ appears particularly promising, and since enhanced UCP-3 
expression is associated with improvements in glycemic regulation, it can be hypothesized that 
inducing PPAR-β/δ-dependent upregulation of UCP-3 and other genes could prevent the metabolic 
and physiological alterations associated with muscle unloading (Fig. 8.1). This model of PPAR-β/δ 
as a switch could be also used to test the predictions made by different theories of ageing about the 
relationships between senescence and oxidative stress. 
 
 
 
 
         Fig. 8.1   The proposed role of PPAR
inflexibility during the acute phase of skeletal muscle immobilization 
             Acute HLS increased in the 
genes (UCP-3, CPT-1b, CPT-2), as well as 
of metabolic adaptation to the stress induced by unloading. 
upstream, downstream or independently of AMPK
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                             8.1.2 The role of NR4A family in mediating the multiple effects of caloric 
restriction on skeletal muscle physiology in rats                                
       In the CR model it was demonstrated for the first time an increased expression of 
all three members of NR4A family in rodent skeletal muscle (Fig. 3.8A). No significant changes 
were observed in brain, demonstrating tissue-specificity in expression patterns following CR (Oita 
et al., 2009). Upregulation of several known NR4A transcriptional targets such as UCP-3, AMPK-
γ3, PGC-1α and PGC-1β was also observed (Fig. 3.9). NR4A receptors respond to changes in the 
cellular environment, including neuroendocrine stimuli, regulating the expression of various genes 
in the hypothalamus–pituitary–adrenal (HPA) axis including POMC, the precursor to 
adrenocorticotropic hormone which is the main regulator of adrenal glucocorticoid synthesis 
(Philips et al., 1997). Alterations to neuroendocrine status are one of the many proposed 
mechanisms by which CR increases lifespan and retards ageing, and it was shown that food-
restricted rats exhibit daily periods of hyperadrenocorticism (Nelson et al., 1995) which may be a 
major contributor to CR-induced delay of ageing processes and lifespan extension.                 
       The knock-out or transgenic models of NR4A subgroup did not show any 
obvious changes in lifespan or in the ageing phenotypes, although they have not been especially 
investigated in this respect (Mullican et al., 2007; Pan T. et al., 2008; Zheng et al., 1998). The fact 
that NR4A are expressed mainly in energy-dependent tissues such as skeletal muscle, brain, 
adipose tissue, heart and liver suggests that they have a critical role in regulating energy and 
metabolism. NR4A1 is regulated by glucose levels (Susini et al., 1998) and a recent report showed 
that while insulin or thiazolidinediones challenges increased NR4A1 and NR4A3 expression (Fu et 
al., 2007), their expression was nevertheless reduced in animal models of insulin resistance. These 
findings provide evidence for a link between NR4A receptors and the complex metabolic shift 
observed in animals following CR. Interestingly, increased expression of all three NR4A receptors 
is also associated with skeletal muscle recovery following endurance exercise (Mahoney et al., 
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2005; Mahoney and Tarnopolsky, 2005). In addition to their function in muscle metabolism NR4A 
receptors are also thought to be involved in adipose tissue and in liver metabolic regulation. In 3T3-
L1 cultured adipocytes all three members of NR4A subgroup are rapidly and transiently induced by 
the PPAR-γ agonist rosiglitazone (Fu et al., 2005). Since adipose, liver and muscle are major sites 
of lipid and glucose metabolism and are important targets for metabolic therapies, it is possible that 
the modulation of NR4A receptors may represent a novel strategy for treatment of metabolic 
disorders. This concept has already been explored (Hsu et al., 2004) and has generated a great deal 
of interest in recent years, but further investigation is necessary to determine whether any of the 
NR4A receptors represent suitable targets for pharmaceutical intervention.                      
           A recent report (Pei et al., 2006) demonstrated that NR4A receptors act as 
downstream mediators of cAMP action in vitro and in response to glucagon or fasting in vivo. 
These data support our observed upregulation of NR4A receptors in muscle and liver following CR 
and suggest that these receptors respond to nutritional cues such as insulin levels through yet 
unknown mechanism. This hypothesis is consistent with the previously described role of 
mammalian target of rapamycin (mTOR)-dependent nutrient signaling in mediating the effects of 
caloric restriction (Linford et al., 2007). Although there is no direct link between mTOR and 
NR4As, there are indications of a possible indirect crosstalk between AMPK and mTOR has been 
established (Hardie, 2008a, b). Since NR4A receptors are regulated by cAMP it is possible that 
they respond to changes in AMP: ATP ratio similarly to both AMPK and uncoupling proteins. 
These data suggest that multiple nutrient-sensing and signaling mechanisms may contribute to the 
complex metabolic adaptations that occur following CR and that NR4A receptors might a role in 
this process.                               
  In conclusion, I identified an increased expression of the members of NR4A 
subgroup in the skeletal muscle of the caloric restricted animals simultaneously with a change in 
expression of some of the previously known NR4A target genes regulating lipid and glucose 
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metabolism, oxidative stress and inflammation. Based on previous filtered knowledge, detailed in 
the discussion from chapter 3, it can be speculated that in the case of caloric restricted skeletal 
muscle NR4A1 acts mainly on the glucose and lipid metabolism, NR4A2 has an important impact 
on inflammatory response and NR4A3 mainly regulates genes critical for lipid metabolisms (Fig. 8. 
2). The prospect of screening of selective activators/inducers of NR4As (unavailable yet) to reduce 
the metabolic inflexibility in aged skeletal muscle justifies further research in this area.    
  Furthemore, since the change in NR4A family expression was restricted only to 
some of the tissues investigated so far, than they could be used as markers to estimate the tissue-
differential aspects of ageing, as explained in the introduction.  
 
     
 
 
 
 
 
 
 
 
 
 
                         Fig.8. 2 The proposed role of NR4A subgroup
effects of caloric restriction on lipid and glucose metabolism, oxidative stress and inflammation 
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                        8.2 The putative effects of visfatin (eNampt) on skeletal muscle 
ageing- related processes                  
          
                             8.2.1 Visfatin (eNampt) and insulin-dependent signalling pathway  
       The most contentious academic issue concerning the extracellular, circulating 
version of visfatin is the hypothesis that it is able to bind to the insulin receptor expressed by 
peripheral tissues and activate PI3K/Akt signalling pathway, increasing therefore the rate of 
glucose uptake (Fukuhara et al., 2005). While the identity of visfatin as a genuine secreted 
adipokine is firmly established and widely accepted (Antuna-Puente et al., 2008; Beltowski, 2006; 
Hammarstedt et al., 2006), the insulin-mimetic property of such a secreted form is still highly 
contentious and controversial (Moschen et al., 2007). The initial paper proposing this insulin 
mimetic hypothesis (Fukuhara et al., 2005) was retracted by the publishing journal for scientific 
improprieties and subsequent independent experiments done in vivo, ex vivo or in vitro discovered 
that such activation occurs only in a few limited cases of cellular systems and experimental 
conditions  (Adya et al., 2008a; Xie et al., 2007; Lim et al., 2008). Numerous independent 
experiments in other cellular systems failed to prove any insulin mimetic properties upon 
incubation with visfatin (Li et al., 2008; Revollo et al., 2007; Wanecq et al., 2009; Wang et al., 
2009).                            
     Since there were no previous reports about the effects of exogenous visfatin on 
skeletal muscle which is a main target for adipokines action and the main organ responsible for the 
removal of the glucose from the plasma, I tested whether visfatin can activate PI3K/Akt signalling 
pathway that mediates the effects of insulin on the rate of glucose uptake through the translocation 
of GLUT4 transporter to the plasma membrane (Valverde et al., 2005). The stimulation of C2C12 
cells with 100 ng/ml  visfatin did not induce an increase in the phosphorylation of Akt at Ser472 or 
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at Thr308 residues in the first 15 minutes as seen by western blot (Fig. 4.10B), unlike insulin 
challenge that triggered a robust response after 5 minutes at the AktSer472 residue (Fig. 4.10A). 
Since the culture medium for C2C12 differentiation lacked insulin there is no reason to assume that 
C2C12 cells were insulin-resistant/-insensitive. Visfatin did not change either the phosphorylated 
levels of Akt upstream activator (PDK1) and upstream inhibitor (PTEN), or of the downstream 
targets like GSK-3β and c-Raf (Fig. 4.10B).  Furthermore, pre-incubation of C2C12 cells with 
visfatin for 18 hours did not impair nor augment the ability of insulin to activate PI3K/Akt after 5 
minutes (Fig. 4.10A). This showed that in C2C12 cells visfatin did not activate the PI3K/Akt 
signalling pathway in acute or chronic stages, suggesting that in the case of skeletal muscle visfatin 
is not an insulin-mimetic agent.                             
       The concentration used (100ng/ml) is consistent also with previous reports 
(Lovren et al., 2009; Moschen et al., 2007; Xie et al., 2007) and higher concentration values (up to 
500 ng/ml) had no effect on PI3K/Akt-signalling pathway either (data not shown). The 
concentration chosen in this thesis is within the limits identified as physiological relevant by 
measurement of human visfatin plasma levels in both normal and pathological samples  (Dogru et 
al., 2007), and an eventual activation of PI3K/Akt by using higher than physiological 
concentrations of visfatin will have no medical applicability nor theoretical relevance. Also, since 
three different versions of commercially available visfatin have been employed, produced in 
bacteria or in mammalian cells, and since all these three versions showed the same consistent 
results it can be concluded therefore that the experimental conclusions of the thesis presented were 
both accurate and representative. It is important to stress nevertheless that my experiments did not 
explore whether visfatin can bind to insulin receptor in cultured and differentiated myotubes, only 
if such incubation can activate the insulin receptor-dependent PI3K/Akt signalling pathway because 
this is a better proof of a possible effect on the rate of glucose uptake. Multiple explanations could 
be proposed for the discrepancies between the conclusions derived from independent experiments 
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published so far.  For example, different cell types could be characterized by significant differences 
in the number of insulin receptors expressed or localized at the cellular membrane, or they could 
differ in the sensitivity of activation of PI3K/Akt signalling pathway. The cellular models showing 
PI3K/Akt activation upon visfatin treatment like endothelial cells, osteoblasts and ventricular 
cardiomyocytes could alternatively present a higher expression of other membrane receptors such 
as IGF-IR that was proved already to mediate an additional PI3K/Akt activation upon insulin 
treatment. Interestingly, it was proved that in HUVEC cells that showed a visfatin-dependent 
phosphorylation of PI3K/Akt pathway after 5 minutes of incubation (Adya et al., 2008b) the IGF-
IR gene is expressed at significantly higher levels than insulin receptor gene (Nitert et al., 2005). 
This could indicate that the membrane receptor which mediates the visfatin action on PI3K/Akt-
signalling pathway was in fact IGF-IR, not the insulin receptor. Nevertheless, since I did not 
quantify IGF-IR levels of expression in C2C12 cells, at the present stage this remains only a 
hypothesis yet to be explored. Another theoretical possibility independently proposed already is the 
existence of another, still unidentified, membrane receptor specific only for visfatin that could 
activate the PI3K/Akt pathway in the tissues or cells where it is expressed or functional (Li et al., 
2008). Nevertheless, until now there are no published reports detailing any attempts to identify 
such a putative receptor, and this subject was not covered in the present thesis.                     
           The long-term incubation of cultured myotubes with visfatin (<24 hours) might still 
modify the rate of glucose uptake or glucose metabolism independently of Akt signalling, possibly 
through the modulation of other physiological processes like a robust NAD metabolism as shown 
before (Revollo et al., 2007). Therefore the next question to be answered was whether the chronic 
incubation of C2C12 cells with visfatin could modify the levels of glucose uptake. The 
measurement of the rate of glucose uptake in both basal (Fig. 5.7C) and insulin-stimulated 
conditions by 2-NBDG assay (Fig. 5.8B) showed no difference between control and 24 hours 
visfatin-treated cells. In addition, the incubation of C2C12 cells with visfatin for 24 hours did not 
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change the gene expression levels of known glucose transporters such as GLUT1 and GLUT4 (Fig. 
5.10A, B). This proved that in the case of cultured skeletal myocytes visfatin is not an insulin 
mimetic agent, which is also a strong argument to dismiss the possibility of any effects on skeletal 
muscle in vivo too. My findings correlate with previous data indicating that the increase in the rate 
of glucose uptake upon the challenge with the exogenous visfatin (eNampt) was noticed only in 
those cells that presented simultaneously an activation of PI3K/Akt signalling pathway (Lim et al., 
2008), event missing in my experiments.                 
        Unlike visfatin treatment, chronic triglyceride challenge reduced the levels of 
phosphorylated forms of Akt and GSK-3β (one of Akt substrates) in the insulin-stimulated state, 
but not in the basal state (Fig. 5.9A, B). In the same time, as shown by 2-NBDG assay, triglyceride 
challenge increased the rate of glucose uptake in basal state (Fig. 5.7C), reducing it nevertheless in 
the insulin stimulated state (Fig. 5.8B). The decrease in the rate of glucose uptake upon stimulation 
with insulin after the pre-treatment with triglycerides correlates with the reduced insulin-stimulated 
activation of Akt signalling. In addition, both findings correlate with the research done previously 
in vitro by using palmitate (Ragheb et al., 2009) and in vivo by using animal models fed with a high 
fat diet (Vinayagamoorthi et al., 2008). In addition of blocking PI3K/Akt signalling, the treatment 
of cultured myotubes with triglycerides reduced also the expression level of GLUT4 after 24 hours 
(Fig. 5.10B). Such a reduction in GLUT4 gene expression could also explain the impaired glucose 
uptake in the insulin-stimulated state upon triglyceride challenge as shown by the 2-NBDG assay. 
The fluorescent-based assays showed also that triglycerides treatment increased the glucose uptake 
in basal state and this correlated with previous findings that used palmitate challenge and with other 
studies on the mechanisms of insulin resistance (Hardy et al., 1991; Usui et al., 1999). This 
phenomenon can be explained by the increased expression of GLUT1 transporter (Fig. 5.10A) after 
triglyceride challenge that likely increased the rate of glucose uptake. The lack of reduction in 
phospho-Akt levels after triglycerides treatment in the basal state indicates that PI3K/Akt signalling 
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pathway is not mediating the increased GLUT1 expression noticed.                      
         These experimental conclusions about the triglyceride treatment correlate with 
the independent data reported previously about the effects of ectopic accumulation of lipids in 
skeletal muscle in vivo during advanced stages of obesity and with the results of in vitro studies that 
used free fatty acids such as palmitate. This certifies also that the fat emulsion StructolipidTM can be 
used to model in vitro the effects of the lipid-dependent stress as an alternative to the free fatty 
acids strategy.  
 
                               8.2.2   Visfatin and the regulation of oxidative stress levels                  
                    In the fourth chapter it was shown that incubating murine fused and 
differentiated C2C12 myotubes with different concentrations of exogenous murine visfatin 
(eNampt) (<200 ng/ml) induced oxidative stress as monitored by fluorescent-based assays (Fig. 
4.1- 4.4). Unlike previous reports that identified the generation of free radicals in the first hour 
during the early stage of the incubation of endothelial cells with visfatin (Kim et al., 2008), the 
experiments shown in chapter 4  indicated that the earliest time point for a significant increase was 
in the chronic stage of treatment between 4-6 hours, with a maximum peak reached after 18 hours 
(Fig. 4.2). Additional incubation time did not further increase the levels of free radicals detected. 
Therefore, visfatin showed a different ROS-inducing pattern in cultured myotubes compared to 
cytokines such as TNF-α  (Li et al., 1999;Li et al., 1998) or endotoxins like LPS (Maitra et al., 
2009) that can generate reactive oxygen species within the first hour of treatment, being more 
similar in this respect with other adipokines such as leptin (Xu et al., 2004) and  adiponectin 
(Ikegami et al., 2009). Nevertheless, this increase in free radicals by visfatin did not change the 
total levels of oxidized proteins (Fig. 4.5) or the levels of oxidized lipids (Fig. 4.6). This is not 
unusual since in many other cases there were recorded differences in measured values for different 
markers of oxidative stress. For example, there were recorded differences in the quantified values 
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of ROS and of the oxidized products by measuring the levels of carbonylated proteins and other 
biochemical methods in cultured myocytes (Astruc et al., 2007), between the levels of carbonylated 
proteins and fluorescent microscopy-derived values in the case of the nematode C. elegans (Yasuda 
et al., 2006), or between the levels of carbonylated proteins and fluorescent microscopy-derived 
values in the rat liver after endurance exercise (Sun et al., 2009). Carbonylation of proteins is an 
irreversible change that occurs after a prolonged and sustained level of oxidative stress, and such 
carbonylated proteins are usually digested by the proteasomal complex (Nystrom, 2005) . The 
existence of an increased level of free radicals in the absence of increased oxidized products 
suggests that such event is not affecting the integrity of cellular processes or the cell structure.   
                 The increased levels of intracellular ROS by visfatin could be explained by an 
increased production of ROS, by a reduced/impaired antioxidant capability of the cells 
(Lyakhovich et al., 2006), or by a combination of both factors. Such events could appear as a 
consequence of the reactions occurring at the enzymatic complexes localized not only at 
mitochondria and peroxisomes but also as a consequence of the activation of NADPH oxidases 
(NOX) that were discovered recently to be localized in the cytosol and sarcoplasmic reticulum of 
skeletal myocytes (Xia et al., 2003), with still unclear roles.                            
        A more theoretically revealing and critical question than whether a certain agent 
induces oxidative stress as measured by fluorescent-assays or by quantifying the levels of oxidized 
products is the question if such a stress has any effect on the physiological status-quo or on the 
structural integrity of the cell. As shown by NADH assay, visfatin treatment did not affect the 
cellular viability which indicated that such a stress is not impairing significantly myotubes survival 
(Fig. 4.8). This is not an unique phenomenon since many oxidative stress inducers do not generate 
apoptosis or cellular damage, and in certain circumstances such increase in free radicals has even 
an anti-inflammatory, protective role (Tang et al., 2009).        
               Whether the increased level of intracellular ROS detected is caused by an increased 
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production of free radicals or by an impaired antioxidant defence is still unclear.  Because it was 
detected an increase in ROS levels without an increase in the levels of oxidized products or 
impaired viability after visfatin challenge, I further hypothesized that this might be explained by a 
simultaneous improvement of the antioxidant capacity of the cells to resist such a stress. It was 
already shown that incubation of other types of cells like macrophages (Li et al., 2008) and  
cardiomyocytes (Lim et al., 2008) with visfatin improved the resistance against toxic agents and 
this process might occur through an improved antioxidant protection. Such a hypothetical scenario 
would correlate therefore with a case of increased levels of free radicals as a consequence of an 
accelerated production of ROS, not an impaired antioxidant defence. The measurement of this 
global cellular ability to protect against oxidative stress was performed by using the ABTS assay 
that did not show any global change in the antioxidant potential of C2C12 cells after the treatment 
with visfatin, compared to the control (Fig. 4.7). This suggests that such a potential increase in 
antioxidant ability of cells by visfatin could be localized, not global, targeting the organelles and 
cellular compartments where free radicals are produced such as peroxisomes, mitochondria and SR. 
Such a putative limited and localized improved antioxidant defence might not be detected therefore 
by ABTS method. Furthermore, since it was not detected by ABTS assay a reduction in the 
antioxidant capability upon visfatin challenge it is likely that the higher ROS level noticed is 
caused by an increased production of free radicals, not by an impaired defence status.                   
  The treatment of C2C12 cells with 0.2 mg/ml triglycerides for 24 hours induced 
similar oxidative stress as measured by fluorescent microscopy (Fig. 5.2).  Unlike in visfatin 
treatment case it was noticed an increase in the level of oxidized proteins by 80% after a minimum 
incubation time of 24 hours (Fig. 5.3). A band localized around 30 kDa showed a significant 
increase in the carbonylated form, but the identity of such a band is still unexplored and this 
question was not covered in the present thesis. So far I did not identify another independent report 
to confirm or support my particular finding. The pattern is also different from the one noticed in the 
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skeletal muscle of diabetic animal models presenting increased depots of intracellular lipids in 
skeletal muscle  (Oh-Ishi et al., 2003), in the skeletal muscle of mice fed with a high-fat diet 
(Bonnard et al., 2008) or from the pattern shown by the aged skeletal muscle  (Feng et al., 2008).  
 
      8.2.3 Identification of the gene networks possibly involved in ROS 
production by visfatin           
                Triglycerides treatment for 24 hours increased the expression of genes that have an 
antioxidant role such as SOD1, CAT and SOD2 and of transcription factors involved in the 
antioxidant defence such as NRF1, NRF2 and HIF1A (Fig. 5.4). This increase indicates that the 
stress induced by triglycerides was significant and this correlates with previous reports about the 
effects of free fatty acids or high-fat diet on skeletal muscle. For example, it was shown that 
palmitate treatment increased the expression of SOD2 in cultured human myocytes, similarly to the 
pattern shown by obese or insulin-resistant skeletal muscle (Reyna et al., 2008). In addition, it was 
shown that palmitate treatment increased the expression of NRF2 in cultured hepatoma cells (Das 
et al., 2010). The increase in the expression of the above mentioned antioxidant defence genes by 
triglycerides suggests that the oxidative stress induced is critical, subsequently triggering the 
activation of defensive, antioxidant mechanisms. This interpretation of my results is further 
supported by the previous discovery that skeletal muscle of obese children with metabolic 
syndrome had a reduced antioxidant defence status (Molnar et al., 2004) and by the fact that  
overexpression of antioxidant genes such as SOD1, CAT and SOD2 reduced the activation of 
caspase-3 and the apoptotic process triggered by  palmitate challenge of cultured cells (Cacicedo et 
al., 2005). Furthermore, it is also known that mice heterozygous for SOD2 presented increased 
oxidative stress levels in liver (Kokoszka et al., 2001) and that cardiomyocytes derived from 
NRF2-null mice had increased ROS levels when cultured in high glucose levels conditions 
compared to the control cells (He et al., 2009). In addition, the fact that triglyceride treatment 
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decreased the expression of GPX3 gene (Fig. 5.6), another important antioxidant defence member, 
could indicate a significant reduction in the antioxidant defence ability (Chung et al., 2009). It was 
shown for example that a reduction in GPX3 expression or function is a marker of obesity and this 
correlated with an increased level of oxidative stress (Lee et al., 2008). This decrease in GPX3 
levels was not observed nevertheless in the cells challenged with visfatin, suggesting a non-critical 
level of oxidative stress induced in this case.                          
              On the other hand, the only genes from the list that were changed by visfatin 
treatment were SOD1 and NOX4 (Fig. 5.5). The fact that NOX4 was increased opened the 
possibility of a new pathway of ROS production by visfatin, possibly independent of mitochondria 
and peroxisomes, but this is a subject for future studies.  Cu/ZnSOD (SOD1) is another important 
member of the antioxidant defence network changed by visfatin challenge. It was shown before to 
be localized mainly in the cytosol, nucleus and mitochondria (Okado-Matsumoto and Fridovich, 
2001). Mutations in the motor neuronal-specific Sod1 gene were shown to be important in the 
development of ALS (Miao and St Clair, 2009). The role of SOD1 in the skeletal muscle 
physiology is less explored and it was studied so far mainly in the relationship with the 
pathogenesis of ALS. The SOD1 -/- mutant mice had decreased muscle mass, increased levels of 
ROS and accelerated signs of ageing resembling sarcopennia (Muller et al., 2006). Nevertheless, 
although in the cells with high levels of superoxide production as cardiomyocytes an increased 
expression or activity of SOD1 has a protective role (Tanaka et al., 2004), in the cells with low 
levels of superoxide an overexpression of SOD1 alone has surprisingly deleterious effects. For 
example, the expression of wild-type human SOD1 in the skeletal muscle of transgenic mice led to 
significant myopathy and motor neurological degenerative phenotypes through aggregation and 
increased levels of nitric and oxidative stress (Wong and Martin, 2010). In another report, the 
expression of G93A mutant allele of the gene in the wild-type healthy skeletal muscle led to 
increased muscle atrophy due to higher levels of oxidative stress, mitochondrial dysfunctions and 
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sarcolemmal damage (Dobrowolny et al., 2008). The increased expression of SOD1 upon visfatin 
challenge could signify the presence of a localized antioxidant defence response against the 
oxidative stress generated simultaneously that can explain the lack of the oxidized proteins or 
lipids, but this issue requires future studies. The fact that visfatin treatment did not increase the 
expression levels of many other antioxidant factors as the triglycerides challenge indicate a 
different pattern of ROS production and possibly a non-critical oxidative stress level, which could 
explain the lack of oxidized products noticed. The conclusion is reinforced by the fact that GPX3 
expression level was not changed by exogenous visfatin. 
 
                               8.2.4 Exploration of possible signalling pathways regulating the 
increase in ROS by visfatin                                      
  Another way to elucidate the mechanisms beyond ROS production by visfatin 
was the identification of any signalling pathways already known to modulate it. 
 
         8.2.4.1 Visfatin (eNampt) treatment and PI3K/Akt signalling pathway 
              I showed in the forth chapter that acute or chronic treatment visfatin did not activate 
the PI3K/Akt pathway. To further dismiss the possibility that PI3K/Akt pathway is involved in the 
increase in ROS noticed, PI3K activity has been blocked by its specific inhibitor before visfatin 
treatment. Additional fluorescent-based measurement of ROS levels did not show any changed 
values in the cells pre-treated with inhibitor prior adipokine challenge comparing to visfatin-only 
treated cells (Fig. 4.11).  This proved that the observed ROS production induced by visfatin 
treatment in C2C12 cells is independent of Akt signalling.  
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                               8.2.4.2 Visfatin (eNampt) treatment and MAPKs-dependent signalling 
                    Previously it was reported that in non-skeletal myocytes exogenous visfatin 
treatment can activate MAPKs such as p38 and ERK1/2 in the first 30 minutes of incubation (Lim 
et al., 2008; Adya et al., 2008a; Kim et al., 2007). It is also well known that MAPKs activation can 
lead to an increase in intracellular ROS levels (Cao et al., 2004). MAPKs/SAPKs are mitogen- or 
stress-activated kinases that can modify cellular physiology by changing the global genomic profile 
through the phosphorylation of numerous transcriptional factors like ATF-2  (Raingeaud et al., 
1995), Max  (Zervos et al., 1995), Elk-1 (Marais et al., 1993), c-Jun  (Leppa et al., 2001) and MEF2 
(Kyriakis and Avruch, 2001). Recently it was also discovered that MAPKs-induced effects can be 
independent of transcriptional regulation through the direct phosphorylation of cellular targets, 
other than regulators of gene expression.  For example it was reported that JNK, another member of 
MAPK family, can phosphorylate cytosolic proteins regulating axodendritic growth in neurons 
such as microtubule-associated protein 2 (MAP2) (Bjorkblom et al., 2005) and superior cervical 
ganglion-10 protein (SCG10) (Tararuk et al., 2006), affecting neurogenesis.  Therefore, it is also 
possible for p38 and ERK to directly phosphorylate proteins involved in antioxidant defence and 
oxygen metabolism and modify their enzymatic properties, eventually leading to increased levels of 
ROS.  The western blots experiments for the phosphorylated forms of p38 and ERK1/2 showed 
nevertheless no significant increase in their levels in the first 30 minutes of incubation of C2C12 
cells with exogenous visfatin compared to control cells (Fig.6.2). This correlates with previous 
published research data showing that MAPKs activations in non-muscle cells by exogenous visfatin 
were dependent on Akt (Adya et al., 2008a,b), event absent in my experiments. Since there were no 
previous reports of JNK activation upon visfatin challenge this possibility was not tested either, 
being a subject for future studies.                                  
             Nevertheless, it is still possible that MAPKs activations can occur later in the 
chronic stages of treatment of C2C12 cells with visfatin, independently of PI3K/Akt signalling, and 
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such activations could mediate a ROS increase. To test this possibility the activities of p38 and 
ERK have been blocked by using their specific inhibitors before incubation with exogenous 
visfatin. The fluorescent-based detection of the signal from the cells pre-treated with MAPKs 
inhibitors followed by visfatin challenge failed to show any reduction in oxidative stress levels 
generated, compared to visfatin-only treated cells (Fig.6.3). This proved that the ROS increase 
noticed upon visfatin treatment is independent of p38 and ERK signalling pathways.  
 
                             8.2.4.3 Visfatin (eNampt) treatment and NFkB-regulated signalling                     
                  The activation of NFkB by visfatin was previously reported to occur in the acute 
phase of incubation (<60 minutes) of endothelial cells (Lee et al., 2009; Kim et al., 2008), or in the 
chronic phase of incubation of the smooth muscle cells (Romacho et al., 2009). Therefore, the 
possible activation of NFkB-associated signalling pathway was tested by performing western blot 
for the phosphorylated form of p65 subunit of NFkB. The western blot results showed an increase 
in phosphorylated levels of p65 subunit at Ser536 residue after 4 hours of incubation with visfatin, 
with a maximum value around 6 hours of incubation (Fig.6.4). The activation of NFkB signalling 
pathway was proved also by the increased phosphorylated levels of p65 upstream activator (IKK 
α/β at Ser176/180) and of p65 inhibitor (IkBα at Ser32) in the same time interval. After the 
phosphorylation by IKK at Ser32 the inhibitor IkBα is degraded through proteasome, releasing a 
fully functional p65 subunit (Magnani et al., 2000). The fact that NFkB signalling pathway was 
activated by visfatin treatment opened the possibility that it might be involved in the increased 
levels of oxidative stress noticed. Therefore, the activation of IKK (p65 upstream activator) was 
blocked for one hour before visfatin treatment for another 18 hours by using a specific inhibitor. 
Fluorescent microscopy assays of the signal from the cells pre-treated with NFkB inhibitor 
followed by visfatin challenge showed a reduction in ROS levels with cca. 40% compared to cells 
challenged only with visfatin (Fig.6.5). This indicates that visfatin-induced oxidative stress is 
218 
 
dependent on de novo synthesis of a new set of genes. To explore the possibility that other 
transcriptional pathways besides NFkB might be involved in the ROS increase, transcription and 
translation were blocked by using their specific inhibitors before visfatin treatment. This showed 
that the levels of ROS produced after 18 hours were reduced with almost 70% compared to the 
cells treated only with visfatin (Fig.6.8). Therefore, it can be concluded that there are other 
pathways mediating the stress responses induced by visfatin besides NFkB, unknown yet.                                
              
                                8.2.4.4    Visfatin (eNampt) treatment and inflammatory signals  
                      NFkB-dependent signalling can increase the expression levels of many genes 
that could further induce a positive loop in ROS production such as nitric oxide synthases (Taylor 
et al., 1998), TNF-α (Wullaert et al., 2006) and IFN-γ (Briscoe et al., 2006; Malmberg et al., 2001). 
Nitric oxide is an important mediator of stress responses in skeletal muscle, being synthesized by 
nitric oxide synthases (Mungrue et al., 2003). The dominant isoform in skeletal muscle is the 
neuronal type (nNOS) that has higher levels of expression in myocytes than the inducible (iNOS) 
and endothelial (eNOS) forms, and is localized mainly beneath the sarcolemma (Grozdanovic, 
2001). An increased expression of nitric oxide synthases can lead therefore to higher levels of nitric 
oxide that could be further converted to peroxynitrate by the reaction with superoxide anion, 
generating additional ROS (Yang et al., 1998). RT-PCR assay showed that the expression level of 
nitric oxide synthase 1 (NOS1) was only moderately increased. The fact that I did not detect a 
significant increase in the levels of nitrotyrosine residues after 24 hours of incubation of C2C12 
cells with visfatin suggested nevertheless that there was no significant nitric stress produced (Fig. 
4.9). There are also previous reports indicating a positive association of higher visfatin plasma 
levels with increased TNF-α expression and inflammatory phenotypes (Erten et al., 2008; Samara 
et al., 2008). TNF-α treatment was also proved to lead to a further increase in ROS levels in gastric 
cells (O'Hara et al., 2009), in the arteries of diabetic mice models (Gao et al., 2008) and in the 
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intestinal epithelial cells (Jin et al., 2008). Interestingly, TNF-α is expressed by skeletal muscle and 
although blocking TNF-α by using monoclonal antibody-based therapy reduces oxidative stress and 
necrosis levels in muscular dystrophy animal models (Grounds and Torrisi, 2004), the specific 
deletion of TNF-α in skeletal muscle impaired nevertheless the regeneration ability of skeletal 
myocytes (Collins and Grounds, 2001), possibly through a reduced expression of myogenic 
differentiation protein 1 (MyoD) (Warren et al., 2002).  A similar pattern was identified also in the 
case of IFN-γ (Yoo et al., 2008; Higuchi et al., 1997). For example, while IFN-γ treatment induced 
ROS production in cultured keratinocytes (Qi et al., 2011) and microglial cells (Jung et al., 2010), 
the reduction of IFN-γ expression in skeletal muscle was nevertheless associated with an impaired 
regeneration capability of cultured skeletal myocytes (Cheng et al., 2008). RT-PCR assays showed 
that expression levels of these two known mediators of oxidative stress production such as TNF-α 
and IFN-γ were in fact reduced. This shows that ROS production is not mediated by an increased 
expression of TNF-α or IFN-γ. The relevance of such a decrease for the lack of oxidized products 
upon visfatin challenge is unknown yet.         
    Since NOX4 is also a NFkB target (Moe et al., 2006; Basuroy et al., 2009; Park et 
al., 2006) and, as shown in the fifth chapter, its gene expression is increased by visfatin treatment 
(Fig.5.5), the activation of NFkB was blocked for one hour prior visfatin challenge for another 24 
hours. RT-PCR assay showed that NOX4 gene expression was reduced in cells pre-treated with 
IKK inhibitor followed by visfatin challenge with cca. 50% compared to visfatin-only treated cells 
(Fig.6.7). This indicates that there are other pathways mediating NOX4 gene transcription besides 
NFkB, unknown yet. The precise role of NOX4 and NOX complexes in the generation of oxidative 
stress in the case of skeletal muscle represents a recent discovery and its elucidation will require 
further studies. Whether this reduction in NOX4 expression levels upon NFkB inhibition is 
responsible for the reduction in oxidative stress noticed is still unknown. It was noticed also an 
increased expression of VEGFa gene upon exogenous visfatin stimulation, another target gene of 
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NFkB. Increased expression of VEGFa was previously associated with decreased antioxidant 
defence in vitreous fluid in the case of diabetic patients (Yokoi et al., 2005). It was also shown that 
VEGFa expression was increased in the serum and skeletal muscle samples of patients with 
inflammatory diseases affecting skeletal muscle such as polymyositis and dermatomyositis 
(Grundtman et al., 2008). The precise mechanisms possibly affected by increased expression of 
VEGFa in skeletal muscle are not clear still.            
           Other known cytokines such as IL-6 and IL-15 were also increased upon visfatin 
challenge of C2C12 cells. Increased IL-6 expression was previously associated with a higher level 
of oxidative stress in brain (Penkowa and Hidalgo, 2000), alveolar epithelia  (Haddad et al., 2001), 
macrophages (Chang et al., 2010a) and vascular cells (Szeto et al., 2008). IL-6 was reported also to 
be secreted by skeletal myocytes as a genuine myokine (Pedersen and Febbraio, 2008). 
Nevertheless, the relevance of such muscle-specific secretion of IL-6 for the skeletal muscle stress 
responses and inflammation is still contentious and highly debated. It is established at least that 
skeletal muscle-specific IL-6 has a significant role in regulation of fatty acid oxidation and glucose 
metabolism, especially during endurance exercise (Nielsen and Pedersen, 2007). Furthermore, 
changes in IL-6 expression have a major impact on the regulation of skeletal mass (Frost et al., 
2004). It appears therefore that while plasma level of IL-6 is associated with a pro-oxidant state, as 
a myokine IL-6 is correlated nevertheless with an increased level of antioxidant defence in skeletal 
muscle (Sacheck et al., 2006). IL-15 is also a myokine with a clear role in the regulation of adipose 
tissue mass and inflammation (Almendro et al., 2008; Nielsen and Pedersen, 2007) which was 
increased by exogenous visfatin challenge. It was shown so far that IL-15 has a lower expression 
during ageing and ageing-associated diseases  (Marzetti et al., 2009a) and that reduced plasma level 
of IL-15 is associated with reduced expression of glutathione and increased oxidative stress in 
obese patients (Di Renzo et al., 2010). The relevance of IL-15 in the context of skeletal muscle is 
currently unknown, besides the fact of being broadly regulated by inflammatory signals and stress 
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inducers (Perera, 2000). Whether such an increase in IL-6 and IL-15 cytokines is involved in ROS 
production or antioxidant defence upon visfatin challenge in C2C12 cells is still unclear.  
     Interestingly, a previous report (Adya et al., 2008a) showed that while visfatin treatment 
increased NFkB activity in human endothelial cells, it was able nevertheless to reduce an additional 
NFkB activation upon TNF-α challenge.  These data suggest that the relationships between visfatin 
and NFkB activation are not linear and only partially understood. The complex effects of visfatin 
on NFkB signalling indicate that in different tissues or pathologic conditions it has diverse and 
versatile immunomodulatory properties, only partially mapped and explored. As in the case of 
PPAR-β/δ during acute HLS discussed above, visfatin could act also as a complex switch between 
pro/antioxidative stress forces or between pro- and anti-inflammatory signalling pathways affecting 
skeletal muscle. This is nevertheless a hypothetical scenario that will require further studies. 
        Another hypothesis to explain the effects of extracellular form of visfatin on cellular 
stress is based on the putative synthesis of NMN from nicotinamide and 5-phosphoribosyl 1-
pyrophosphate in the plasma or in the extracellular space, not only in the intracellular space. Once 
synthesized by eNampt in extracellular space, NMN could be transported across plasma membrane 
through specialized transporters (Revollo et al., 2007) and generate ROS as a consequence of an 
increase in NAD synthesis as proposed (Romacho et al., 2009). Since nicotinamide is present in the 
DMEM culture medium used for C2C12 differentiation, the possibility attracted considerable 
attention. Nevertheless, the hypothesis of visfatin as a systemic enzyme was rejected recently       
(Hara et al., 2011), based on the fact that the reaction requires the presence of ATP at miliomolar 
levels, and culture medium used lacks ATP.  
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                              8.2.5 Visfatin (eNampt) treatment and PPARs                               
       In the seventh chapter I showed that the activation of PPAR-β/δ-dependent 
signalling reduced the ROS levels induced by visfatin. Diverse studies performed in vitro, ex vivo 
and in vivo (animal models or human subjects) already proved that the activation of PPAR-β/δ 
signalling pathway has antioxidant properties in multiple tissues. Treatment of cultured 
cardiomyoblasts with GW-501516 conferred protection against oxidative stress-induced apoptosis 
through the upregulation of protective genes such as catalase (Pesant et al., 2006). The role of 
PPAR-β/δ as a sensor of oxidative stress levels was further proved by the fact that the activity of 
the receptor was increased in the hepatocytes treated with the compound 4-hydroxynonenal (4-
HNE), a lipid species that induces oxidative stress (Coleman et al., 2007). In addition, in the same 
paper it was reported that activation of PPAR-β/δ in hepatocytes by the agonist GW-9662 conferred 
protection and resistance against the lipid-dependent toxicity. The repetitive low-level oxidative 
stress challenge by using hydrogen peroxide activated PPAR-β/δ activity in cultured endothelial 
cells, protecting against a critical subsequent oxidative stress-mediated apoptotic event (Jiang et al., 
2009). In vascular endothelium the activation of PPAR-β/δ by GW-501516 increased the 
expression levels of hem oxygenase-1 (HO-1), reducing further the levels of oxidative stress 
induced by an additional treatment with hydrogen peroxide and overall the atherogenic phenotype 
(Ali et al., 2010). Some of the genes relevant for antioxidant defence such as carnitine 
palmitoyltransferase-1 (CPT-1b) and pyruvate dehydrogenase kinase 4 (PDK4) were shown to be 
upregulated by GW-501516 (Coll et al., 2010). An increase in the expression of these two genes 
and of PPAR-β/δ was also identified in the acute phase of hindlimb suspension, as discussed in the 
third chapter. In endothelial cells it was shown that the activation of PPAR-β/δ by GW-501516 
increased the expression of many crucial antioxidant genes such as catalase, superoxide dismutase 
1 and thioredoxin (Fan et al., 2008). Furthermore, in human primary skeletal cells GW-501516 
treatment increased expression level of UCP-3 gene that has antioxidant effects (Terada et al., 
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2006). These reports suggest that activation of PPAR-β/δ in C2C12 cells reduced the oxidative 
stress levels induced by exogenous visfatin likely by improving the pre-existent antioxidant 
defence ability to resist the stress, rather than directly interfering with visfatin-induced effects.  
              The nexus role of PPAR-β/δ as anti-inflammatory mediator was shown by the fact 
that while the administration of GW-501516 was able to reduce the inflammation in a T-cell 
mediated autoimmune disease model of multiple sclerosis (Kanakasabai et al., 2010), it was 
nevertheless ineffective in a case of an antibody-induced demyelination that acts independently of 
inflammation (Defaux et al., 2009). Furthermore, GW-501516 ameliorated the insulin resistance 
induced by the treatment of cultured skeletal myotubes with palmitate by modifying the expression 
levels of genes involved in the fatty acid oxidation, AMPK phosphorylation and antioxidant 
defence (Coll et al., 2010). Activation of PPAR-β/δ had also anti-inflammatory effects in cultured 
keratinocytes upon UV-B exposure and in skin psoriasis models (Rivier et al., 1998). Nevertheless, 
as shown by Fig. 7.3, administration of the agonist GW-501516 failed to reduce in C2C12 cells the 
activation of NFkB signalling pathway by exogenous visfatin treatment. This is not surprising since 
it was already shown that the pre-treatment with GW-501516 agonist reduced the activation of 
NFkB by LPS in cultured adipocytes by blocking the upstream activation of ERK ½ kinase 
(Rodriguez-Calvo et al., 2008), activation that was missing in my case. This shows that the 
reduction in ROS levels by GW-501516 is occurring independently of the inhibition of NFkB-
signalling. This suggests also that NFkB activation occurs independently of pre-existing reactive 
oxygen species since PPAR-β/δ treatment did not reduce its activation. This also correlates with the 
fact that inhibition of NFkB reduced only partially NOX4 levels induced by visfatin (Fig. 6.7).            
         It appears also that visfatin expression and secretion levels can be modulated by 
PPARs agonists in tissues of interests for ageing research such as skeletal muscle, adipose tissue 
and immune cells (Choi et al., 2005). The roles of exogenous visfatin in the modulation of skeletal 
muscle physiology have not been directly addressed until our published paper (Oita et al., 2010). 
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As discussed in detail in the fourth chapter, there are likely differences between the intracellular 
form (iNampt) and the extracellular form of visfatin (eNampt) in this respect, especially in the case 
of oxidative stress and inflammatory regulatory mechanisms relevant for ageing. For example, it 
was shown that free, circulating visfatin plasma levels were reduced in overweight women 
subjected to caloric restriction, simultaneously with a reduction in body weight and adipose tissue 
mass (Lee et al., 2010). The intracellular form of visfatin is also crucial for the anti-ageing effects 
triggered by activation of sirtuins in adipocytes or in skeletal muscle upon caloric restriction 
challenge through the modulation of NAD metabolism (Hsu et al., 2008; Imai, 2009b; Lu et al., 
2009b).             
                  By using an ELISA assay I showed that visfatin is not secreted in the culture 
medium of C2C12 cells in neither basal nor in GW-501516-stimulated conditions. Why visfatin 
was detected in the supernatant of cultured L6 rat myocytes (Wang et al., 2010) and not in the 
supernatant of C2C12 mouse myocytes (Fig. 7.4) is a question unanswered yet, being a subject for 
future studies. A possible explanation could be the fact that in the previously reported experiment 
with rat L6 cells the culture medium was taken after 3 days of incubation, an interval that partially 
reflected the process of L6 differentiation from proliferating myoblasts to differentiated and fused 
myotubes in low-level serum culture medium. In my experiments C2C12 cells have been used only 
after reaching full differentiation status in serum-free medium. Therefore, it is possible that visfatin 
could be involved in the process of differentiation and be secreted only at the myoblast stage, or 
during the transition process from myoblasts to myotubes. Nevertheless, since the focus of the 
present thesis was the effect of visfatin on differentiated skeletal muscle as a model of ageing, the 
possibility that visfatin could be detected in culture medium of proliferating C2C12 myoblasts 
instead of differentiated C2C12 myotubes was not explored.     
  Therefore, there are no indications so far that exogenous visfatin challenge could 
have an effect on PPARs expression in adult skeletal muscle, and no indication that the activation 
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of PPAR-β/δ induced a secretion of visfatin from skeletal muscle as a myokine. Whether visfatin is 
a genuine myokine is still debated, and in my case it was not discovered in the conditioned medium 
from C2C12 differentiated and fused myotubes. Activation of PPAR-β/δ reduced the oxidative 
stress produced by visfatin, likely through the upregulation of its known target genes that increased 
the antioxidant defence status in cultured myocytes, but it did not affect directly the activation of 
NFkB.  
                            
                              8.3 Visfatin- a promising and intriguing adipokine relevant for 
skeletal muscle research   
   In conclusion, although exogenous visfatin treatment did not induce an 
insulin-mimetic effect in cultured myotubes, it triggered nevertheless an increase in oxidative stress 
levels and inflammation after a chronic stimulation.  The fact that the oxidative stress induced was 
different from the pattern generated by ectopic lipid accumulation suggests that it harbours still 
interesting unknown aspects.  As seen from the model depicted in Fig. 8.3,  visfatin could increase 
simultaneously both the levels of free radicals through the action of prooxidant enzymes such as 
NOX4 and the antioxidant ability to resist such as stress through the increase in expression of 
enzymes such as SOD1. As such, visfatin research could be used to construct a useful model for 
testing the theoretical predictions of the free radical theory of ageing described in the introduction 
since it has versatile effects, being in different tissues pro- or antioxidant, pro- or anti-
inflammatory, or being associated with insulin resistance or insulin sensitivity. The next crucial 
step in elucidating visfatin function will be the identification of its putative membrane receptor(s) 
that mediates its effects, as well as the downstream signalling pathways. Whether the insulin-
mimetic effects in non-muscle cells are mediated by the same membrane receptor that induces ROS 
and inflammation is another important question to be approached.  
              Fig. 8.3 Schematic diagram of the proposed mechanism of action of visfatin (eNampt) on 
skeletal muscle myocytes 
 Visfatin binds to a membrane receptor 
triggers and increase in ROS levels
Simultaneously, visfatin increase
such as SOD1 and of genes that could mediate the increase in ROS 
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